
<html lang="en"     class="pb-page"  data-request-id="37454176-20d2-47ae-9e3a-bec639f04523"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-3;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm4014828;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition" /></meta><meta name="dc.Creator" content="Dean G.  Brown" /></meta><meta name="dc.Creator" content="Peter R.  Bernstein" /></meta><meta name="dc.Creator" content="Andrew  Griffin" /></meta><meta name="dc.Creator" content="Steve  Wesolowski" /></meta><meta name="dc.Creator" content="Denis  Labrecque" /></meta><meta name="dc.Creator" content="Maxime C.  Tremblay" /></meta><meta name="dc.Creator" content="Mark  Sylvester" /></meta><meta name="dc.Creator" content="Russell  Mauger" /></meta><meta name="dc.Creator" content="Phillip D.  Edwards" /></meta><meta name="dc.Creator" content="Scott R.  Throner" /></meta><meta name="dc.Creator" content="James J.  Folmer" /></meta><meta name="dc.Creator" content="Joseph  Cacciola" /></meta><meta name="dc.Creator" content="Clay  Scott" /></meta><meta name="dc.Creator" content="Lois A.  Lazor" /></meta><meta name="dc.Creator" content="Mehrnaz  Pourashraf" /></meta><meta name="dc.Creator" content="Vijayaratnam  Santhakumar" /></meta><meta name="dc.Creator" content="William M.  Potts" /></meta><meta name="dc.Creator" content="Simon  Sydserff" /></meta><meta name="dc.Creator" content="Pascall  Giguère" /></meta><meta name="dc.Creator" content="Carine  Lévesque" /></meta><meta name="dc.Creator" content="Mohammed  Dasser" /></meta><meta name="dc.Creator" content="Thierry  Groblewski" /></meta><meta name="dc.Description" content="A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tole..." /></meta><meta name="Description" content="A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tole..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 27, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm4014828" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm4014828" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm4014828" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm4014828" /></link>
        
    
    

<title>Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm4014828" /></meta><meta property="og:title" content="Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0024.jpeg" /></meta><meta property="og:description" content="A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only σ2 (62% at 10 μM). Compound 6s demonstrated free-plasma exposures above the IC50 (∼50×) with a brain-to-plasma ratio of ∼3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm4014828"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm4014828">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm4014828&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm4014828&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm4014828&amp;href=/doi/10.1021/jm4014828" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 733-758</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401438g" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401492x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean+G.++Brown">Dean G. Brown</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+R.++Bernstein">Peter R. Bernstein</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Griffin">Andrew Griffin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Wesolowski">Steve Wesolowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Denis++Labrecque">Denis Labrecque</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maxime+C.++Tremblay">Maxime C. Tremblay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Sylvester">Mark Sylvester</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Russell++Mauger">Russell Mauger</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Phillip+D.++Edwards">Phillip D. Edwards</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+R.++Throner">Scott R. Throner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+J.++Folmer">James J. Folmer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Cacciola">Joseph Cacciola</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Clay++Scott">Clay Scott</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lois+A.++Lazor">Lois A. Lazor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mehrnaz++Pourashraf">Mehrnaz Pourashraf</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vijayaratnam++Santhakumar">Vijayaratnam Santhakumar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+M.++Potts">William M. Potts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Sydserff">Simon Sydserff</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pascall++Gigu%C3%A8re">Pascall Giguère</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carine++L%C3%A9vesque">Carine Lévesque</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mohammed++Dasser">Mohammed Dasser</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thierry++Groblewski">Thierry Groblewski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">AstraZeneca Montréal, 7171 Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">OmegaChem, 480 Rue Perreault, Saint-Romuald, Québec G6W 7 V6, Canada</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#791d1c1817571b0b160e1739180a0d0b18031c171c1a18571a1614"><span class="__cf_email__" data-cfemail="1b7f7e7a75357969746c755b7a686f697a617e757e787a35787476">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm4014828&amp;href=/doi/10.1021%2Fjm4014828" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 733–758</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 10, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 September 2013</li><li><span class="item_label"><b>Published</b> online</span>27 January 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 February 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm4014828" title="DOI URL">https://doi.org/10.1021/jm4014828</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D733%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDean%2BG.%2BBrown%252C%2BPeter%2BR.%2BBernstein%252C%2BAndrew%2BGriffin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D3%26contentID%3Djm4014828%26title%3DDiscovery%2Bof%2BSpirofused%2BPiperazine%2Band%2BDiazepane%2BAmides%2Bas%2BSelective%2BHistamine-3%2BAntagonists%2Bwith%2Bin%2BVivo%2BEfficacy%2Bin%2Ba%2BMouse%2BModel%2Bof%2BCognition%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D758%26publicationDate%3DFebruary%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm4014828"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2247</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm4014828" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;G. Brown&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;R. Bernstein&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Griffin&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Wesolowski&quot;},{&quot;first_name&quot;:&quot;Denis&quot;,&quot;last_name&quot;:&quot;Labrecque&quot;},{&quot;first_name&quot;:&quot;Maxime&quot;,&quot;last_name&quot;:&quot;C. Tremblay&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Sylvester&quot;},{&quot;first_name&quot;:&quot;Russell&quot;,&quot;last_name&quot;:&quot;Mauger&quot;},{&quot;first_name&quot;:&quot;Phillip&quot;,&quot;last_name&quot;:&quot;D. Edwards&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;R. Throner&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;J. Folmer&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Cacciola&quot;},{&quot;first_name&quot;:&quot;Clay&quot;,&quot;last_name&quot;:&quot;Scott&quot;},{&quot;first_name&quot;:&quot;Lois&quot;,&quot;last_name&quot;:&quot;A. Lazor&quot;},{&quot;first_name&quot;:&quot;Mehrnaz&quot;,&quot;last_name&quot;:&quot;Pourashraf&quot;},{&quot;first_name&quot;:&quot;Vijayaratnam&quot;,&quot;last_name&quot;:&quot;Santhakumar&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;M. Potts&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Sydserff&quot;},{&quot;first_name&quot;:&quot;Pascall&quot;,&quot;last_name&quot;:&quot;Giguère&quot;},{&quot;first_name&quot;:&quot;Carine&quot;,&quot;last_name&quot;:&quot;Lévesque&quot;},{&quot;first_name&quot;:&quot;Mohammed&quot;,&quot;last_name&quot;:&quot;Dasser&quot;},{&quot;first_name&quot;:&quot;Thierry&quot;,&quot;last_name&quot;:&quot;Groblewski&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;733-758&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm4014828&quot;},&quot;abstract&quot;:&quot;A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only σ2 (62% at 10 μM). Compound 6s demonstrated free-plasma exposures above the IC50 (∼50×) with a brain-to-plasma ratio of ∼3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4014828&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4014828" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4014828&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4014828" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4014828&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4014828" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm4014828&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4014828&amp;href=/doi/10.1021/jm4014828" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm4014828" /></input><a href="/doi/pdf/10.1021/jm4014828" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm4014828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm4014828%26sid%3Dliteratum%253Aachs%26pmid%3D24410637%26genre%3Darticle%26aulast%3DBrown%26date%3D2014%26atitle%3DDiscovery%2Bof%2BSpirofused%2BPiperazine%2Band%2BDiazepane%2BAmides%2Bas%2BSelective%2BHistamine-3%2BAntagonists%2Bwith%2Bin%2BVivo%2BEfficacy%2Bin%2Ba%2BMouse%2BModel%2Bof%2BCognition%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D3%26spage%3D733%26epage%3D758%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291870" title="Piperidines">Piperidines</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jmcmar.2014.57.issue-3/production/jmcmar.2014.57.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A new series of potent and selective histamine-3 receptor (H<sub>3</sub>R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H<sub>3</sub>R functional assay. Exemplar compound <b>6s</b> demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only σ2 (62% at 10 μM). Compound <b>6s</b> demonstrated free-plasma exposures above the IC<sub>50</sub> (∼50×) with a brain-to-plasma ratio of ∼3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), <b>6s</b> demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H<sub>3</sub> receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The histamine-3 receptor (H<sub>3</sub>R) is an autoreceptor that operates presynaptically in histaminergic neurons.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Evidence suggests that selective blockade of H<sub>3</sub>R results in increased levels not only of histamine but also of noradrenaline, acetylcholine, and dopamine.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As such, H<sub>3</sub>R antagonists have been the focus of many recent drug discovery efforts, with interests spanning sleep disorders, cognition, attention deficit hyperactivity disorder (ADHD), osteoarthritis, Tourette syndrome, neuropathic pain, and metabolic disorders.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11">(3-11)</a> Over the years, selective antagonists at this receptor evolved from analogues of the endogenous ligand histamine into more advanced ligands that arguably are structurally distinct from histamine because they lack the imidazole chemotype.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Publications continue to emerge with a diversity of core scaffolds capable of inhibiting H<sub>3</sub> receptors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Cardiovascular safety has proven to be an area of recurring concern, potentially because of off-target effects such as those arising from <i>human ether-à-go-go-related gene</i> (hERG) potassium channel binding.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">In the course of this project, we discovered a new class of selective H<sub>3</sub>R antagonists. Of interest to us in this class of molecules was the lack of an aromatic ring that is present in most structures within the published H<sub>3</sub> literature. We hypothesized that the lack of aromaticity in the pharmacophore may reduce off-target issues.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The challenges of safety of H<sub>3</sub> antagonists have been recently discussed in a review by Plancher,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> in particular, hERG, phospholipidosis (PLD), and mutagenicity, which can be mitigated in certain structural classes but still remain an issue with this type of pharmacophore. Because hERG tends to favor large hydrophobic groups often satisfied by hydrophobic aromatic elements,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> this series, which exemplified the exclusion or reduction of aromatic rings, offered the opportunity to test our hypothesis. Our investigation began with 6-azaspiro[2.5]octane carboxamides (spirocyclopropyl core) and then expanded to core modifications such as 7-azaspiro[3.5]nonane carboxamides (spirocyclobutyl core) as well as five- and six-membered ring spirofused analogues. A number of molecules made in this effort possessed two basic groups, which is a feature present in the pharmacophore of other H<sub>3</sub> antagonists such as the natural products Aplysame-1<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and Conessine<a onclick="showRef(event, 'cit18a cit18b cit18c'); return false;" href="javascript:void(0);" class="ref cit18a cit18b cit18c">(18a-18c)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) as well as the two synthetic examples from JNJ, namely, JNJ-5207852 and Bavisant (JNJ-31001074).<a onclick="showRef(event, 'cit13e cit13f ref19 ref20'); return false;" href="javascript:void(0);" class="ref cit13e cit13f ref19 ref20">(13e, 13f, 19, 20)</a> Both the piperazine and diazepane scaffolds have been useful pharmacophoric elements in the field, with a wide amount of structural diversity of attachments to these cores. Three examples of advanced compounds in the field with these elements are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> (NNC-38-1049,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> GSK 334429, and JNJ 39220675<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a>). We report herein the structure–activity relationships (SAR), in vitro drug metabolism pharmacokinetics (DMPK), and in vivo assessment of example molecules from this effort.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative H<sub>3</sub> scaffolds with dibasic, piperazine, and diazepane scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of the basic core 6-azaspiro[2.5]octane carboxamide scaffold is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Intermediate exocyclic olefin <b>2</b> was generated by Wittig olefination of Cbz-protected piperidin-4-one <b>1</b>. The spirocycle was then introduced by reaction of CuCN and ethyldiazoacetate to give ester <b>3</b>. Deprotection of the Cbz group with catalytic hydrogenation gave free amine <b>4</b>, which was subsequently alkylated under reductive amination conditions to give intermediate ester <b>5</b>. To finish the sequence, the ester was cleaved, and the carboxamide was introduced by coupling to the appropriate piperazine to give final products <b>6a</b>–<b>e</b> and <b>6g</b>–<b>i</b>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>PCH<sub>3</sub><sup>+</sup>Br<sup>–</sup>, <i>n</i>-BuLi, THF, 54%; (b) CuCN, ethyldiazoacetate, CH<sub>2</sub>Cl<sub>2</sub>, 45%; (c) EtOH, Pd/C, H<sub>2</sub>, 44%; (d) 1,2-DCE, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Na(OAc)<sub>3</sub>BH, rt, 64%; (e) LiOH, MeOH, quan.; (f) HBTU, DMF, DIPEA, amine, 34–80%.</p></p></figure><div class="NLM_p">An alternative method was employed to add versatility for incorporating diversity elements to the route in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, which is illustrated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Intermediate <b>3</b> from Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> was hydrolyzed to give intermediate acid <b>7</b>, which was then coupled with Boc-protected piperazine to provide <b>8</b>. The Cbz group on the piperidine nitrogen was then removed under catalytic hydrogenation to provide <b>9</b> and subsequently reacted with a ketone under reducing conditions to provide <b>10</b>. At this point, the piperazine was deprotected to provide free amine <b>11</b>, which was subjected to a second reductive amination to give final compound <b>6f</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LiOH, THF, 94%; (b) HBTU, DIPEA, <i>tert</i>-butyl piperazine-1-carboxylate, 69%; (c) EtOH, Pd/C, H<sub>2</sub>, AcOH (cat.), 99%; (d) EtOH, NaBH<sub>3</sub>CN, AcOH (cat.), dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one; (e) CH<sub>2</sub>Cl<sub>2</sub>, TFA, 99%; (f) CH<sub>2</sub>Cl<sub>2</sub>, cyclohexanone, PS-CNBH<sub>4</sub>, 66%.</p></p></figure><div class="NLM_p">Entry into analogues wherein the two N-alkyl groups were reversed is outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Intermediate <b>7</b> was coupled with 1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazine to provide <b>12</b>, which in turn underwent reductive amination, providing <b>6j</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HBTU, 1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazine dihydrochloride, 11%; (b) Pd/C, H<sub>2</sub>, MeOH, cyclobutanone, 46%.</p></p></figure><div class="NLM_p">A series of spiropiperidine analogues were made in a similar fashion where the piperazine ring was held constant with a cyclohexyl substituent. The synthesis of these analogues is provided in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Intermediate <b>7</b> was acylated with 1-cyclohexylpiperazine to provide <b>13</b> and deprotected to give <b>6k</b>. This intermediate was acylated, alkylated, or aminated under Buchwald–Hartwig conditions<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> to provide title compounds <b>6l</b>–<b>q</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, HBTU, DIPEA, 1-cyclohexylpiperazine, 70%; (b) MeOH, Pd/C, H<sub>2</sub>, rt, 95%; (c) 4-Cl-pyridine, K<sub>2</sub>CO<sub>3</sub>, DMSO, 26%; (d) PhMe, Li(HMDS), PhBr, PdCl<sub>2</sub>[P(<i>o</i>-tol)<sub>3</sub>]<sub>2</sub>, 12%; (e) 1,2-DCE, R<sub>2</sub>-CHO, Na(OAc)<sub>3</sub>BH, rt, 30–60%.</p></p></figure><div class="NLM_p">Optically pure material was accessed through the route illustrated in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Racemic Cbz-protected ester <b>3</b> was separated by chiral supercritical fluid chromatography (SFC) to provide pure stereoisomers <b>3a</b> and <b>3b</b>. The Cbz groups were removed by hydrogenolysis to provide intermediate amines <b>4a</b> and <b>4b</b>, which were assigned to their absolute relative configurations using computed and observed vibrational circular dichroism (VCD) spectra (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Chiral SFC, quan.; (b) Pd/C, H<sub>2</sub>, EtOH, rt, 59% for <b>4a</b> and 82% for <b>4b</b>; (c) NaOH, MeOH, H<sub>2</sub>O, quan; (d) HBTU, 1-isopropylpiperazine, quan.; (e) Pd/C, H<sub>2</sub>, MeOH, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, 30 psi, 45% for <b>6r</b> and 68% for <b>6s</b>.</p></p></figure><div class="NLM_p">Cbz-protected intermediates <b>3a</b> and <b>3b</b> were hydrolyzed with aqueous sodium hydroxide to provide (<i>R</i>) and (<i>S</i>) stereoisomers <b>7a</b> and <b>7b</b>, respectively. The optically pure acids were coupled to 1-isopropylpiperazine to provide Cbz-protected piperazines <b>14a</b> and <b>14b</b>. Deprotection and reductive amination were conducted in the same reaction to provide final compounds <b>6r</b> and <b>6s</b>.</div><div class="NLM_p">The synthesis of an analogue in which the spiropiperidine basic nitrogen was removed and replaced with a spirocyclohexane is outlined in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Starting with ketone <b>15</b>, Wittig olefination was performed to provide ester <b>16</b> with 72% yield. Cyclopropanation was then achieved using dimethylsulfonium ylide under basic conditions to provide <b>17</b>. Subsequent hydrolysis and amide bond formation with cyclobutyl piperidine provided final compound <b>6t</b>.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, NaH, (MeO)<sub>2</sub>PCH<sub>2</sub>CO<sub>2</sub>Me, cyclohexanone, 72%; (b) DMF, NaH, Me<sub>3</sub>S<sup>+</sup>I<sup>–</sup>, 49%; (c) LiOH, THF, quan.; (d) DMF, HBTU, DIPEA, cyclobutylpiperazine, 69%.</p></p></figure><div class="NLM_p">The construction of spirocyclobutyl analogues is detailed in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>. The synthesis began with <i>tert</i>-butyl 4-methylenepiperidine-1-carboxylate <b>18</b>, which was converted to dichloroketone <b>19</b> by reaction with Cl<sub>3</sub>COCl. The chlorine atoms were subsequently removed with Zn to provide ketone <b>20</b>. The ketone was then reduced with NaBH<sub>4</sub> and converted to the mesylate, providing intermediate mesylate <b>21</b>. The mesylate was then displaced with cyanide and hydrolyzed to give Boc-protected ester <b>23</b>.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Zn–Cu, Et<sub>2</sub>O, Cl<sub>3</sub>COCl, 40%; (b) NH<sub>4</sub>Cl, MeOH, Zn, 97%; (c) NaBH<sub>4</sub>, MeOH, 99%; (d) Et<sub>3</sub>N, MsCl, CH<sub>2</sub>Cl<sub>2</sub>, 97%; (e) NaCN, TBAB, DMF, 57%; (f) EtOH, H<sub>2</sub>SO<sub>4</sub>; Boc<sub>2</sub>O, 41%; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 83%; (h) MeOH, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Pd/C, H<sub>2</sub>, rt, 58%; (i) MeOH, 1 N NaOH, reflux, quan.; (j) DMF, HBTU, amine, DIPEA, 76%; (k) CO<sub>2</sub>Cl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; DIPEA, R<sup>1</sup>-amine, CH<sub>2</sub>Cl<sub>2</sub>, 32–65%.</p></p></figure><div class="NLM_p">Preparation of final analogues on the cyclobutyl scaffold is shown in bottom synthetic pathway of Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>. Boc-protected ester <b>23</b> was deprotected and subjected to reductive amination with dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one under catalytic hydrogenation to give intermediate ester <b>28</b>. Hydrolysis and amide bond coupling with varying piperazines provided final compounds <b>29a</b>–<b>f</b>.</div><div class="NLM_p">An alternative synthesis illustrated in Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a> was employed to provide intermediates for analogues on the cyclobutyl scaffold. Cbz-protected olefin <b>2</b> (previously described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) was reacted with dichloroketene precursor to give intermediate dichloroketone <b>24</b>. This was reduced to ketone <b>25</b> with Zn and then converted to aldehyde <b>26</b> by Wittig olefination. The final intermediate was then obtained by 2,2,6,6-tetramethylpiperidine oxide (TEMPO) oxidation to provide acid <b>27</b>.</div><div class="NLM_p">Intermediate <b>27</b> was utilized to explore substitution projecting from the piperidine nitrogen atom. The route employed for these compounds is shown in the bottom synthetic pathway of Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>. Intermediate <b>27</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> was reacted with 1,4-cyclobutyl piperazine and 1,4-cyclobutyl diazepane to form intermediate Cbz-protected piperazines <b>30g</b> and <b>30j</b>. The Cbz group was removed, and various coupling strategies were employed to derivatize the N atom, such as sulfonamide formation (<b>29g</b>), Buchwald–Hartwig amination (<b>29h</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and acylation (<b>29i</b> and <b>29j</b>).</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Et<sub>2</sub>O, Zn–Cu, Cl<sub>3</sub>COCl, DME, 40%; (b) MeOH, NH<sub>4</sub>Cl, Zn, 74%; (c) THF, KO<i>t</i>-Bu, BuOH, Ph<sub>3</sub>PCH<sub>2</sub>OMe<sup>+</sup>Cl<sup>–</sup>, 48%; (d) CH<sub>2</sub>Cl<sub>2</sub>/NaHCO<sub>3</sub>, NaOCl, TEMPO, NaBr, 72%; (e) DMF, DIEA, amine, HBTU, 78% or SO<sub>2</sub>Cl<sub>2</sub>, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, quan.; (f) EtOH, Pd/C, H<sub>2</sub> 50 psi, 88–96%; (g) CH<sub>2</sub>Cl<sub>2</sub>, TEA, MeSO<sub>2</sub>Cl, 39%; (h) PhMe, Ph-Br, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, BINAP, 110 °C, 18h, 46%; (i) CH<sub>2</sub>Cl<sub>2</sub>, DIPEA, PhCOCl, 33–64%.</p></p></figure><div class="NLM_p">An azetidine analogue was prepared according to Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>. Spirofused azetidine <b>32</b> was acylated with <i>p</i>-nitrophenyl carbonochloridate and then reacted with isopropyl piperidine to provide intermediate <b>33</b>. This intermediate was converted to final compound <b>34</b> under the reductive amination conditions previously described in Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>.</div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, 4-NO<sub>2</sub>PhOCOCl, DIPEA, 1-isopropylpiperazine, reflux, 72%; (b) HCl, MeOH, rt, quan.; (c) MeOH, TEA, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Pd/C, H<sub>2</sub>, rt, 28%.</p></p></figure><div class="NLM_p">Spirocyclic fused pyrrolidines attached to the 3 and 4 positions of the piperidine ring are illustrated in Schemes <a class="ref internalNav" href="#sch10" aria-label="10">10</a> and <a class="ref internalNav" href="#sch11" aria-label="11">11</a>. For N-tetrahydropyran, isopropyl piperidine, and diazepane analogues, the synthesis began with spirofused intermediate <b>35</b> or <b>39</b> (Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>). The free nitrogen of <b>35</b> was acylated with carbonyldiimidazole (CDI), and the intermediate was methylated with methyl iodide and then reacted with 1-isopropylpiperazine to give <b>36b</b>. This was converted into the final test compounds through reductive amination to provide <b>37b</b>. Access to the 4-piperidine spirofused cyclopentanes began with <b>39</b>. This was converted to the intermediate urea by reaction with <i>p</i>-nitrophenyl carbonochloridate and 1,4-isopropyl piperazine. Deprotection of the Boc group with HCl followed by reductive amination provided <b>41a</b>. In an analogous fashion, Scheme <a class="ref internalNav" href="#sch11" aria-label="11">11</a> illustrates the synthesis of cyclobutyl piperidines and diazpeines for the 3- and 4-substituted piperidines. In this set, several N substituents were explored, such as N-acyl and N-sulfonyl, following the chemistry outlined in Scheme <a class="ref internalNav" href="#sch11" aria-label="11">11</a>.</div><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 10. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, CDI, Et<sub>3</sub>N; (b) ACN, MeI; (c) CH<sub>2</sub>Cl<sub>2</sub>, R<sup>1</sup>-amine, Et<sub>3</sub>N, 40% steps a–c; (d) HCl, <i>i</i>PrOH, Et<sub>2</sub>O, quan.; (e) NaBH(OAc)<sub>3</sub>, 1,2-DCE, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, AcOH, Et<sub>3</sub>N, 40–44%; (f) THF, 4-NO<sub>2</sub>PhOCOCl, −78 °C, 1-isopropylpiperazine, reflux, DIPEA, 28%; (g) HCl, MeOH, 75%; (h) MeOH, TEA, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Pd/C, H<sub>2</sub>, rt, 62%.</p></p></figure><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 11. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, CDI, Et<sub>3</sub>N; (b) ACN, MeI; (c) CH<sub>2</sub>Cl<sub>2</sub>, R<sup>1</sup>-amine, Et<sub>3</sub>N, 40% steps a–c; (d) HCl, <i>i</i>PrOH, Et<sub>2</sub>O, quan.; (e) NaBH(OAc)<sub>3</sub>, 1,2-DCE, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, AcOH, Et<sub>3</sub>N, 36%; (f) CH<sub>2</sub>Cl<sub>2</sub>, PhCOCl, TEA, 48%; (g) PhSO<sub>2</sub>Cl, TEA, 50%; (h) THF, CDI, Et<sub>3</sub>N, quan.; (i) ACN, MeI, quan.; (j) CH<sub>2</sub>Cl<sub>2</sub>, R<sup>1</sup>-amine, Et<sub>3</sub>N, 65–67%; (k) HCl, <i>i</i>PrOH, quan.; (l) CH<sub>2</sub>Cl<sub>2</sub>, PhCOCl, TEA, 85–88%; (m) R<sub>2</sub>SO<sub>2</sub>Cl, TEA, 77–85%.</p></p></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch12" aria-label="12">12</a> illustrates the synthetic protocol used to access the piperidine replacement of the right-hand-side piperazine. Boc-protected spirofused intermediate <b>42</b> was acylated with benzoyl chloride to provide <b>43</b>, which then underwent coupling with 1-(<i>tert</i>-butoxycarbonyl)piperidine-4-carboxylic acid to yield intermediate <b>44</b>. This intermediate was subjected to reductive amination with cyclobutanone to give final compound <b>41g</b>.</div><figure id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 12. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-MeTHF, PhCO<sub>2</sub>H, DIPEA, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium, 61%; (b) HCl, MeOH, quan.; (c) 2-MeTHF, DIPEA, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium, 1-(<i>tert</i>-butoxycarbonyl)piperidine-4-carboxylic acid, 22%; (d) dioxane, HCl, 64%; (e) DMF, NaCNBH<sub>4</sub>, cyclobutanone, 37%.</p></p></figure><div class="NLM_p">The final synthetic protocol is shown in Scheme <a class="ref internalNav" href="#sch13" aria-label="13">13</a>, which illustrates the route employed to gain access to the spirofused bis-piperidine scaffold. The scheme was analogous to that used in Schemes <a class="ref internalNav" href="#sch10" aria-label="10">10</a> and <a class="ref internalNav" href="#sch11" aria-label="11">11</a>, whereby starting spirofused amine <b>45</b> was converted to urea <b>46</b> to provide final compound <b>41h</b> using protocols outlined in Scheme <a class="ref internalNav" href="#sch13" aria-label="13">13</a>.</div><figure id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 13. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, CDI, Et<sub>3</sub>N, quan.; (b) ACN, MeI, quan.; (c) CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 1-cyclobutyl-1,4-diazepane, 80%; (d) HCl, <i>i</i>PrOH, quan.; (e) benzoyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 75%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Initial investigations in this program began with the 6-azaspiro[2.5]octane (spirocyclopropyl) core reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Functional data was determined using an agonist-stimulated [<sup>35</sup>S]GTPγS (GTPγS) binding assay with membranes from CHO-K1 cells stably transfected with the long form of the human H<sub>3</sub>R (445 amino acids).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> To complement the functional assay, a binding assay was also utilized that measured the ability of test compounds to displace [<sup>3</sup>H]-<i>N</i>-α-methylhistamine binding to human H<sub>3</sub>R-K1 membranes.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Because of the good correlation of the two assays and the translational importance of the functional assay, the functional GTPγS assay became the only SAR-driving assay utilized for the project, with an occasional confirmatory test using the binding assay. This series of H<sub>3</sub> antagonists was not routinely assessed for inverse-agonist activity. However, <b>6d</b> reduced basal GTPγS binding to membranes expressing recombinant human H<sub>3</sub>R, which is consistent with inverse-agonist activity and has been reported for other H<sub>3</sub> antagonists.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Because the pharmacophore possesses a lipophilic basic amine and prior H<sub>3</sub> compounds were known to have a history of hERG activity, the hERG data (electrophysiological measurements in CHO cells) is also reported even though only a few compounds in the series ever demonstrated even a modest signal.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Spirocyclopropyl Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0020.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0021.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Compounds were tested for activity at inhibiting agonist-stimulated [<sup>35</sup>S]GTPγS binding to membranes from CHO-K1 cells stably transfected with the long form of the H<sub>3</sub> receptor (445 amino acids). Results are an average of <i>n</i> > 2 with standard error <20%.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">SPA binding assay utilized hH<sub>3</sub> transfected CHO membranes and [<sup>3</sup>H]-<i>N</i>-α-methylhistamine. Results are an average of <i>n</i> > 2 with standard error <50%.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Values determined in CHO-K1-hERG cells using electrophysiological measurements.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">logD values between octanol and water, as determined by shake-flask HPLC methods. nm, not measured.</p></div></div><div></div></div><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> highlights the importance of the SAR of the N-alkyl piperazine substituent. N-Me derivative <b>6a</b> has relatively weak activity in both the functional and binding assays (1100 and 1300 nM, respectively). The addition of isopropyl (<b>6b</b>), cyclopropyl (<b>6c</b>), and cyclobutyl (<b>6d</b>) led to functional activity in the double- and single-digit nanomolar region, with no discernible hERG activity (GTPγS IC<sub>50</sub> = 3.2, 19, and 3.6 nM, respectively). The isopropyl and cyclobutyl appeared optimal, as moving to larger groups such as cyclohexyl (<b>6f</b>) and cycloheptyl (<b>6g</b>) demonstrated a subtle but gradual loss of functional activity (GTPγS IC<sub>50</sub> = 12 and 74 nM, respectively). Polar modifications at the terminal N-alkyl piperazine, such as N-4-pyridyl (<b>6i</b>), also led to decreased activity relative to the small alkyl derivatives. Compound <b>6j</b> was an attempt to understand the promiscuity of the pharmacophore by swapping the N-alkyl side pieces relative to <b>6d</b>. A loss of ∼18-fold functional activity relative to <b>6d</b> was observed, suggesting that a proper orientation of these two pieces significantly contributes to the binding and functional activity. A series of analogues was explored where the N-alkyl piperazine derivative was fixed as a cyclohexyl group (<b>6k</b>–<b>q</b>), and the piperidine N-alkyl group was subsequently explored. The absence of an N-alkyl group (<b>6k</b>) led to a 30-fold drop in activity relative to <b>6f</b>. Replacement of the tetrahydro-2<i>H</i>-pyran in <b>6f</b> with a cyclohexyl (<b>6l</b>) gave an equipotent compound; however, hERG activity began to appear in the series for the first time (20.8 μM). This observation led us to conclude that having two hydrophobic groups, one off of the piperidine N atom and one off the piperazine N atom, led to deterioration of the clean off-target profile in compounds such as <b>6f</b> and hence having a polar group off the piperidine N atom was important for avoiding these issues. Smaller hydrophobic groups such as isopropyl <b>6m</b> were also tolerated. Addition of an aromatic ring at varying distances was also explored. Direct attachment of a phenyl ring (<b>6n</b>) led to a compound with poor binding activity (1670 nM), and as a result, the functional activity was not measured. This compound is expected to be a monobasic compound, given the p<i>K</i><sub>a</sub> of the aniline nitrogen makes it unlikely to be protonated at physiological pH. However, examples shown later in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> illustrate that certain monobasic compounds can have good potency. The reason for the lack of activity for the phenyl (<b>6n</b>) is unclear, but we speculate it has more to do with a steric interaction than with a lack of protonatable amine at the left-hand-side piperidine. Benzyl-linked compound <b>6o</b> demonstrated more potent H<sub>3</sub> binding than the phenyl analogue (103 nM), although it was still not as potent as polar tetrahydro-2<i>H</i>-pyran analogue <b>6f</b>. Extension to the phenethyl analogue <b>6p</b> gave activity more comparable to <b>6f</b>. Replacement of the tetrahydro-2<i>H</i>-pyran with a 4-pyridyl (<b>6q</b>) led to a compound with only a slight change from initial starting point <b>6f</b> as well, further reinforcing the promiscuity of this pocket with respect to binding and functional activity. This promiscuity thus provided opportunities to identify the best substituent from a pharmacokinetic and off-target perspective while maintaining intrinsic activity at the H<sub>3</sub> receptor.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Azetidine and Pyrrolidne Analogues with N-Tetrahydropyran-2<i>H</i>-pyran</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0022.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Compounds were tested for activity at inhibiting agonist-stimulated [<sup>35</sup>S]GTPγS binding to membranes from CHO-K1 cells stably transfected with the long form of the H<sub>3</sub> receptor (445 amino acids). Results are an average of <i>n</i> > 2 with standard error <20%.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Values determined in CHO-K1-hERG cells using electrophysiological measurements.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">logD values between octanol and water, as determined by shake-flask HPLC methods. nm, not measured.</p></div></div><div></div></div><div class="NLM_p">The separation and assignment of enantiomers of <b>6b</b> was conducted by separation on chiral SFC chromatography of intermediates <b>3a</b> and <b>3b</b> and assignment based on calculated and measured VCD spectra.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (<i>S</i>) stereoisomer <b>6s</b> demonstrated a more favorable functional and binding profile compared with (<i>R</i>) stereoisomer <b>6r</b> (GTPγS IC<sub>50</sub> = 8.3 and 87 nM and binding IC<sub>50</sub> = 0.8 and 16 nM, respectively). Compound <b>6s</b> was thus selected as a tool compound to benchmark the pharmacokinetic and in vivo efficacy of this scaffold. Finally, a piperidine replacement, 4-cyclohexyl <b>6t</b>, was synthesized and tested and demonstrated a complete loss of activity (>10 uM), thus reinforcing the importance of a heteroatom in the left-hand-side piperidine position. Furthermore, the impact of solubility on this change was dramatic, as might be expected, with <b>6t</b> having a measured solubility of ∼1 μM (data not shown), whereas most other piperidine analogues were >500 μM.</div><div class="NLM_p">The SAR was next investigated on a 7-azaspiro[3.5]nonan-2-yl core (spirocyclobutyl) and is reported in Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. In the spirocyclobutyl series, piperazine modifications on right-hand-side <b>29a</b>, <b>29b</b>, and <b>29c</b> provided very potent functional antagonists (GTPγS IC<sub>50</sub> = 0.8, 1.9, and 1.6 nM, respectively). In comparison to the spirocyclopropyl matched pairs <b>6h</b>, <b>6d</b>, and <b>6f</b>, all three spirocyclobutyl compounds were more potent (cf. GTPγS IC<sub>50</sub> = 17, 3.6, 12 nM, respectively, for spirocyclopropyl vs spirocyclobutyl matched pairs). One possible explanation could be that the spirocyclopropyl analogues are all racemic (whereas the achiral spirocyclobutyl is not), so potentially pure separated spirocyclopropyl stereoisomers could be more potent (but only theoretically up to a factor of 2). Because the spirocyclobutyl series is achiral, it proved advantageous over spirocyclopropyl compounds with regards to time spent on chiral separation and characterization. Bicyclic variant <b>29d</b> demonstrated comparable potency to the acyclic analogues, suggesting that there was room for further expansion at the α-position of the piperazine ring. Matched pairs <b>29e</b> and <b>29f</b> were designed to understand the impact of piperazine compared to 1,4-diazepane, where the isopropyl group was held constant. The results indicated a negative impact on the larger core (1,4-diazepane) and was consistent with the trends observed in the spirocyclopropyl series (<b>6d</b> vs <b>6h</b>). These results are inconsistent with the equipotent matched pairs of <b>29a</b> and <b>29b</b> mentioned earlier, which suggests that there is a unique trajectory and binding mode utilized by the spirocyclobutyl core with an N-cyclobutyl right-hand-side chain. Azetidine analogue <b>34</b> is an N-matched-pair variant of <b>29f</b> that demonstrated a significant loss in potency compared with <b>29f</b> (GTPγS IC<sub>50</sub> = 900 vs 1.7 nM, respectively). This trend was not observed with pyrrolidine analogues <b>37a</b>, <b>37b</b>, and <b>37c</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). N-isopropyl derivative <b>37b</b> is ∼5–6-fold more potent than comparator azetidine analogue <b>34</b>. A more dramatic increase in potency is observed on switching to 1,4-diazepane N-cyclobutyl <b>37a</b> (GTPγS IC<sub>50</sub> = 4.4 nM). Exploration of the spirocyclic 4-pyrrolidine core modification led to <b>41a</b> (GTPγS IC<sub>50</sub> = 32 nM), which was ∼4-fold more potent than spirocyclic 3-pyrrolidine matched pair <b>37b</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Spirofused Pyrrolidine and Piperidines with N Substituents</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0023.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Compounds were tested for activity at inhibiting agonist-stimulated [<sup>35</sup>S]GTPγS binding to membranes from CHO-K1 cells stably transfected with the long form of the H<sub>3</sub> receptor (445 amino acids). Results are an average of <i>n</i> > 2 with standard error <20%.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Values determined in CHO-K1-hERG cells using electrophysiological measurements.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">logD values between octanol and water, as determined by shake-flask HPLC methods. nm, not measured.</p></div></div><div></div></div><div class="NLM_p">For <b>29g</b>–<b>I</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), the N-cyclobutyl piperazine was held constant, and series of N-sulfonyl (<b>29g</b>), N-phenyl (<b>29h</b>), and N-benzoyl (<b>29i</b>) derivatives were made. All of these derivatives were less potent than N-tetrahydro-2<i>H</i>-pyran comparator <b>29b</b> by ∼10–30-fold, as measured in the GTPγS functional assay. The N-isopropyl 1,4-diazepane with the N-benzoyl attachment to the piperidine ring was prepared (<b>29j</b>) and demonstrated equal potency to N-tetrahydro-2<i>H</i>-pyran comparator <b>29e</b> (GTPγS IC<sub>50</sub> = 12 vs 14 nM). N-linked spirocyclic modifications such as azetidine, 3-pyrrolidine, 4-pyrrolidine, and 4-piperidine were next explored. Replacement of the N-tetrahydro-2<i>H</i>-pyran in <b>37a</b> with N-benzoyl <b>37c</b> gave a compound with equal potency (GTPγS IC<sub>50</sub> = 4.0 nM). Replacement of the N-benzoyl with N-phenylsulfonyl (<b>37d</b>) also led to a compound with similar potency (GTPγS IC<sub>50</sub> = 6.5 nM), suggesting a wide tolerance of functional groups with the 3-pyrrolidine-1,4-diazepane-N-cyclobutyl motif. Extension of the SAR with N-benzoyl, N-phenyl sulfonyl, and N-isopropylsulfonyl (<b>41b</b>, <b>41c</b>, and <b>41d</b>) led to compounds with single-digit nanomolar potency comparable to spirocyclic 3-pyrroldine matched pairs <b>37c</b> and <b>37d</b>. (N-isopropylsulfonyl was not made in the 3-pyrrolidine series.) Analogues <b>41e</b> and <b>41f</b> were made to explore the comparison of N-1,4-cyclobutyl piperazine to N-1,4-cyclobutyl diazepane with the N-benzoyl and N-phenylsulfonyl groups attached on the piperidine. The N-1,4-cyclobutyl piperazine was not as potent as the analogues with the diazepane ring (<b>41e</b>, GTPγS IC<sub>50</sub> = 13 nM and <b>41f</b>, GTPγS IC<sub>50</sub> = 21 nM compared with 3.6 and 2.6 nM for matched pairs with the diazepane ring). Compound <b>41g</b> was prepared to examine replacement of the piperazine ring with a piperidine ring. A significant drop in activity was observed (GTPγS IC<sub>50</sub> = 340 nM). The 4-piperidine right-hand side is expected to have less of a planar geometry than the corresponding piperazine ring, perhaps suggesting the importance of this as a spatial requirement. Finally, 4-spirocyclic piperidine ring core modification <b>41h</b> was prepared and demonstrated ∼6-fold drop in activity compared to 4-spirocyclic pyrrolidine analogue <b>41b</b>.</div><div class="NLM_p">Various molecular overlays were derived from conformations generated with molecular mechanics methods (see <a class="ref internalNav" href="#sec5_5" aria-label="Computational Spectral Simulations">Computational Spectral Simulations</a>) and were used to help to try to understand the topological features that may be essential for activity. Conessine was chosen as a useful benchmark (hH<sub>3</sub><i>K</i><sub>i</sub> binding = 5.4 nM, hH<sub>3</sub> (GTPγS) IC<sub>50</sub> = 11 nM)<a onclick="showRef(event, 'cit18b'); return false;" href="javascript:void(0);" class="ref cit18b">(18b)</a> given its structural rigidity and availability of an X-ray structure.<a onclick="showRef(event, 'cit18c'); return false;" href="javascript:void(0);" class="ref cit18c">(18c)</a> Compound <b>6s</b> (hH<sub>3</sub><i>K</i><sub>i</sub> binding = 0.8 nM, hH<sub>3</sub> IC<sub>50</sub> (GTPγS) = 8.3 nM) was found to have low-lying conformations with appropriately placed diamines that mapped well to the structure of Conessine (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a). Three other compounds were modeled (<b>29f</b>, <b>34</b>, and Bavisant; Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>b), and energetically reasonable conformers were found in each case to superimpose on one another. This set of structures highlights that even though a gross approximation of pharmacophore match can be gained from these types of analyses, the granularity of activity may not be easily discerned. For example, <b>34</b> is weakly active (hH<sub>3</sub><i>K</i><sub>i</sub> binding = 97 nM, hH<sub>3</sub> (GTPγS) IC<sub>50</sub> = 900 nM) compared to <b>29f</b> (<i>K</i><sub>i</sub> binding = 0.3 nM, hH<sub>3</sub> (GTPγS) IC<sub>50</sub> = 1.7 nM) and Bavisant (example of a potent, conformationally constrained clinical candidate with reported in vitro <i>K</i><sub>i</sub> binding = 5.4 nM).<a onclick="showRef(event, 'cit13f'); return false;" href="javascript:void(0);" class="ref cit13f">(13f)</a> The three structural overlays of these molecules can be found that show very little distinction. It is possible that either unanticipated electronic changes happen between the cyclobutyl and azetinde linkers or that further subtleties of the substantially large set of low-lying conformers exist, and simple overlays based only on access to low-lying conformations are not an accurate predictor of the bioactive conformation or potential excluded volume for this linker. Furthermore, the model would be most useful in predicting binding energetics and not functional activity because the protein conformational changes that must occur for a binding ligand to become a functional ligand are unknown. From a binding perspective, it may not be possible to distinguish potent binders (e.g., <b>29f</b><i>K</i><sub>i</sub> = 0.3 nM and <b>34</b><i>K</i><sub>i</sub> = 97 nM) with a simple conformational overlay approach. Rank ordering with this approach was not possible, but it did serve to help understand the general pharmacophore features within a loose-fit model.</div><figure id="fig2" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (left) Molecular overlays of Conesine (gray, small-molecule X-ray structure) and <b>6s</b> (purple, low-lying conformation). (right) Molecular overlays of <b>29f</b> (red), <b>34</b> (green), and Bavisant (light blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A subset of compounds was examined by in vitro DMPK profiling, which is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. All of the compounds tested had high solubility (>500 μM) and significant free-drug concentrations, as determined in both rat and human plasma protein binding assays (∼50–90% free in most cases). Most compounds demonstrated high permeability, as measured in the Madin-Darby canine kidney (MDCK) permeability assay, except for an occasional molecule, such as <b>6e</b>, which showed modest efflux and low permeability relative to other compounds. In general, most compounds were not significantly metabolized by rat or human microsomes, with many compounds measuring <4 μL/min/mg. Again, compound <b>6e</b> was an outlier, demonstrating relatively higher rat clearance (43 μL/min/mg). It is not clear why the pyrrolidine ring on the right-hand-side piperazine results in these modest changes on these properties. None of the compounds tested demonstrated any significant inhibition of cytochrome P450 enzymes in a representative panel (CYP2D6, CYP3A4, and CYP2C9). There was no observed difference between separated chiral isomers and racemic compounds in this panel of in vitro DMPK assays; thus, racemic compounds were tested for expediency. Measured logD values are reported in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. In general, the logD varied as expected. For example, the tetrahydropyran substituent contributed to low and sometimes negative logD values (e.g., <b>6s</b>, logD = −0.26 and <b>6i</b>, logD = −1.09), and hydrophobic substituents gave higher logD values (e.g., <b>29h</b> N-phenyl, logD = 3.25 and <b>29i</b> N-benzoyl, logD = 2.09). However, it did not appear that the increasing logD contributed substantially to any increased hERG liability or in vitro DMPK liability because most of the compounds, regardless of logD value, maintained low hERG and in vitro DMPK liabilities.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro DMPK</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">sol<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">hPPB<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">rPPB<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">MDCK perm<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">efflux<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">hClint<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">rClint<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">CYP 2D6 (IC<sub>50</sub>)<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></th><th class="colsep0 rowsep0" align="center">CYP 3A4 (IC<sub>50</sub>)<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></th><th class="colsep0 rowsep0" align="center">CYP 2C9 (IC<sub>50</sub>)<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="left">69</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">nm</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left"><2.2</td><td class="colsep0 rowsep0" align="left">>5.5</td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6l</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left"><1.7</td><td class="colsep0 rowsep0" align="left">>2.0</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nm</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6s</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29b</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">nm</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29f</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29g</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">8.3</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41d</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="left">6.0</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41e</b></td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">nm</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Equilibrium solubility (pH 7.4).</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Human plasma protein binding expressed as the percent free.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Rat plasma protein binding expressed as the percent free.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Permeability measured in MDCK cell lines (A to B <i>P</i><sub>app</sub> 1 × 10<sup>–6</sup> cm/s).</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Efflux as measured in MDCK cell lines (ratio of A-to-B <i>P</i><sub>app</sub> over B-to-A <i>P</i><sub>app</sub>).</p></div><div class="footnote" id="t4fn6"><sup>f</sup><p class="last">Human liver microsomal clearance expressed as μL/min/mg.</p></div><div class="footnote" id="t4fn7"><sup>g</sup><p class="last">Rat liver microsomal clearance expressed as μL/min/mg.</p></div><div class="footnote" id="t4fn8"><sup>h</sup><p class="last">In vitro inhibition of cytochrome P450 CYP2D6, CYP3A4, and CYP2C9 isoforms (IC<sub>50</sub> values).</p></div></div></div><div class="NLM_p">Compounds were profiled in a small panel of off-target receptors as well as against closely related histamine receptors. A sampling of some of these receptors is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Neither <b>29b</b> nor <b>6s</b> demonstrated activity against the other three histamine receptors (H<sub>1</sub>, H<sub>2</sub>, and H<sub>4</sub>) or other biogenic amine receptors sometimes seen with basic and hydrophobic motifs. Compound <b>6s</b> was further tested in expanded panel of 144 in vitro assays to assess any off-target liabilities (see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a> for panel list). The only hit from these screens was modest σ2 receptor activity for <b>6s</b> (62% at 10 μM), with the remainder below the defined criteria for activity for that particular assay at 10 μM single-concentration testing. Compound <b>6s</b> was also found to be inactive in an Ames mutagenicity screen as well as in a phospholipidosis assay (EC<sub>50</sub> >300 μM).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Phospholipidosis (PLD) is a concern among the lipophilic basic amine scaffolds prominent in the H<sub>3</sub> field<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and has been extensively studied by the J&J group. As an example, compounds such as JNJ-5207852 can be predicted on the basis of their in vitro PLD values to predict in vivo PLD findings.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The logD was measured for <b>6s</b> and found to be −0.26, which was consistent with many compounds in the dibasic series. Representative logD values are recorded in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. It was speculated that the low logD in the dibasic motif gave rise to the lack of activity in the PLD assay; however, compounds of higher logD were not tested in the PLD assay, which would have provided a stronger basis for this hypothesis. On the basis of the positive in vitro DMPK and off-target profile, compounds <b>29b</b> and <b>6s</b> were followed up with in vivo studies.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Representative Off-Target Activity</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><b>29b</b> (activity at 10 μM)</th><th class="colsep0 rowsep0" align="center"><b>6s</b> (activity at 10 μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H<sub>1</sub></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H<sub>2</sub></td><td class="colsep0 rowsep0" align="center">nt</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H<sub>4</sub></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A2a</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT1A</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NAchE</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NET</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M<sub>2</sub></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2</sub></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GABA</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE<sub>4</sub></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Representative binding values at 10 μM concentration against a sampling of targets (Ricerca testing laboratories).</p></div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pharmacokinetics</h3><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> summarizes the in vivo pharmacokinetic (PK) data on six representative compounds. All of the dibasic compounds (including <b>6s</b> mentioned earlier) had very high volumes of distribution and long half-lives. For example, <b>29b</b> and <b>29f</b> had calculated volumes of distribution of 74 and 64 L/kg, respectively, with half-lives >10 h. For those compounds with this profile, the long half-life did not allow for precise characterization of the volume of distribution. Compound <b>6s</b> demonstrated the lowest rate of clearance of the three dibasic compounds by a factor of ∼4. The monobasic compounds, such as <b>29g</b>, <b>41d</b>, and <b>41e</b>, all demonstrated much lower half-lives and volumes of distribution (e.g., <b>29g</b><i>V</i><sub>ss</sub> 1.44 L/kg and <i>t</i><sub>1/2</sub> = 0.40) but had higher rates of clearance than <b>6s</b>. The high volume of distribution and long half-life for dibasic compounds has been reported in the H<sub>3</sub> area; for example, JNJ 5207852 is reported to have similar characteristics.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo DMPK and PK Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Clint (mL/min/kg)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>n</i><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">dose (μmol/kg)<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">charge<a class="ref internalNav" href="#t6fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6s</b></td><td class="colsep0 rowsep0" align="left">34.6 ± 1.5</td><td class="colsep0 rowsep0" align="left">25.3 ± 0.6</td><td class="colsep0 rowsep0" align="left">16.4 ± 0.8</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">dibasic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29b</b></td><td class="colsep0 rowsep0" align="left">74.0 ± 9.1</td><td class="colsep0 rowsep0" align="left">14.2 ± 3.9</td><td class="colsep0 rowsep0" align="left">81.2 ± 17.6</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">dibasic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29f</b></td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">11.7</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">dibasic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29g</b></td><td class="colsep0 rowsep0" align="left">1.4 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="left">69.8 ± 5.6</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">monobasic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41d</b></td><td class="colsep0 rowsep0" align="left">2.1 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.6 ± 0.1</td><td class="colsep0 rowsep0" align="left">53 ± 0.9</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">monobasic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41e</b></td><td class="colsep0 rowsep0" align="left">3.7 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="left">91 ± 3.7</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">monobasic</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Mean volume of distribution measured after IV dosing in male fasted rats.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Mean half-life as measured from IV dosing in rats.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Mean clearance as measured from IV dosing in rats.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Number of rats used in the experiment.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Dose administered.</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">Number of predicted basic groups.</p></div></div></div><div class="NLM_p">A more comprehensive evaluation of pharmacokinetics and central nervous system (CNS) penetration of test compound <b>6s</b> was completed in male Sprague–Dawley rats (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The plasma clearance calculated on the basis of area under the curve (AUC) from 0–24 h was high at 53 mL/min/kg. This represents an overestimate of the true clearance, which is likely to be in the moderate range but would require longer sampling times to characterize fully. The volume of distribution was very high and the apparent half-life was long at 15 h, but these parameters could not be precisely characterized with confidence using a 24 h sampling protocol. The oral bioavailability, estimated on the basis of comparison of the AUC (0–10 h) following IV and oral administration, was high at 99%. Approximately 14% of the dose was recovered in the urine during the first 24 h following intravenous bolus administration. Compound <b>6s</b> distributed into the CNS as demonstrated by a brain/plasma ratio of 3.0 and cerebrospinal fluid (CSF)/plasma ratio of 0.19 (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>).</div><figure id="fig3" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plasma concentrations and arterial pharmacokinetic parameters of <b>6s</b> following a 3 μmol/kg IV (fasted rats) dose and 3 μmol/kg PO (fed rats) dose in male Sprague–Dawley rats using a crossover study design with a PO formulation of 10% DMA and 18% SBECD, pH 4.73.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vivo DMPK Brain and Plasma Concentrations</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">plasma (nM)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Brain (nmol/kg)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">CSF (nM)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Br/Pl<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Cpd<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (nM)<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">%F<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6s</b>, IV, <i>n</i> = 4</td><td class="colsep0 rowsep0" align="left">180 ± 40</td><td class="colsep0 rowsep0" align="left">540 ± 120</td><td class="colsep0 rowsep0" align="left">34 ± 6</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.7</td><td class="colsep0 rowsep0" align="left"><b>6s</b>, PO<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a>, <i>n</i> = 3</td><td class="colsep0 rowsep0" align="left">71 ± 9.7</td><td class="colsep0 rowsep0" align="left">6.0</td><td class="colsep0 rowsep0" align="left">99 ± 18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Sample taken after 1 h, IV dose (3 μmol/kg).</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Average plasma concentrations after 1 h with standard devation. Average brain concentration reported with standard deviation. Brain concentrations are not corrected for vascular contamination of ∼2–3%. Nonspecific binding during CSF sampling was not evaluated.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Brain/plasma ratio.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Oral route of administration with <i>n</i> = number of animals, details described in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">3 μmol/kg, 1:9 ratio of 10% DMA to 90% SBECD, pH 4.73, as vehicle.</p></div><div class="footnote" id="t7fn6"><sup>f</sup><p class="last">Maximal concentration of oral dose.</p></div><div class="footnote" id="t7fn7"><sup>g</sup><p class="last">Percent oral bioavailability.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vivo Efficacy</h3><div class="NLM_p">Compound <b>6s</b> was tested for activity in a mouse model of learning and recognition memory.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Briefly, male CF-1 mice were placed in a test environment that contained two identical objects and were allowed to explore the environment (acquisition phase). The mice were removed from the environment, and one of the objects was replaced with a novel object. Fifteen minutes later, the mice were returned to the test environment and monitored for time spent exploring the novel object versus the familiar object. A ratio of novel to familiar interaction was produced where a score of 50% (1:1) would equate to a random (no preference) interaction. The compound (<b>6s</b>) significantly increased novel object exploration relative to vehicle treatment in mice dosed with 1, 3, or 10 mg/kg (s.c.) 60 min prior to the acquisition phase (<i>p</i> < 0.01, 0.05, and 0.05, respectively, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Even though the compound had excellent oral bioavailability, the dosing for this efficacy test was routinely run with subcutaneous administration (s.c.) to stay consistent with the protocol established for other compounds.</div><figure id="fig4" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>6s</b> significantly increased novel object exploration 30 min after acquisition relative to vehicle treatment in mice dosed with 1, 3, and 10 mg/kg 60 min prior to acquisition (<i>p</i> < 0.01, 0.05, and 0.05 respectively). All data are mean ± SD ratio of novel/familiar object interaction. Analysis was performed on manual assessment of interaction scores using ANOVA followed by Newman–Keuls posthoc analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have identified a potent and selective series of H<sub>3</sub> antagonists originating from the azaspiro[2.5]octane carboxamide scaffold. Modifications of the spirocyclic core to spirocyclobutyl, 3- and 4-pyrrolidine, and 4-piperidine were largely tolerated. These molecules possess favorable off-target profiles for both secondary pharmacology as well as favorable in vitro DMPK properties. It has been our experience that basic lipophilic amines tend to have multiparameter undesirable SAR (off-target selectivity, microsomal clearance, phospholipidosis, etc.) that often tracks with the primary and desired pharmacology. To optimize to the primary pharmacology, significant chemistry resources are often employed to try to separate the desired functional activity from the undesired activity. We have found that this scaffold, as exemplified by <b>6s</b>, lacked many of these undesirable features. This may be due in part to the lack of aromatic rings or perhaps the low logD (e.g., <b>6s</b> = −0.26, measured logD). An exemplar compound from the spirocyclic cyclopropanes, <b>6s</b>, demonstrated high brain exposures, high oral bioavailability, and efficacy in a mouse novel object recognition study. The high volumes of distribution and long half-lives of the dibasic compounds provide a significant challenge in both interpretation of PK data and prediction of pharmacodynamic (PD) response. Because the H<sub>3</sub> receptor is hypothesized to be involved in wakefulness, this may present a liability as the compound also possesses high CNS exposure with an exceptionally long half-life. The monobasic compounds provide a very different PK profile with shorter half-lives and lower volumes of distribution that potentially may have better alignment with the intended indication. Compounds from both of these subtypes should provide useful starting points and tools to investigate further the importance of selective H<sub>3</sub> antagonists for drug therapy in a variety of potential disease states.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Experimental</h3><div class="NLM_p last">Proton magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Bruker Avance DPX 300 or 500 MHz spectrometer, and the chemical shifts are reported in parts per million (δ) from a tetramethylsilane (TMS) internal standard. The MS detection was performed with a Micromass Platform ZMD or LCZ spectrometers using the indicated ionization method. High-resolution mass spectra were recorded on an Agilent Technologies 6210 time-of-flight LC–MS spectrometer. Chemical purities of final compounds were determined to be >95% as determined by HPLC-MS analysis at UV 220 nm. Unless otherwise indicated, all starting materials were obtained from commercial suppliers. Preparatory HPLC procedure A: Preparatory HPLC was conducted using a 21 × 150 mm, 5 μm Gemini C18 column at pH 10 [0.125 M ammonium bicarbonate] with ACN/H<sub>2</sub>O as the mobile phase (solvent flow was 50 mL/min and a gradient from 10% acetonitrile to 93% acetonitrile over 33 min). Preparatory HPLC procedure B: Preparative HPLC was conducted using a long, high pH, shallow gradient method. The mobile phase was as follows: 30–50% B; A: H<sub>2</sub>O with 15 mM ammonium bicarbonate and 0.375% NH<sub>4</sub>OH v/v, B: CH<sub>3</sub>CN. The run was 25 min on XBridge Prep C18 OBD, 30 × 150 mm, Waters reverse-phase column. Preparatory HPLC procedure C: Preparative HPLC was conducted using normal-phase HPLC (mobile phase: CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH, flow: 16 mL/min, 40 g column, gradient running from 100:0:1 to 80:20:1 over 1 h). Analytical HPLC procedure D: Analytical HPLC used a high pH gradient method (mobile phase: 5–95% B; A: H<sub>2</sub>O with 10 mM NH<sub>4</sub>CO<sub>3</sub> and 0.375% NH<sub>4</sub>OH v/v, B: MeOH, 2.25 min run) on X-Bridge C18, 2.1 × 30 mm, 5 μm particle size. Compounds <b>6a</b>–<b>g</b>, <b>6j</b>–<b>m</b>, <b>6o</b>–<b>r</b>, and <b>6s</b> have been described in a previous patent application by our group, and experimental details are included below.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> All final compounds were isolated in >95% purity as judged by LC–MS. Conformations of compounds <b>6s</b>, <b>29f</b>, <b>34</b>, and Bavisant were generated via Monte Carlo searching with the OPLS95 force field in a continuum water model as implemented in MacroModel.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Molecular overlays comparing these conformational sets to the small-molecule X-ray structure of Conessine were produced using shape and chemical feature matching with ROCS.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Default settings and parameters were used throughout the calculations.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Benzyl 4-Methylenepiperidine-1-carboxylate (<b>2</b>)</h3><div class="NLM_p last">A solution of methyltriphenylphosphonium bromide (88.2 mmol, 31.5 g) was cooled in 600 mL of THF to 0 °C. To this solution, <i>n</i>-BuLi (2.5M, in hexanes, 35.3 mL, 1.2 equiv) was slowly added whereupon a precipitate gradually formed, and the reaction turned reddish-orange in color. The reaction was stirred for 1 h at 0 °C, at which point benzyl 4-oxopiperidine-1-carboxylate <b>1</b> was added (73.5 mmol, 17.1 g, in 30 mL THF), and the reaction was stirred for an additional 1 h at 0 °C. The volatiles were removed under reduced pressure, and the reaction mixture was poured onto a pad of SiO<sub>2</sub> and flushed with a 4:1 mixture of hexanes/EtOAc. The product was purified via column chromatography (SiO<sub>2</sub>, hexanes/EtOAc) as a clear oil (9.11 g, 54%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.23 (t, <i>J</i> = 5.7 Hz, 4H), 3.53 (t, <i>J</i> = 5.9 Hz, 4H), 4.78 (s, 2H), 5.17 (s, 2H), 7.30–7.39 (m, 5H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 232.1.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 6-Benzyl 1-Ethyl 6-Azaspiro[2.5]octane-1,6-dicarboxylate (<b>3</b>)</h3><div class="NLM_p last">Benzyl 4-methylenepiperidine-1-carboxylate <b>2</b> (39.6 mmol, 9.17 g) was dissolved in 1300 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> followed by the addition of CuCN (39.6 mmol, 3.54 g), and the reaction was stirred at room temperature. Ethyl diazoacetate (87.2 mmol, 9.17 mL) was dissolved in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> and slowly added (0.2 mL/h, over roughly 100 h). The solution was filtered through SiO<sub>2</sub>, and the volatiles were removed. The residue was purified via column chromatography (100% hexanes to 4:1 hexanes/EtOAc) to give the title compound as a clear oil (5.68 g, 45% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.95 (dd, <i>J</i> = 8.0, 4.6 Hz, 1H), 1.20 (t, <i>J</i> = 5.0 Hz, 1H), 1.28 (t, <i>J</i> = 7.1 Hz, 3H), 1.42–1.48 (m, 2H), 1.56–1.61 (m, 1H), 1.69–1.76 (m, 2H), 3.33–3.41 (m, 1H), 3.49–3.65 (m, 3H), 4.16 (q, <i>J</i> = 8.4 Hz, 2H), 5.16 (s, 2H), 7.35–7.38 (m, 5H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 318.2.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<i>R</i>)-6-Benzyl 1-Ethyl 6-Azaspiro[2.5]octane-1,6-dicarboxylate (<b>3a</b>)</h3><div class="NLM_p last">The material was purified by chiral supercritical fluid chromatography (SFC, AD column with MeOH and 0.1% dimethyl ethlyl amine, isocratic at 35%, 10 mL/min, main eluent CO<sub>2</sub>, column temperature 35 °C) to give the title compound with quantitative recovery (<i>t</i><sub>R</sub> = 2.67 min). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>-<i>d</i>) δ 0.94 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 1.18 (t, <i>J</i> = 4.8 Hz, 1H), 1.27 (t, <i>J</i> = 7.2 Hz, 3H), 1.44 (br s, 2H), 1.57 (dd, <i>J</i> = 7.8, 5.4 Hz, 1H), 1.73 (br s, 2H), 3.30–3.41 (m, 1H), 3.47–3.66 (m, 3H), 4.14 (q, <i>J</i> = 7.16 Hz, 2H), 5.14 (s, 2H), 7.29–7.35 (m, 1H), 7.35–7.40 (m, 4H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>23</sub>NO<sub>4</sub> (M + H)<sup>+</sup>, 318.1699; found, 318.1695. [α]<sub>D</sub><sup>20</sup> = −70.4 (<i>c</i> 2.490, MeOH).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>S</i>)-6-Benzyl 1-Ethyl 6-Azaspiro[2.5]octane-1,6-dicarboxylate (<b>3b</b>)</h3><div class="NLM_p last">The material was purified by chiral SFC chromatography as in <b>3a</b> to give the title compound with quantitative recovery (<i>t</i><sub>R</sub> = 2.43 min). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>-<i>d</i>) δ 0.94 (dd, <i>J</i> = 8.2, 4.7 Hz, 1H), 1.18 (t, <i>J</i> = 4.88 Hz, 1H), 1.27 (t, <i>J</i> = 7.2 Hz, 3H), 1.44 (br s, 2H), 1.57 (dd, <i>J</i> = 8.2, 5.5 Hz, 1H), 1.72 (br s, 2H), 3.30–3.42 (m, 1H), 3.47–3.66 (m, 3H), 4.14 (q, <i>J</i> = 7.3 Hz, 2H), 5.14 (s, 2 H), 7.30–7.35 (m, 1H), 7.35–7.41 (m, 4H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>23</sub>NO<sub>4</sub> (M + H)<sup>+</sup>, 318.1699; found, 318.1699. [α]<sub>D</sub><sup>20</sup> = +71.7 (<i>c</i> 2.306, MeOH).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Ethyl 6-Azaspiro[2.5]octane-1-carboxylate (<b>4</b>)</h3><div class="NLM_p last">To 6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate <b>3</b> (6.45 g, 20.3 mmol) in ethanol (100 mL) was added 5% Pd/C (0.65 g, 0.30 mmol), and a balloon filled with hydrogen was placed on top of the reaction. The reaction was left to stir at room temperature overnight. The mixture was filtered through Celite, and the solvent was removed under reduced pressure. The resulting oil was placed under high vacuum. The crude material was chromatographed (SiO<sub>2</sub> 100 g, 5–10% gradient of 7 N NH<sub>3</sub>/MeOH in CH<sub>2</sub>Cl<sub>2</sub>). The solvent was removed from the combined fractions under reduced pressure to give title compound <b>4</b> (1.83g, 44%) as an amber oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.87 (dd, <i>J</i> = 8.0, 4.4 Hz, 1H), 1.13 (t, <i>J</i> = 4.9 Hz, 1H), 1.27 (t, <i>J</i> = 7.1 Hz, 3H), 1.41 (q, <i>J</i> = 5.2 Hz, 2H), 1.48–1.52 (m, 2H), 1.66–1.71 (m, 2H), 2.70–2.78 (m, 1H), 2.81–2.85 (m, 1H), 2.89 (t, <i>J</i> = 5.4 Hz, 2H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 184.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>R</i>)-Ethyl 6-Azaspiro[2.5]octane-1-carboxylate (<b>4a</b>)</h3><div class="NLM_p last">The procedure was identical to <b>4b</b> except (<i>R</i>)-6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate <b>3a</b> was used to give the title compound in 59% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.88 (dd, 1H), 1.09–1.16 (m, 1H), 1.27 (t, <i>J</i> = 7.0 Hz, 3H), 1.34–1.47 (m, 2H), 1.50 (dd, <i>J</i> = 7.8, 5.4 Hz, 1H), 1.58 (br s, 1H), 1.61–1.76 (m, 2H), 2.68–2.79 (m, 1H), 2.80–2.87 (m, 1H), 2.89 (t, <i>J</i> = 5.8 Hz, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H). [α]<sub>D</sub><sup>20</sup> = −115.1 (<i>c</i> 1.285, MeOH). Stereochemistry assigned as (<i>R</i>) based on calculated and observed VCD spectra (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>S</i>)-Ethyl 6-Azaspiro[2.5]octane-1-carboxylate (<b>4b</b>)</h3><div class="NLM_p">A mixture of (<i>S</i>)-6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate <b>3b</b> (0.50 g, 1.58 mmol), Pd/C (5%, 8.38 mg, 0.08 mmol), and ethanol (31.5 mL) was shaken overnight in a Parr apparatus under a 20 psi atmosphere of hydrogen. The mixture was filtered over a Celite pad, and the solvent was concentrated. The residue was loaded over a small SiO<sub>2</sub> pad using CH<sub>2</sub>Cl<sub>2</sub> and was purified by gravity filtration using CH<sub>2</sub>Cl<sub>2</sub> first to elute the yellow colored impurity and then using 5% MeOH, 10% acetone in CH<sub>2</sub>Cl<sub>2</sub> to give the title compound as a colorless liquid (0.23 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.89 (dd, <i>J</i> = 7.8, 4.3 Hz, 1H), 1.13 (t, <i>J</i> = 4.8 Hz, 1H), 1.27 (t, <i>J</i> = 6.8 Hz, 3H), 1.44 (dd, <i>J</i> = 9.3,4.7 Hz, 2H), 1.51 (dd, <i>J</i> = 7.8, 5.4 Hz, 1H), 1.64–1.79 (m, 2H), 2.34 (br s, 1H), 2.70–2.80 (m, 1H), 2.83–2.89 (m, 1H), 2.91 (t, <i>J</i> = 5.2 Hz, 2H), 4.14 (q, <i>J</i> = 6.7 Hz, 2H). [α]<sub>D</sub><sup>20</sup> = +106.8 (<i>c</i> 1.367, MeOH). Stereochemistry was assigned as (<i>S</i>) based on calculated and observed VCD spectra (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. VCD Spectra of the Boltzmann-weighted average of the computed VCD spectra along with the experimental spectra for <b>4b</b> (<i>S</i>) and <b>4a</b> (<i>R</i>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Ethyl 6-(Tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octane-1-carboxylate (<b>5</b>)</h3><div class="NLM_p last">To ethyl 6-azaspiro[2.5]octane-1-carboxylate <b>4</b> (1.85 g, 10.0 mmol) in 1,2-dichloroethane (25 mL) was added dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (1.00 mL, 11.0 mmol), and the solution was stirred 25 min. To this was added sodium triacetoxyborohydride (2.50 g, 12.1 mmol), and the reaction was left to stir at room temperature. After 5 h, the reaction was partitioned between EtOAc and NaHCO<sub>3</sub> (aq. sat.). The organic layer was removed, and the solvent was evaporated to give a pale oil. The material was chromatographed on SiO<sub>2</sub> (50 g, 7 N NH<sub>3</sub>/MeOH in CH<sub>2</sub>Cl<sub>2</sub>), and the combined purified fractions were removed of solvent to give the title compound (1.82 g, 64%) as a pale oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.87 (dd, <i>J</i> = 8.0, 4.5 Hz, 1H), 1.12 (t, <i>J</i> = 4.9 Hz, 1H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H), 1.47–1.52 (m, 3H), 1.56–1.65 (m, 2H), 1.72–1.78 (m, 4H), 2.39–2.61 (m, 5H), 3.37 (td, <i>J</i> = 11.7, 2.1 Hz, 2H), 4.02 (dd, <i>J</i> = 11.5, 4.5 Hz, 2H), 4.13 (q, <i>J</i> = 7.0 Hz, 2H). <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 268.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (4-Methylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6a</b>)</h3><div class="NLM_p last">The material was made in an analogous fashion to compound <b>6d</b> using 1-methylpiperiazine as the starting material to give the title compound in 45% yield. The material was converted to the citrate salt. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.71–0.75 (m, 1H), 1.26 (t, <i>J</i> = 4.7 Hz, 1H), 1.32–1.51 (m, 2H), 1.55–1.82 (m, 8H), 2.28 (s, 3H), 2.38–2.66 (m, 6H), 2.67–2.78 (m, 1H), 3.39 (td, <i>J</i> = 11.7, 1.8 Hz, 2H), 3.46–3.60 (m, 2H), 3.66 (t, <i>J</i> = 4.7 Hz, 2H), 3.72–3.84 (m, 1H), 4.04 (dd, <i>J</i> = 11.1, 4.0 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 322.2489; found, 322.2499.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (4-Isopropylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6b</b>)</h3><div class="NLM_p last">This example was prepared according to the procedure for compound <b>6d</b> using commercially available 1-isopropylpiperazine. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.71 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 1.04 (d, <i>J</i> = 6.5 Hz, 6H), 1.24 (t, <i>J</i> = 4.8 Hz, 1H), 1.36–1.47 (m, 2H), 1.58–1.67 (m, 5H), 1.69–1.76 (m, 2H), 2.39–2.59 (m, 8H), 2.68–2.73 (m, 2H), 3.37 (t, <i>J</i> = 11.6 Hz, 2H), 3.51 (m, 1H), 3.63 (s, 2H), 3.76 (m, 1H), 4.02 (dd, <i>J</i> = 11.3, 4.3 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>35</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 350.2802; found, 350.2799.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (4-Cyclopropylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6c</b>)</h3><div class="NLM_p last">This example was prepared according to the procedure for compound <b>6d</b> using commercially available 1-cyclopropylpiperiazine. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.41–0.45 (m, 2H), 0.46–0.50 (m, 2H), 0.69–0.73 (m, 1H), 1.24 (t, <i>J</i> = 4.8 Hz, 1H), 1.35–1.46 (m, 2H), 1.57–1.66 (m, 5H), 1.69–1.76 (m, 3H), 2.43–2.72 (m, 9H), 3.37 (t, <i>J</i> = 11.2 Hz, 2H), 3.49 (m, 1H), 3.59 (s, 2H), 3.69 (m, 1H), 4.02 (dd, <i>J</i> = 11.1, 4.1 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 348.2646; found, 348.2654.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (4-Cyclobutylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6d</b>)</h3><div class="NLM_p last">To ethyl 6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octane-1-carboxylate <b>5</b> (1.82 g, 6.81 mmol) were added MeOH (25 mL), 1 N LiOH (7.20 mL, 7.20 mmol), and water (1 mL). The cloudy reaction was left to stir at room temperature. After 5 h, 1 N NaOH (7.2 mL, 7.2 mmol) and 20 mL MeOH were added, and the reaction was stirred at room temperature. After 2 h, solid NaOH (290 mg, 7.3 mmol) was added followed by 5 mL of THF, and the cloudy reaction was stirred overnight. The reaction was then heated to reflux for 2 h, and the solvent was removed under reduced pressure. The gummy residue was dissolved in 15 mL of water, and the pH was adjusted to ∼6 by adding 6 N HCl (3.8 mL). The water was removed under reduced pressure, and residual water was removed from the resulting material by azeotropic distillation with MeOH. The addition and subsequent removal of methanol under reduced pressure was performed several times, and the resulting pale yellow solid was put under high vacuum. To this was added 15 mL of MeOH, and the solution was decanted from the insoluble material. The solvent was removed under reduced pressure to give 2.45 g of crude 6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octane-1-carboxylic acid, which was used as is without further purification (∼quan. recovery). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 240. To the intermediate acid (150 mg, 0.63 mmol) were added HBTU (238 mg, 0.63 mmol), DMF (2.0 mL), and DIPEA (0.328 mL, 1.88 mmol), and the reaction was stirred for 5 min. In a separate vial, 1-cyclobutylpiperazine to (160 mg, 0.75 mmol), DMF (1.0 mL), and DIPEA (0.263 mL, 1.50 mmol) were combined. This solution was added to the first reaction, and the yellow solution was stirred at room temperature. After 1.5 h, the reaction was diluted with EtOAc (5 mL), and the organic layer was separated. The aqueous layer was washed three times with CH<sub>2</sub>Cl<sub>2</sub> and combined with the first organic layer. The organics were washed three times with saturated NaHCO<sub>3</sub> and twice with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure, and the residue was put under high vacuum. The crude material was chromatographed on 20 g silica with 10% (7 N NH<sub>3</sub>/MeOH)/CH<sub>2</sub>Cl<sub>2</sub>, and the combined purified fractions removed of solvent under reduced pressure. The solid was triturated with Et<sub>2</sub>O, and the resulting precipitate was collected by filtration to give the title compound (77 mg, 34%) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.71 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 1.24 (t, <i>J</i> = 4.8 Hz, 1H), 1.35–1.45 (m, 2H), 1.56–1.75 (m, 9H), 1.84–1.92 (m, 2H), 2.01–2.07 (m, 2H), 2.18–2.62 (m, 8H), 2.67–2.76 (m, 2H), 3.37 (t, <i>J</i> = 11.2 Hz, 2H), 3.52 (m, 1H), 3.64 (t, <i>J</i> = 4.7 Hz, 2H), 3.75 (m, 1H), 4.02 (dd, <i>J</i> = 11.2, 4.1 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>35</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 362.2802; found, 362.2808.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (4-Cyclopentylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6e</b>)</h3><div class="NLM_p last">This example was prepared in an analogous fashion to compound <b>6d</b> using 1-cyclopentylpiperazine dihydrochloride.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.71 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 1.24 (t, <i>J</i> = 4.8 Hz, 1H), 1.37–1.48 (m, 3H), 1.55–1.76 (m, 12H), 1.83–1.88 (m, 2H), 2.36–2.62 (m, 9H), 2.70–2.74 (m, 1H), 3.37 (t, <i>J</i> = 11.0 Hz, 2H), 3.52 (m, 1H), 3.65 (t, <i>J</i> = 4.8 Hz, 2H), 3.76 (m, 1H), 4.03 (dd, <i>J</i> = 11.3, 4.1 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 376.2959; found, 376.2957.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (4-Cyclohexylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6f</b>)</h3><div class="NLM_p last">Piperazin-1-yl(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone <b>11</b> (0.36 mmol, 0.19 g), cyclohexanone (1.08 mmol, 0.11 mL), 3 drops of glacial acetic acid, and polystyrylmethyl trimethylammonium cyanoborohydride (0.70 mmol, 0.19 g, 4.1 mmol/g of resin) were slurried in 20 mL of CH<sub>2</sub>Cl<sub>2</sub> and stirred overnight at room temperature. The solution was filtered through a nylon filter, and the volatiles were removed. The residue was purified via column chromatography, and the product was eluted with CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> containing 10% (2 M NH<sub>3</sub>/MeOH) on SiO<sub>2</sub> over 30 min. The product was isolated as a white solid (92 mg, 66% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.61–0.65 (m, 1H), 0.95–0.98 (m, 1H), 1.07–1.22 (m, 6H), 1.30–1.55 (m, 6H), 1.55–1.82 (m, 6H), 2.25–2.58 (m, 11H), 3.22–3.29 (m, 2H), 3.58–3.64 (m, 3H), 3.84–3.89 (m, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>40</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 390.3115; found, 390.3115.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (4-Cycloheptylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6g</b>)</h3><div class="NLM_p last">This example was prepared according to the procedure for compound <b>6d</b> using commercially available 1-cycloheptylpiperazine. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.70 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 1.24 (t, <i>J</i> = 4.8 Hz, 1H), 1.37–1.82 (m, 21H), 2.39–2.60 (m, 9H), 2.67–2.71 (m, 1H), 3.37 (t, <i>J</i> = 11.7 Hz, 2H), 3.46 (m, 1H), 3.65 (s, 2H), 3.76 (m, 1H), 4.02 (dd, <i>J</i> = 11.2, 4.1 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>41</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 404.3272; found, 404.3278.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (4-Cyclobutyl-1,4-diazepan-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6h</b>)</h3><div class="NLM_p last">To a solution of 6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octane-1-carboxylic acid (0.10 g, 0.42 mmol) in DMF (2 mL) were added HOBT (0.096 g, 0.63 mmol), 1-cyclobutyl-1,4-diazepane dihydrochloride (0.11 g, 0.50 mmol), DIPEA (0.15 mL, 0.84 mmol), and EDCI (0.12 g, 0.63 mmol) followed by DMF (2.0 mL). The reaction was then stirred overnight at room temperature. The solvent was removed, and residual material was purified with preparatory HPLC procedure A to provide the title compound as a white solid (0.15, 46%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.70 (dd, <i>J</i> = 10.0, 5.0 Hz, 1H), 1.25–1.27 (m, 2H), 1.47–1.48 (m, 1H), 1.58–1.63 (m, 9H), 1.74–1.92 (m, 6H), 2.00–2.03 (m, 2H), 2.27–2.31 (m, 2H), 2.46–2.49 (m, 2H), 2.61–2.63 (m, 2H), 2.72–2.74 (m, 1H), 2.84 (quin, <i>J</i> = 10.0 Hz, 1H), 3.37 (t, <i>J</i> = 10.0 Hz, 2H), 3.75–3.57 (m, 4H), 4.02 (dd, <i>J</i> = 10.0 Hz, 5.0 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 376.2958; found, 376.2963.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (4-(Pyridin-4-yl)piperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6i</b>)</h3><div class="NLM_p last">The material was prepared in a similar fashion to compound <b>6d</b> beginning with 1-(pyridin-4-yl)piperazine (0.09 g, 21%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.79 (dd, <i>J</i> = 8.0, 4.8 Hz, 1H), 1.29 (t, <i>J</i> = 4.7 Hz, 1H), 1.32–1.42 (m, 1H), 1.42–1.53 (m, 1H), 1.53–1.74 (m, 4H), 1.74–1.95 (m, 3H), 2.37–2.60 (m, 3H), 2.60–2.69 (m, 1H), 2.69–2.81 (m, 1H), 3.26–3.51 (m, 6H), 3.67–3.91 (m, 4H), 4.03 (dd, <i>J</i> = 11.1, 4.1 Hz, 2H), 6.67 (d, <i>J</i> = 6.2 Hz, 2H), 8.33 (d, <i>J</i> = 5.1 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>32</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 385.2598; found, 385.2595.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (6-Cyclobutyl-6-azaspiro[2.5]octan-1-yl)(4-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazin-1-yl)methanone (<b>6j</b>)</h3><div class="NLM_p last">To benzyl 1-(4-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate <b>12</b> (0.10 g, 0.23 mmol) were added MeOH (1.0 mL), Pd/C (4.82 mg, 4.53 μmol), oven-dried 3 Å powdered molecular sieves, and cyclobutanone (0.04 mL, 0.45 mmol), and a balloon filled with H<sub>2</sub> (excess) was fixed atop the reaction. This was stirred overnight. The reaction was filtered, the solvent was removed, and the clear gum was put under high vacuum. The material was purified by reverse-phase HPLC using procedure A. The fractions were collected, and the solvent was removed, and the residue was dried under high vacuum to give the title compound (0.08 g, 46%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.71 (m, 1H), 0.88 (M, 1H), 1.24 (t, <i>J</i> = 4.5 Hz, 1H), 1.39–1.49 (m, 2H), 1.60–1.75 (m, 7H), 1.86–1.90 (m, 2H), 2.01–2.09 (m, 2H), 2.13–2.29 (m, 2H), 2.58–2.62 (m, 5H), 2.63–2.67 (m, 2H), 2.69–2.72 (m, 2H), 2.73–2.86 (m, 1H), 3.35 (t, <i>J</i> = 11.5 Hz, 2H), 3.60–3.63 (m, 2H), 3.77–3.79 (m, 1H), 4.00 (d, <i>J</i> = 11.5 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 362.2802; found, 362.2801.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (4-Cyclohexylpiperazin-1-yl)(6-azaspiro[2.5]octan-1-yl)methanone (<b>6k</b>)</h3><div class="NLM_p last">To benzyl 1-(4-cyclohexylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (3.21 g, 7.30 mmol) in MeOH (25 mL) was added 5% Pd/C (0.31 g, 0.15 mmol), and a balloon of hydrogen was fixed atop the reaction. The reaction was stirred at room temperature. After 2 h, the reaction was filtered through Celite and concentrated. The filtrate was removed of solvent, and the residual white solid was put under high vacuum to give the title compound (2.12 g, 95%). The material was used without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.71–0.75 (m, 1H), 1.10–1.40 (m, 8H), 1.56–1.58 (m, 5H), 1.76–1.85 (m, 4H), 2.26–2.29 (m, 1H), 2.43–2.46 (m, 1H), 2.52–2.57 (m, 2H). 2.64–2.66 (m, 1H), 2.74–2.79 (m, 2H), 2.80–2.94 (m, 2H), 3.46–3.49 (m, 1H), 3.60–3.65 (m, 2H), 3.75–3.78 (m, 1H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>31</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 306.2539; found, 306.2542.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (6-Cyclohexyl-6-azaspiro[2.5]octan-1-yl)(4-cyclohexylpiperazin-1-yl)methanone (<b>6l</b>)</h3><div class="NLM_p last">The title compound was prepared in analogous fashion to compound <b>6b</b> (0.03 g, 25%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.68–0.69 (m, 1H), 1.23–1.30 (m, 10H), 1.39–1.44 (m, 2H), 1.57–1.60 (m, 6H), 1.81–1.84 (m, 8H), 2.43–2.48 (m, 2H), 2.55–2.59 (m, 6H), 2.64–2.66 (m, 2H), 3.44–3.47 (m, 1H), 3.60–3.63 (m, 2H), 3.73–3.75 (m, 1H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>41</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 388.3322; found, 388.3328.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (4-Cyclohexylpiperazin-1-yl)(6-isopropyl-6-azaspiro[2.5]octan-1-yl)methanone (<b>6m</b>)</h3><div class="NLM_p last">The title compound was prepared in analogous fashion to compound <b>6b</b> (0.03 g, 26%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.75–0.72 (m, 1H), 1.02–1.07 (m, 6H), 1.22–1.26 (m, 6H), 1.42–1.45 (m, 2H), 1.60–1.63 (m, 2H), 1.78–1.84 (m, 6H), 2.24–2.27 (m, 1H), 2.36–2.39 (m, 1H), 2.48–2.52 (m, 5H), 2.69–2.71 (m, 2H), 2.78 (quin, <i>J</i> = 10.5 Hz, 1H), 3.47–3.49 (m, 1H), 3.58–3.63 (m, 2H), 3.76–3.79 (m, 1H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>37</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 348.3009; found, 348.3010.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (4-Cyclohexylpiperazin-1-yl)(6-phenyl-6-azaspiro[2.5]octan-1-yl)methanone (<b>6n</b>)</h3><div class="NLM_p last">To (4-cyclohexylpiperazin-1-yl)(6-azaspiro[2.5]octan-1-yl)methanone <b>6k</b> (0.10 g, 0.33 mmol) in toluene (1.5 mL) were added bromobenzene (0.05 mL, 0.43 mmol), <i>trans</i>-dichlorobis(tri-<i>o</i>-tolyl-phosphine)palladium(II) (0.03 g, 0.03 mmol), and LiHMDS (1 M in toluene, 0.39 mL, 0.39 mmol). The reaction was heated at 100 °C for 1 h. The reaction was quenched with 2 mL of EtOAc, and the precipitate was filtered off and put under high vacuum overnight. The sample was chromatographed (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub> to 5% (7 N NH<sub>3</sub>)/MeOH). The fractions were collected and dried to yield a crude solid. The HCl salt was made by dissolving in 1 N HCl/MeOH, and the solvent was removed. The solids were triturated with Et<sub>2</sub>O, filtered, and put under high vacuum. The compound was further purified by dissolving in MeOH and passing through 4 g Isolute NH<sub>2</sub> column with MeOH. The product was removed of solvent, dissolved in ACN, and filtered through a 0.45 μM frit. After sitting at room temperature for a while, the material crystallized out, filtered, and dried under high vacuum at 50 °C for 5 h to give the title compound as a white solid (0.015 g, 12%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.71 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 1.10–1.24 (m, 5H), 1.32 (t, <i>J</i> = 4.5 Hz, 1H), 1.50–1.65 (m, 3H), 1.74–1.82 (m, 6H), 2.76 (app t, <i>J</i> = 11 Hz, 1H), 2.46–2.48 (m, 2H), 2.56–2.61 (m, 2H), 2.56–2.61 (m, 2H), 3.07–3.10 (m, 1H), 3.17–3.27 (m, 1H), 3.29–3.30 (m, 1H), 3.48–3.50 (m, 1H), 3.62–3.65 (m, 2H), 3.73–3.76 (m, 1H), 6.84 (t, <i>J</i> = 7 Hz, 1H), 6.95 (d, <i>J</i> = 8 Hz, 2H), 7.23 (m, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>35</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 382.2852; found, 382.2850.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (6-Benzyl-6-azaspiro[2.5]octan-1-yl)(4-cyclohexylpiperazin-1-yl)methanone (<b>6o</b>)</h3><div class="NLM_p last">The title compound was prepared in analogous fashion to compound <b>6b</b> (0.07 g, 54%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.83–0.84 (m, 1H), 1.26–1.32 (m, 6H), 1.48–1.50 (m, 4H), 1.58–1.61 (m, 3H), 1.75–1.86 (m, 4H), 2.24–2.31 (m, 2H), 2.52–2.64 (m, 6H), 3.48–3.50 (m, 1H), 3.52 (s, 2H), 3.60–3.61 (m, 2H), 3.70–3.74 (m, 1H), 7.22–7.30 (m, 5H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>37</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 396.3009; found, 396.3004.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (4-Cyclohexylpiperazin-1-yl)(6-phenethyl-6-azaspiro[2.5]octan-1-yl)methanone (<b>6p</b>)</h3><div class="NLM_p last">To (4-cyclohexylpiperazin-1-yl)(6-azaspiro[2.5]octan-1-yl)methanone <b>6k</b> (0.10 g, 0.33 mmol) was added 1,2-dichloroethane (2 mL) and 2-phenylacetaldehyde (37 μL, 0.33 mmol). The reaction was stirred 30 min, and sodium triacetoxyborohydride (0.76 g, 0.36 mmol) was added. The reaction was stirred at room temperature overnight. To the reaction mixture was added 1.5 mL of 1 N NaOH, and the mixture was stirred for 20 min. The aqueous layer was removed, to this were added Et<sub>2</sub>O and saturated NaCl, and the mixture was stirred for 5 min. The aqueous layer was removed, the organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, the solvent was removed, and the material was put under high vacuum at 50 °C overnight. The material was purified on 12 g silica gel eluting with CH<sub>2</sub>Cl<sub>2</sub> to 10% (7 N NH<sub>3</sub>/MeOH)/CH<sub>2</sub>Cl<sub>2</sub>. The product was removed of solvent and put under high vacuum. The material was dissolved in hot hexanes and cooled in a freezer to give a white solid that was collected to give the final compound. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.82–0.85 (m, 1H), 1.25–1.31 (m, 6H), 1.57–1.58 (m, 2H), 1.63–1.67 (m, 4H), 1.79–1.85 (m, 4H), 2.24–2.27 (m, 1H), 2.58–2.69 (m, 10H), 2.80–2.84 (m, 2H), 3.51–3.57 (m, 1H), 3.62–3.64 (m, 2H), 3.79–3.81 (m, 1H), 7.18–7.21 (m, 3H), 7.27–7.30 (m, 2H), HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>39</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 410.3165; found, 410.3169.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (4-Cyclohexylpiperazin-1-yl)(6-(pyridin-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6q</b>)</h3><div class="NLM_p last">To (4-cyclohexylpiperazin-1-yl)(6-azaspiro[2.5]octan-1-yl)methanone <b>6k</b> (0.10 g, 0.33 mmol) were added 4-chloropyridine hydrochloride (0.05 g, 0.33 mmol), K<sub>2</sub>CO<sub>3</sub> (0.11 mg, 0.82 mmol), and DMSO (2 mL). The reaction was sealed and placed in a 90 °C bath overnight. The reaction was diluted with EtOAc/NaCl (sat.) and washed with NaCl (sat., 2×), dried over Na<sub>2</sub>SO<sub>4</sub>, and stripped to give an orange oil. The material was purified by chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub> to 10% (7 N NH<sub>3</sub>/MeOH)/CH<sub>2</sub>Cl<sub>2</sub>). The product was removed of solvent and put under high vacuum at 50 °C overnight to give the title compound as a white solid (0.02 g, 26%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.71 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 1.46–1.30 (m, 6H), 1.46–1.48 (m, 1H), 1.50–1.55 (m, 1H), 1.54–1.58 (m, 2H), 1.63–1.69 (m, 2H), 1.74–1.81 (m, 4H), 2.24–2.27 (m, 1H), 2.47–2.57 (m, 2H), 2.57–2.70 (m, 2H), 3.20–3.25 (m, 1H), 3.28–3.32 (m, 1H), 3.33–3.43 (m, 1H), 3.50–3.55 (m, 2H), 3.55–3.60 (m, 2H), 3.65–3.72 (m, 1H), 6.60 (d, <i>J</i> = 5.5 Hz, 2H), 8.26 (d, <i>J</i> = 5.5 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>34</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 383.2805; found, 383.2805.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>R</i>)-(4-Isopropylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6r</b>)</h3><div class="NLM_p last">The procedure was the same as <b>6s</b> except (<i>R</i>)-benzyl 1-(4-isopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate was used to give the title compound (2.46 g, 45%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.79 (dd, 1H), 1.09 (d, <i>J</i> = 6.6 Hz, 6H), 1.14 (t, <i>J</i> = 4.8 Hz, 1H), 1.40–1.51 (m, 1H), 1.51–1.74 (m,5H), 1.77–1.89 (m, 3H), 2.46 (ddd, <i>J</i> = 11.3, 7.8, 3.1 Hz, 1H), 2.50–2.62 (m, 5H), 2.62–2.81 (m, 4H), 3.40 (t, <i>J</i> = 11.9 Hz, 2H), 3.50 (ddd, <i>J</i> = 13, 7.7, 3.3 Hz, 1H), 3.70 (dt, <i>J</i> = 6.6, 3.3 Hz, 1H), 3.74 (t, <i>J</i> = 5.0 Hz, 2H), 3.99 (dd, <i>J</i> = 11.0, 4.5 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>35</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 350.2802; found, 350.2796. [α]<sub>D</sub><sup>20</sup> = +32.4 (<i>c</i> 1.766, MeOH).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-(4-Isopropylpiperazin-1-yl)(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>6s</b>)</h3><div class="NLM_p last">Pd/C (5%, 0.015 g, 0.14 mmol) was added to a solution of (<i>S</i>)-benzyl 1-(4-isopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (2.80 g, 7.01 mmol) and dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (1.05 g, 10.51 mmol) in methanol (28 mL). The reaction mixture was shaken overnight in a Parr apparatus under 30 psi of a H<sub>2</sub> atmosphere. The reaction mixture was filtered over a Celite bed, and the solvent was concentrated. The product was purified by chromatography (SiO<sub>2</sub>, using 5% of (7 N NH<sub>3</sub> in MeOH) in CH<sub>2</sub>Cl<sub>2</sub> as the eluent) to provide the title compound as white solid (1.68 g, 68.6%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.79 (dd, 1H), 1.09 (d, <i>J</i> = 6.2 Hz, 6H), 1.14 (t, <i>J</i> = 4.8 Hz, 1H), 1.40–1.51 (m, 1H), 1.51–1.74 (m, 5H), 1.78–1.89 (m, 3H), 2.42–2.50 (m, 1H), 2.50–2.62 (m, 5H), 2.63–2.79 (m, 4H), 3.40 (t, <i>J</i> = 11.9 Hz, 2H), 3.50 (ddd, <i>J</i> = 13, 7.6, 3.1 Hz, 1H), 3.70 (ddd, <i>J</i> = 6.4, 3.5, 3.3 Hz, 1H), 3.74 (t, <i>J</i> = 5.0 Hz, 2H), 3.99 (dd, <i>J</i> = 11.5, 4.4 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>35</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 350.2802; found, 350.2796. [α]<sub>D</sub><sup>20</sup> = −31.1 (<i>c</i> 1.766, MeOH).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (4-Cyclobutylpiperazin-1-yl)(6-cyclohexylspiro[2.5]octan-1-yl)methanone (<b>6t</b>)</h3><div class="NLM_p last">6-Cyclohexylspiro[2.5]octane-1-carboxylic acid was prepared by hydrolysis from <b>17</b> via a route analogous to preparation of compound <b>7</b>. To 6-cyclohexylspiro[2.5]octane-1-carboxylic acid (0.20 g, 0.85 mmol) and <i>O</i>-benzotriazol-1-yl-tetramethyluronium hexafluorophosphate (0.32 g, 0.85 mmol) were added DMF (10 mL) and DIPEA (0.74 mL, 4.23 mmol). The mixture was stirred for 5 min, and solid 1-cyclobutylpiperazine·2HCl (0.27 g, 1.27 mmol) was added. The reaction was stirred for 15 min, and the solvent was removed. The material was purified by preparatory HPLC procedure A to give the title compound (0.30 g, 69%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.60–0.62 (m, 1H), 0.82–0.85 (m, 1H), 1.09–1.19 (m, 10H), 1.43–1.49 (m, 3H), 1.67–1.72 (m, 10H), 1.80–1.82 (m, 2H), 1.94–1.96 (m, 2H), 2.20–2.24 (m, 1H), 2.26–2.30 (m, 1H), 2.30–2.45 (m, 2H), 2.68–2.70 (m, 1H), 3.42–3.47 (m, 1H), 3.50–3.55 (m, 1H), 3.65–3.68 (m, 1H), 3.72–3.75 (m, 1H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>39</sub>N<sub>2</sub>O (M + H)<sup>+</sup>, 359.3057; found, 359.3072.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (<b>7</b>)</h3><div class="NLM_p last">6-Benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate <b>3</b> (4.06 mmol, 1.29 g) was dissolved in MeOH (8 mL), THF (8 mL), and H<sub>2</sub>O (8 mL). To this was added LiOH (8.13 mmol, 0.33 g), and the reaction was stirred overnight at room temperature. After the reaction was complete, it was acidified to pH ∼1 with 1 N HCl and extracted with EtOAc. The organics were dried over MgSO<sub>4</sub> and filtered, and the residual material was dried under vacuum to give the title compound as a white solid (1.10 g, 94% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.83–0.94 (m, 1H), 1.09–1.15 (m, 1H), 1.30–1.40 (m, 2H), 1.46–1.52 (m, 1H), 1.61–1.70 (m, 2H), 3.23–3.54 (m, 4H), 5.06 (s, 2H), 7.20–7.28 (m, 5H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 290.1.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>R</i>)-6-Benzyl 1-Ethyl 6-Azaspiro[2.5]octane-1,6-dicarboxylate (<b>7a</b>)</h3><div class="NLM_p last">The procedure was identical to <b>7b</b> except (<i>R</i>)-6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate <b>3a</b> was used to give the title compound as a colorless oil (2.77 g, 100%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.03 (dd, 1H), 1.18–1.26 (m, 1H), 1.46 (br s, 2H), 1.59 (dd, <i>J</i> = 7.81, 5.47 Hz, 1H), 1.77 (br s, 2H), 3.41–3.50 (m, 1H), 3.50–3.61 (m, 3H), 5.14 (s, 2H), 7.30–7.34 (m, 1H), 7.35–7.40 (m, 4 H).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>S</i>)-6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic Acid (<b>7b</b>)</h3><div class="NLM_p last">NaOH (9.58 mL, 19.16 mmol) was added to a solution of (<i>S</i>)-6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate (3.04 g, 9.58 mmol) in methanol (30 mL) and water (10 mL). The reaction mixture was heated and stirred until all of the starting material was consumed, as indicated by TLC. The solvent was concentrated, and water was added. The solution was acidified to pH ∼2 using a 2 M HCl solution. The product was extracted with EtOAc (3 × 50 mL). The organics were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to provide the title compound (2.80 g, 101%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.01 (dd, 1H), 1.17–1.25 (m, 1H), 1.45 (br s, 2H), 1.58 (dd, <i>J</i> = 7.81, 5.47 Hz, 1 H), 1.76 (br s, 2H), 3.38–3.48 (m, 1 H), 3.48–3.61 (m, 3H), 5.14 (s, 2H), 7.29–7.34 (m, 1H), 7.34–7.40 (m, 4H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 290.1. [α]<sub>D</sub><sup>20</sup> = +69.2 (<i>c</i> 2.349, MeOH).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Benzyl 1-(4-(<i>tert</i>-Butoxycarbonyl)piperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>8</b>)</h3><div class="NLM_p last">6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid <b>7</b> (1.90 mmol, 0.55 g), <i>O</i>-(7-azabenzotriazole-1-yl)-<i>N</i>, <i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (3.80 mmol, 1.44 g), DIPEA (3.80 mmol, 0.66 mL), and piperazine-1-carboxylic acid <i>tert-</i>butyl ester (2.85 mmol, 0.53 g) were combined in 50 mL of anhydrous acetonitrile and stirred at room temperature overnight. The reaction was diluted with EtOAc and washed with 100 mL of 1 N NaOH. The organics were then dried over MgSO<sub>4</sub> and filtered through a silica gel plug, and the volatiles were removed under reduced pressure. The residue was purified by column chromatography (SiO<sub>2</sub>, hexanes/ethyl acetate gradient (100% hexanes to 50% hexanes over 30 min)) to produce the title compound (0.60 g, 69% yield) as a tan solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.74 (dd, <i>J</i> = 7.7, 4.6 Hz, 1H), 1.19–1.27 (m, 2H), 1.40 (s, 9H), 1.45–1.62 (m, 4H), 3.18–3.69 (m, 12H), 5.06 (s, 2H), 7.34 (s, 5H). MS (ES+) <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> = 480.2.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>tert</i>-Butyl 4-(6-Azaspiro[2.5]octane-1-carbonyl)piperazine-1-carboxylate (<b>9</b>)</h3><div class="NLM_p last">Benzyl 1-(4-(<i>tert</i>-butoxycarbonyl)piperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (1.31 mmol, 0.60 g) was dissolved in 100 mL of EtOH and purged with N<sub>2</sub> for 15 min. This was followed by the addition of 3 drops of glacial acetic acid and 5% Pd/C (0.06 g, 10% by weight of piperazine), and the reaction was placed under a balloon of H<sub>2</sub>. The reaction was then stirred overnight at room temperature. The reaction was filtered through a Celite plug, and the volatiles were removed under reduced pressure. The residue was purified via column chromatography and eluted with a CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> containing 10% (2 M NH<sub>3</sub>/MeOH) gradient over 30 min to give the title compound as clear oil (0.42 g, 99% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 0.79 (dd, <i>J</i> = 7.8, 4.3 Hz, 1H), 1.15 (t, <i>J</i> = 4.8 Hz, 1H), 1.32–1.44 (m, 2H), 1.47 (s, 9H), 1.50–1.68 (m, 2H), 1.83 (dd, <i>J</i> = 7.8, 5.3 Hz, 1H), 2.72–2.76 (m, 2H), 2.83–2.89 (m, 2H), 3.37–3.78 (m, 8H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 324.3.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>tert</i>-Butyl 4-(6-(Tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octane-1-carbonyl)piperazine-1-carboxylate (<b>10</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 4-(6-azaspiro[2.5]octane-1-carbonyl)piperazine-1-carboxylate <b>9</b> (1.30 mmol, 0.42 g), dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (1.95 mmol, 0.13 mL), 3 drops of glacial acetic acid, and NaBH<sub>3</sub>CN (2.92 mmol, 0.183 g) were combined in 60 mL of anhydrous EtOH and stirred for 12 h at room temperature followed by heating to reflux for 6 h. The reaction was cooled to room temperature, diluted with EtOAc, and washed with 50 mL of 1 N NaOH. The organics were dried over Na<sub>2</sub>SO<sub>4</sub> and filtered through a glass filter frit, and the volatiles were removed under reduced pressure. The residue was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub> containing 10% (2 M NH<sub>3</sub>/MeOH) gradient over 30 min) to produce the title compound (0.44 g, 83% yield) as a clear oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.82 (dd, <i>J</i> = 8.0, 4.6 Hz, 2H), 1.23 (t, <i>J</i> = 4.8 Hz, 2H), 1.44 (s, 9H), 1.39–1.55 (m, 4H), 1.55–1.75 (m, 4H), 1.80–1.97 (m, 2H), 2.72–2.97 (m, 5H), 3.34–3.58 (m, 6H), 4.03 (dd, <i>J</i> = 11.4, 3.5 Hz, 2H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 408.3.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Piperazin-1-yl(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone (<b>11</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl-4-(6-(tetrahydro-2<i>H</i>-pyran-4-yl)-6-azaspiro[2.5]octane-1-carbonyl)piperazine-1-carboxylate <b>10</b> (1.08 mmol, 0.44 g) was dissolved in 25 mL of CH<sub>2</sub>Cl<sub>2</sub> followed by the addition of 5 mL of TFA, and the reaction was stirred at room temperature for 1.5 h. The volatiles were removed under reduced pressure, and the product was dried overnight under high vacuum to give the title compound (0.57 g as a tan TFA salt, 99% yield), which was used without further purification. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 0.97–1.10 (m, 2H), 1.24–1.65 (m, 4H), 1.71–1.89 (m, 3H), 1.95–2.15 (m, 4H), 3.06–3.49 (m, 5H), 3.55–3.69 (m, 6H), 3.71–4.13 (m, 4H), MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 308.3.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Benzyl 1-(4-(Tetrahydro-2<i>H</i>-pyran-4-yl)piperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>12</b>)</h3><div class="NLM_p last">To 6-(benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid <b>7</b> (1.95 g, 6.74 mmol) were added DMF (50 mL), <i>O</i>-benzotriazol-1-yl-tetramethyluronium hexafluorophosphate (2.56 g, 6.74 mmol), and DIPEA (5.89 mL, 33.7 mmol). After stirring for 5 min, to this was added 1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazine dihydrochloride (1.72 g, 7.08 mmol). The reaction was stirred for 1 h, and the solvent was removed. The material was partitioned between EtOAc/NaHCO<sub>3</sub>. The organic layer was washed with NaHCO<sub>3</sub> (2×) and NaCl (1×) and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed. The material was chromatographed (330 g SiO<sub>2</sub>, with gradient running from pure CH<sub>2</sub>Cl<sub>2</sub> to 5% MeOH). The material was converted to the TFA salt and placed under high vacuum at 50 °C overnight to give the title compound as a white solid (0.44 g, 11%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.02 (br s, 1H), 1.27–1.33 (m, 3H), 1.59–1.61 (m, 1H), 1.70–1.71 (m, 1H), 1.82–1.84 (m, 1H), 1.99–2.25 (m, 4H), 2.94 (br s, 1H), 3.22 (br s 1H), 3.22–3.25 (m, 3H), 3.54–3.57 (m, 3H), 3.63–3.72 (m, 3H), 3.92–4.10 (m, 4H), 4.29–4.41 (m, 3H), 4.83 (br s, 1H), 5.15–5.17 (m, 2H), 7.33–7.48 (m, 5H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 442.2.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Benzyl 1-(4-Cyclohexylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>13</b>)</h3><div class="NLM_p last">To 6-(benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid <b>7</b> (2.99 g, 10.3 mmol) were added DMF (40 mL), HBTU (3.92 g, 10.3 mmol), and DIPEA (5.41 mL, 31.0 mmol), and the mixture was stirred for 5 min. To this was added 1-cyclohexylpiperazine (1.91 g, 11.4 mmol), and the reaction was stirred for 2 h. The DMF was partially removed under vacuum, and the remaining material was partitioned between EtOAc/NaHCO<sub>3</sub>. The organic layer was washed with NaHCO<sub>3</sub> (aq. sat.) and NaCl (aq. sat.) and dried over Na<sub>2</sub>SO<sub>4.</sub> The solvent was removed, and the material was chromatographed (SiO<sub>2</sub>, 2.5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). Fractions were combined, and the solvent was evaporated to give the title compound (3.21 g 70%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 086–0.87 (m, 1H), 1.10–1.30 (m, 8H), 1.40–1.43 (m, 1H), 1.59–1.64 (m, 4H), 1.78–1.83 (m, 4H), 2.25–2.29 (m, 1H), 2.37 (s, 1H), 2.45–2.49 (m, 2H), 2.64–2.65 (m, 1H), 3.28–3.30 (m, 1H), 3.30–3.38 (m, 1H), 3.41–3.48 (m, 1H), 3.60–3.69 (m, 2H), 3.69–3.72 (m, 2H), 5.13 (s, 2H), 7.29–7.32 (m, 1H), 7.32–7.36 (m, 4H).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>R</i>)-Benzyl 1-(4-Isopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>14a</b>)</h3><div class="NLM_p last">The procedure was identical to <b>14b</b> except (<i>R</i>)-6-(benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid <b>7a</b> was used to give the title compound as a white solid (3.7 g, 100%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.75 (br s, 1H), 0.87–1.13 (m, 7H), 1.20–1.35 (m, 2H), 1.39 (br s, 2H), 1.50 (br s, 1H), 1.90 (br s, 1H), 2.37 (br s, 2H), 3.20–3.42 (m, 6H), 3.50 (br s, 4H), 5.07 (s, 2H), 7.27–7.42 (m, 5H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 400.3. [α]<sub>D</sub><sup>20</sup> = +13.1 (<i>c</i> 2.034, MeOH).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>S</i>)-Benzyl 1-(4-Isopropylpiperazine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>14b</b>)</h3><div class="NLM_p last">HBTU (3.98 g, 10.5 mmol) was added to a solution of (<i>S</i>)-6-(benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid <b>7b</b> (2.76 g, 9.54 mmol) in DMF (65 mL). Upon complete dilution, DIEA (5.00 mL, 28.6 mmol) was added, and the reaction mixture was stirred for 5 min. 1-(2-Propyl)-piperazine (1.85 g, 14.3 mmol) was then added, the reaction mixture was stirred for 1 h, and the solvent was concentrated. The residue was recovered in EtOAc (200 mL) and washed with saturated NaHCO<sub>3</sub> solution (3 × 50 mL) and brine. The solution was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. The product was purified on silica gel (120 g, using 5% MeOH, 10% acetone in DCM as eluent) to provide the title compound (3.80 g, 100%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.75 (br s, 1H), 0.84–1.22 (m, 7H), 1.21–1.35 (m, 2H), 1.39 (br s, 2H), 1.50 (br s, 1H), 1.91 (br s, 1H), 2.38 (br s, 2H), 3.33 (br s, 6H), 3.50 (br s, 4H), 5.07 (s, 2H), 7.23–7.44 (m, 5H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 400.4. [α]<sub>D</sub><sup>20</sup> = −12.9 (<i>c</i> 2.052, MeOH).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Methyl 2-(Bi(cyclohexan)-4-ylidene)acetate (<b>16</b>)</h3><div class="NLM_p last">To pentane-washed NaH 60% in mineral oil (0.31 g, 7.77 mmol) were added THF (25 mL) and methyl 2-(dimethoxyphosphoryl)acetate (1.20 mL, 8.32 mmol) dropwise over 20 min, resulting in a very thick suspension. After the reaction ceased bubbling, bi(cyclohexan)-4-one <b>15</b> (1.00 g, 5.55 mmol) (5 mL THF solution) was added. After 1 h, the reaction was filtered and washed with cold EtOAc. The filtrate was removed of solvent and put under high vacuum. The material was chromatographed (80 g SiO<sub>2</sub>, hexanes to 75% CH<sub>2</sub>Cl<sub>2</sub>/hexanes to give the title compound as a clear oil (0.950 g, 72%). The material was used without further purification.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 6-Methyl 6-Cyclohexylspiro[2.5]octane-1-carboxylate (<b>17</b>)</h3><div class="NLM_p last">To unwashed NaH 60% in mineral oil (0.040 g, 1.02 mmol) was added DMF (2 mL) followed by portionwise addition of solid trimethylsulfoxonium iodide (0.233 g, 1.06 mmol). The reaction was stirred for 1.5 h. To this was added methyl 2-(bi(cyclohexan)-4-ylidene)acetate <b>16</b> (0.10 mg, 0.42 mmol) in 1 mL of DMF. A fresh suspension of NaH/DMF (0.04 g, 1.02 mmol) and trimethylsulfoxonium iodide (0.23 g, 1.06 mmol) was prepared and stirred for 10 min, which was then added to the first reaction. The reaction was stirred at room temperature for 48 h, and the solvent was removed. The white solids were triturated with CH<sub>2</sub>Cl<sub>2</sub>, and salts were filtered off. The crude material was chromatographed (SiO<sub>2</sub> 20 g, gradient from pure hexanes to 1:1 hexanes/CH<sub>2</sub>Cl<sub>2</sub>) to give the title compound (0.52 g 49%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.80–0.95 (m, 4H), 1.05–1.27 (m, 7H), 1.40–1.43 (m, 1H), 1.71–1.79 (m, 11H), 3.83 (s, 3H). <sup>13</sup>C MNR δ 20.57, 25.63, 26.86, 28.53, 28.94, 30.34,31.02, 37.29, 42.88, 42.97, 51.47, 173.49.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>tert</i>-Butyl 1,1-Dichloro-2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (<b>19</b>)</h3><div class="NLM_p last">To a suspension of zinc–copper couple (35.4 g) and <i>tert</i>-butyl 4-methylenepiperidine-1-carboxylate <b>18</b> (8.0 g, 40 mmol) in ether (150 mL) was added a solution of trichloroacetyl chloride (24.32 g, 130 mmol) in 1,2-dimetoxy ethane (40 mL) dropwise at room temperature under a nitrogen atmosphere. After stirring the mixture at room temperature for 6 h, the reaction mixture was poured into a saturated solution of NaHCO<sub>3</sub> (150 mL) at 0 °C and filtered. The filtrate was extracted with EtOAc (300 mL × 2), and the combined organic layer was washed with brine (150 mL), dried, and evaporated. The crude material was purified by column chromatography over silica gel using 20% of EtOAc in petroleum ether as an eluent to yield the title dichloro ketone (5.3 g, 40%) as a pale brown oil, which was used in the next step without further characterization.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>tert</i>-Butyl 2-Oxo-7-azaspiro[3.5]nonane-7-carboxylate (<b>20</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 1,1-dichloro-2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (5.3 g, mmol) in saturated NH<sub>4</sub>Cl and MeOH (80 mL) was added zinc (6.0 g) portionwise at room temperature. The reaction mixture was stirred at rt for 10 h and filtered. The filtrate was concentrated under vacuum, and the crude material was purified by column chromatography over silica gel using 20% of EtOAc in petroleum ether as an eluent to yield the title compound (4.0 g, 97%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.46 (s, 9H), 1.70 (t, <i>J</i> = 5.6 Hz, 4H), 2.81 (s, 4H), 3.41 (t, <i>J</i> = 5.6 Hz, 4H).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>tert</i>-Butyl 2-(Methylsulfonyloxy)-7-azaspiro[3.5]nonane-7-carboxylate (<b>21</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate <b>20</b> (3.00 g, 12.5 mmol) in MeOH (30 mL) was added NaBH<sub>4</sub> (0.57 g 15.0 mmol) at 0 °C, and the mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (80 mL), washed with water (30 mL) and brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the intermediate alcohol (3.0 g, 99%) as a white solid, which was used without further purification. To a solution of <i>tert</i>-butyl 2-hydroxy-7-azaspiro[3.5]nonane-7-carboxylate (3.50 g, 14.5 mmol) and Et<sub>3</sub>N (4 mL, 29 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added methane sulphonyl chloride (1.35 mL, 17.4 mmol) at 0–5 °C, and the mixture was stirred at room temperature for 1 h. The reaction mixture was poured onto water (50 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was washed with water (20 mL) and brine (20 mL) and dried over Na<sub>2</sub>SO<sub>4.</sub> The solvent was removed under reduced pressure to give the title compound (4.5 g, 97%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.46 (s, 9H), 1.52–1.63 (m, 4H), 2.04–2.12 (m, 2H), 2.40–2.45 (m, 2H), 3.00 (s, 3H), 3.25–3.37 (m, 4H), 5.00–5.08 (m, 1H).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>tert</i>-Butyl 2-Cyano-7-azaspiro[3.5]nonane-7-carboxylate (<b>22</b>)</h3><div class="NLM_p last">A mixture of <i>tert</i>-butyl 2-(methylsulfonyloxy)-7-azaspiro[3.5]nonane-7-carboxylate (4.50 g, 14 mmol), sodium cyanide (1.35 g, 28 mmol), TBAB (20 mg), and DMF (40 mL) was heated at 120 °C and stirred for 16 h. The reaction mixture was poured into water (200 mL) and extracted with EtOAc (100 mL × 2). The combined organic layer was washed with water and brine, dried, and filtered, and the solvent was removed under reduced pressure. The crude material was purified by column chromatography over silica gel using 20% of EtOAc in petroleum ether as an eluent to yield the title compound (2.0 g, 57%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.45 (s, 9H), 1.55 (m, 2H), 1.64 (m, 2H), 2.19–2.25 (m, 4H), 3.1 (m, 1H), 3.30–3.32 (m, 4H).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 7-<i>tert</i>-Butyl 2-Ethyl 7-azaspiro[3.5]nonane-2,7-dicarboxylate (<b>23</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 2-cyano-7-azaspiro[3.5]nonane-7-carboxylate <b>22</b> (1.4 g, mmol) in ethanol (25 mL) was slowly added sulfuric acid (10 mL), and the mixture was refluxed for 16 h. The reaction mixture was cooled to room temperature, and the solvent was removed under reduced pressure. The residue was added to ice water (20 mL) and treated with sat. NaHCO<sub>3</sub> until basic, and a solution of Boc anhydride (1.54 g, 7.1 mmol) in THF (25 mL) was added at 5–10 °C. The mixture was allowed to come to room temperature and stirred for 16 h. The reaction mixture was extracted with EtOAc (50 mL × 2). The combined organic layer was washed with water and brine, dried, and concentrated. The crude material was purified by column chromatography over silica gel using 0–10% of EtOAc in petroleum ether as an eluent to afford the title compound (0.7 g, 41%) as a colorless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.26 (t, 3H, <i>J</i> = 7.12 Hz), 1.45 (s, 9H), 1.51–1.62 (m, 4H), 2.06 (d, <i>J</i> = 8.76 Hz, 4H), 3.08 (m, 1H), 3.27 (m, 2H), 3.35 (m, 2H), 4.14 (q, <i>J</i> = 7.12 Hz, 1H).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Benzyl 1,1-Dichloro-2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (<b>24</b>)</h3><div class="NLM_p last">In a 500 mL round-bottomed flask were added benzyl 4-methylenepiperidine-1-carboxylate (11.0 g, 47.5 mmol) and zinc–copper couple (41.9 g, 642.0 mmol) combined in ether (150 mL) to give a gray suspension. The reaction suspension was cooled to 0 °C. In a separate flask were combined trichloroacetyl chloride (28.7 mL, 256.8 mmol) and DME (85 mL), which was then transferred to a dropping funnel. This solution was added dropwise to the round-bottomed flask reaction over 30 min. Moderate gas evolution with an exotherm was noted during the acid chloride addition. The reaction was stirred at 0 °C for 1 h and allowed to warm to room temperature by removing the ice bath. The reaction was stirred at room temperature for an additional 18 h. The reaction was quenched by slowly pouring the reaction mixture into a saturated NaHCO<sub>3</sub> solution (500 mL), which was kept at 0 °C. During the addition, vigorous gas evolution occurred. The quenched reaction was filtered through a bed of Celite, and all solids were removed. The filtrate was transferred to a separatory funnel and partitioned with EtOAc (1 L). The aqueous layer was back-extracted with EtOAc (2 × 250 mL). The combined organic layers were washed with brine (2 × 500 mL) and dried over MgSO<sub>4</sub>. The organic layer was concentrated, and the resultant material was purified by SiO<sub>2</sub> chromatography (SiO<sub>2</sub>, 330 g column, 100% hexane to 50% EtOAc/hexane over 30 min). The fractions were collected and evaporated to give the title compound (6.50 g, 40%). MS (ES+) (<i>m</i>/<i>z</i>) = 342, (<i>m</i>/<i>z</i> + 2) = 344. The material was used as is without further characterization.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Benzyl 2-Oxo-7-azaspiro[3.5]nonane-7-carboxylate (<b>25</b>)</h3><div class="NLM_p last">In a 1 L round-bottomed flask were added benzyl 1,1-dichloro-2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (6.45 g, 18.8 mmol) and MeOH (50 mL) to give an orange solution. To this was added a solution of saturated NH<sub>4</sub>Cl/MeOH (125 mL) followed by zinc dust (12.94 g, 197.9 mmol) in 6 equal portions over 15 min. The reaction was stirred at room temperature overnight. The solvent was removed by rotary evaporation, leaving behind a thick, yellow syrup. To this was added CH<sub>2</sub>Cl<sub>2</sub> (100 mL), and the solids were filtered off followed by further concentration of the organics to give a yellow syrup. The residue was purified via SiO<sub>2</sub> chromatography (120 g column, 100% hexane to 50% EtOAc/hexane over 30 min) to give 3.85 g (74%) of the title compound as a pale oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>-<i>d</i>) δ 1.71 (m, 4H), 2.90 (s, 4H), 3.48 (m, 4H), 5.13 (s, 2H), 7.28–7.36 (m, 5H).</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Benzyl 2-Formyl-7-azaspiro[3.5]nonane-7-carboxylate (<b>26</b>)</h3><div class="NLM_p last">Potassium <i>tert</i>-butoxide (1 M in THF, 77 mL, 0.77 mol) was loaded into an oven-dried flask under a nitrogen atmosphere. To this were added <i>t</i>-BuOH (7.38 mL, 77.16 mmol) and THF (70 mL). The mixture was cooled to −78 °C, and methoxymethyltriphenylphosphonium chloride (26.50 g, 77.16 mmol) was added portionwise. The reaction mixture was allowed to warm to room temperature, stirred for 1 h, and cooled back to −78 °C. A solution of benzyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate <b>25</b> (7.03 g, 25.72 mmol) in THF (70 mL) was added dropwise to the reaction mixture over a period of 30 min. The reaction mixture was allowed to warm to room temperature and stirred for 1 h. The reaction was quenched with water (150 mL), and the product was extracted using EtOAc. The combined organic phases were washed with brine and dried over anhydrous MgSO<sub>4</sub>, and the solvent was concentrated. The product was purified on SiO<sub>2</sub> (330 g, 20% EtOAc in heptane as eluent) to provide the title compound (3.53 g, 47.8%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>-<i>d</i>) δ 1.48 (br s, 2H), 1.62 (br s, 2H), 1.91–2.16 (m, 4H), 3.16 (quin, <i>J</i> = 8.6 Hz, 1H), 3.31–3.41 (m, 2H), 3.41–3.50 (m, 2H), 5.12 (s, 2H), 7.28–7.44 (m, 5H), 9.76 (d, <i>J</i> = 1.56 Hz, 1H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 288.1.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 7-(Benzyloxycarbonyl)-7-azaspiro[3.5]nonane-2-carboxylic Acid (<b>27</b>)</h3><div class="NLM_p last">A solution of 6% aqueous sodium hypochlorite (84.0 g, 1.12 mol) was added to a solution of benzyl 2-formyl-7-azaspiro[3.5]nonane-7-carboxylate (3.53 g, 12.28 mmol), NaHCO<sub>3</sub> (saturated) (8 mL), sodium bromide (253 mg, 2.46 mmol), and TEMPO (6 mg, 0.04 mmol, in CH<sub>2</sub>Cl<sub>2</sub> 6 mL solution) in water (30 mL) over a period of 2 h. The reaction mixture was stirred for 2 h, and the pH was adjusted to ∼1 by addition of concentrated hydrochloric acid. The product was extracted using Et<sub>2</sub>O (3 × 70 mL). The combined organic phases were washed with brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was concentrated, and the product was purified on SiO<sub>2</sub> (120 g, eluting with a 3:2 mixture of heptane/EtOAc) to afford 7-(benzyloxycarbonyl)-7-azaspiro[3.5]nonane-2-carboxylic acid (2.69 g, 72.2%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.58 (d, <i>J</i> = 16.8 Hz, 4H), 2.10 (d, <i>J</i> = 8.9 Hz, 4H), 3.13 (quin, <i>J</i> = 8.8 Hz, 1H), 3.33–3.41 (m, 2H), 3.41–3.48 (m, 2H), 5.12 (s, 2H), 7.28–7.41 (m, 5 H). MS (ES+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> = 304.2.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Ethyl 7-(Tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonane-2-carboxylate (<b>28</b>)</h3><div class="NLM_p last">To 7-<i>tert</i>-butyl 2-ethyl 7-azaspiro[3.5]nonane-2,7-dicarboxylate <b>23</b> (0.815 g, 2.74 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.7 mL) was added TFA (2.7 mL) to give an amber solution. The reaction was stirred at room temperature for 3 h, and the solvent was removed. The residue was triturated with ether (1 × 25 mL) and placed on the vacuum manifold for 1 h to give roughly 0.95 g of crude TFA salt. The salt was redissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), and to this was added Si-Amine resin (∼2g, Silicycle, loading of 1.67 mmol/g). The heterogeneous mixture was stirred for 30 min at room temperature. The silica gel was filtered and washed with CH<sub>2</sub>Cl<sub>2</sub>, and the solvent was removed. The compound was placed under high vacuum for 8 h to give the intermediate piperidine as a waxy solid (0.541 g, 83%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.25 (t, <i>J</i> = 7.2 Hz, 3H), 1.69 (m, 4H), 2.06 (d, <i>J</i> = 8.7 Hz, 4H), 2.41 (br s, N-H/TFA-H), 2.82 (app t, <i>J</i> = 5.7 Hz, 2H), 2.88 (app t, <i>J</i> = 5.4 Hz, 2H), 3.08 (quintet, <i>J</i> = 8.7 Hz, 1H), 4.14 (q, <i>J</i> = 7.2 Hz, 2H). MS (ES+) <i>m</i>/<i>z</i> [M]<sup>+</sup> = 198.0. To ethyl 7-azaspiro[3.5]nonane-2-carboxylate (0.47 g, 2.38 mmol) were added MeOH (20 mL), dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (0.80 mL, 9.53 mmol), and Pd/C (0.05 g, 0.05 mmol), and a balloon was attached to the reaction flask filled with H<sub>2</sub>. The reaction was stirred at room temperature overnight. The reaction was filtered, and the solvent was removed in vacuo. The material was purified using SiO<sub>2</sub> chromatography (80 g, solvent gradient of 0–10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to give the title compound (0.39 g, 1.40 mmol, 58%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.25 (t, <i>J</i> = 7 Hz, 3H), 1.56–1.86 (br m, 10H), 2.01 (d, <i>J</i> = 8.5 Hz, 4H), 3.03 (m, 1H), (br m, 4H), 3.36 (app dt, <i>J</i> = 12.0, 1.5 Hz, 2H), 4.01 (dd, <i>J</i> = 11.0, 4.0 Hz, 2H), 4.12 (q, <i>J</i> = 7.0 Hz, 2H). MS (ES+) <i>m</i>/<i>z</i> [M]<sup>+</sup> = 282.4.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (4-Cyclobutyl-1,4-diazepan-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonan-2-yl)methanone (<b>29a</b>)</h3><div class="NLM_p last">The title compound was prepared as in example <b>29c</b> in 39% yield as a film. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.97–0.99 (m, 6H), 1.56–1.61 (m, 6H), 1.61–1.68 (m, 2H), 1.71–1.76 (m, 2H), 1.78–1.81 (m, 2H), 1.94–1.97 (m, 2H), 2.07–2.11 (m, 2H), 2.40–2.47 (m, 2H), 2.55 (s, 1H), 2.55–2.58 (m, 2H), 2.62–2.66 (m, 2H), 2.85–2.91 (quin, <i>J</i> = 7.0 Hz, 1H), 3.12–3.17 (m, 1H), 3.36–3.40 (m, 4H), 3.57–3.60 (m, 2H), 3.99 (d, 1H, <i>J</i> = 4.5 Hz), 4.00 (d, 1H, <i>J</i> = 4.5 Hz). HRMS (TOF) <i>m</i>/z calcd for C<sub>23</sub>H<sub>40</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 390.3115; found, 390.3114.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (4-Cyclobutylpiperazin-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonan-2-yl)methanone (<b>29b</b>)</h3><div class="NLM_p last">To 7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonane-2-carboxylic acid (as prepared in example <b>29c</b>) (0.128 g, 0.39 mmol) were added DMF (3 mL), HBTU (0.150 g, 0.390 mmol), and then DIPEA (0.345 mL, 1.97 mmol). The reaction was stirred for 5 min, and 1-cyclobutylpiperazine dihydrochloride (0.126 g, 0.59 mmol) was added. The reaction was stirred at room temperature for 2 h, and the solvent was removed. The solids were put under high vacuum for 12 h. The material was subjected to SiO<sub>2</sub> chromatography (80 g, using a gradient of 0–10% 7 N NH<sub>3</sub>/MeOH in CH<sub>2</sub>Cl<sub>2</sub>). The impure fractions were collected and further purified with preparatory HPLC using procedure A to provide the title compound as a white solid (0.112 g, 76%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.68–1.83 (m, 12H), 1.85–2.05 (m, 7H), 2.23–2.28 (m, 4H), 2.35–2.47 (m, 4H), 2.70 (ddd, <i>J</i> = 11.4, 7.8, 7.8 Hz, 1H), 3.13 (ddd, <i>J</i> = 13.2, 9, 9 Hz, 1H), 3.31–3.38 (m, 4H), 3.59–3.62 (m, 2H), 3.99 (dd, <i>J</i> = 10.9, 3.9 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 376.2986; found, 376.2986.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (4-Cyclohexylpiperazin-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonan-2-yl)methanone (<b>29c</b>)</h3><div class="NLM_p last">To ethyl 7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonane-2-carboxylate <b>28</b> (0.395 g, 1.40 mmol) were added MeOH (10 mL) and NaOH (1 N, 1.68 mL, 1.68 mmol). The reaction was heated to reflux for 2 h. The reaction was quenched by adding HCl (1 N, 1.684 mL, 1.68 mmol), and then the solvent was removed. The tan foam was placed under high vacuum at 50 °C for 12 h to give the intermediate acid in quantitative yield, which was used as is in the next reaction without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.45–1.69 (m, 8H), 1.86–1.88 (m, 2H), 1.94–1.96 (m, 2H), 2.45–2.50 (m, 3H), 2.98–3.02 (m, 1H), 3.22–3.26 (m, 4H), 3.78–3.88 (m, 2H). MS (ES+) <i>m</i>/<i>z</i> [M]<sup>+</sup> = 254.3. To 7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonane-2-carboxylic acid (309 mg, 1.22 mmol) was added thionyl chloride (10 mL), and the cloudy reaction was stirred at room temperature. After 30 min, the solvent was removed under vacuum, and the resulting white solid was put under high vacuum for 4 h. A sample of this was taken (0.050 g) to make the title compound as follows. To 7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonane-2-carbonyl chloride (0.050 mg, 0.18 mmol) was added a solution of 1-cyclohexylpiperazine (46.4 mg, 0.28 mmol) and DIPEA (0.129 mL, 0.74 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2M, 2.0 mL), and the reaction was stirred for 2 h. The solvent was removed, and the residue was dried under high vacuum at 50 °C overnight. The material was purified by reverse-phase HPLC using procedure A. The fractions were collected, the solvent was removed, and the product was dried under high vacuum at 50 °C overnight (0.074 g, 61%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.14–1.18 (m, 4H), 1.37–1.42 (m, 4H), 1.57–1.59 (m, 5H), 1.61–1.63 (m, 4H), 1.70–1.73 (m, 4H), 1.86 (app t, <i>J</i> = 10 Hz, 4H), 2.22–2.34 (m, 4H), 2.33–2.39 (m, 6H), 3.17–3.21 (m, 2H), 3.32–3.39 (m, 2H), 3.84 (d, <i>J</i> = 5.0 Hz, 1H), 3.85 (d, <i>J</i> = 5 Hz, 1H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>42</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 404.3272; found, 404.3267.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (Dihydro-1<i>H</i>-pyrido[1,2-a]pyrazin-2(6<i>H</i>,7<i>H</i>,8<i>H</i>,9<i>H</i>,9a<i>H</i>)-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonan-2-yl)methanone (<b>29d</b>)</h3><div class="NLM_p last">The material was prepared in an analogous manner to <b>29c</b> using octahydro-1<i>H</i>-pyrido[1,2-<i>a</i>]pyrazine to give the title compound as a white solid (0.69 g, 32%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.40–1.35 (m, 3H), 1.73–1.81 (m, 9H), 2.02–2.07 (m, 4H), 2.06–2.11 (m, 4H), 2.34–2.47 (m, 6H), 2.72–2.77 (m, 2H), 2.77–2.83 (m, 2H), 3.11 (t, <i>J</i> = 8.5 Hz, 1H), 3.20 (t, <i>J</i> = 12.0 Hz, 0.5 H), 3.42 (d, <i>J</i> = 13.5 Hz, 2H), 3.99 (d, <i>J</i> = 11.5 Hz, 0.5 H), 4.01 (dd, <i>J</i> = 11.0 Hz, 4.0 Hz, 2H), 4.30 (d, <i>J</i> = 13.0 Hz, 0.5 H), 4.51 (d, <i>J</i> = 13.5 Hz, 0.5 H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 376.2958; found, 376.2954. The compound appears to exist as rotational isomers based on multiple signals that integrate to less than 1H. These signals coalesce upon heating in DMSO-<i>d</i><sub>6</sub>, which supports this hypothesis.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (4-Isopropyl-1,4-diazepan-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonan-2-yl)methanone dihydrochloride (<b>29e</b>)</h3><div class="NLM_p last">The material was prepared in an analogous manner to <b>29c</b> using 1-isopropyl-1,4-diazepane to give the title compound in 34% yield. The material was converted to the di-HCl salt by addition of aq. 0.2 M HCl and lyophilization. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.25 (d, <i>J</i> = 6.6 Hz, 6H), 1.61–1.80 (m, 2H), 1.78–2.14 (m, 9H), 2.69–3.20 (m, 3H), 3.20–3.44 (m, 8H), 3.43–3.81 (m, 10H), 3.95 (dd, <i>J</i> = 11.33, 3.91 Hz, 2H), 10.45 (br s, 1H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>40</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 378.3115; found, 378.3108.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (4-Isopropylpiperazin-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonan-2-yl)methanone (<b>29f</b>)</h3><div class="NLM_p last">To 7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonane-2-carboxylic acid (as prepared in example <b>29c</b>) (0.309 g, 1.22 mmol) was added thionyl chloride (10 mL), and the cloudy reaction was stirred at room temperature. After 30 min, the solvent was removed, and the white solid was placed under high vacuum for 4 h. A sample of this was taken (0.050 g) to make the title compound as follows. To 7-(tetrahydro-2<i>H</i>-pyran-4-yl)-7-azaspiro[3.5]nonane-2-carbonyl chloride (0.050g, 0.18 mmol) was added a solution of 1-isopropylpiperazine (0.039 mL, 0.28 mmol) and DIPEA (0.129 mL, 0.74 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL). The reaction was stirred at room temperature for 2 h. The solvent was removed, and the gum was put under high vacuum at 50 °C overnight. The material was purified by reverse-phase HPLC using the exact methods as for previous compounds. The resulting gum was placed under high vacuum at 50 °C overnight to give the title compound as a white solid (0.043 g, 65%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.02 (d, <i>J</i> = 6.5 Hz, 6H), 1.58 (m, 4H), 1.65–1.67 (m, 2H), 1.71–1.74 (m, 2H), 1.96–1.98 (m, 2H), 2.08 (m, 2H), 2.39- 2.47 (br m, 9H), 3.11 (quintet, <i>J</i> = 9.0 Hz, 1H), 3.33–3.38 (m, 4H), 3.59–3.61 (m, 2H), 3.99 (d, <i>J</i> = 4.0 Hz, 1H), 4.01 (d, <i>J</i> = 4.0 Hz, 1H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 364.2958; found, 364.2957.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (4-Cyclobutylpiperazin-1-yl)(7-(methylsulfonyl)-7-azaspiro[3.5]nonan-2-yl)methanone (<b>29g</b>)</h3><div class="NLM_p last">Methanesulfonyl chloride (0.032 mL, 0.41 mmol) was added to a solution of (4-cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (0.100 g, 0.34 mmol) and triethylamine (52.1 mg, 0.51 mmol) in dichloromethane (10 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred overnight. The solvent was concentrated. The product was purified on preparative HPLC using procedure B to provide the title compound (49.6 mg, 39.1%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.59–1.72 (m, 3H), 1.72–1.80 (m, 3H), 1.79–1.94 (m, <i>J</i> = 10.1, 9.7, 9.5, 9.5 Hz, 2H), 1.95–2.10 (m, 4H), 2.09–2.20 (m, 2H), 2.22–2.34 (m, 4H), 2.66–2.74 (m, 1H), 2.76 (s, 3H), 3.05–3.15 (m, 2H), 3.14–3.26 (m, 3H), 3.30–3.38 (m, 2H), 3.62 (t, <i>J</i> = 4.8 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub>S (M + H)<sup>+</sup>, 370.2158; found, 370.2160.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (4-Cyclobutylpiperazin-1-yl)(7-phenyl-7-azaspiro[3.5]nonan-2-yl)methanone (<b>29h</b>)</h3><div class="NLM_p last">Cesium carbonate (0.123 g, 0.38 mmol) was added to a solution of (4-cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone <b>31g</b> (0.100 g, 0.340 mmol), Pd(OAc)<sub>2</sub> (0.007 g, 0.03 mmol), BINAP (0.042 g, 0.07 mmol), and bromobenzene (0.056 g, 0.36 mmol) in toluene (5 mL). The reaction mixture was heated at 110 °C for 18 h. The reaction was cooled to room temperature and filtered over Celite. The solvent was concentrated, and the product was purified by preparative HPLC using procedure B to provide the title compound as white solid (59.0 mg, 46.8%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.60–1.75 (m, 4H), 1.75–1.81 (m, 2H), 1.81–1.95 (m, 2H), 1.96–2.10 (m, 4H), 2.10–2.20 (m, 2H), 2.21–2.35 (m, 4H), 2.71 (dq, <i>J</i> = 8.0, 7.7 Hz, 1H), 3.00–3.11 (m, 2H), 3.11–3.26 (m, 3H), 3.31–3.42 (m, 2H), 3.56–3.70 (m, 2H), 6.82 (t, <i>J</i> = 7.2 Hz, 1H), 6.93 (d, <i>J</i> = 7.81 Hz, 2H), 7.18–7.29 (m, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>33</sub>N<sub>3</sub>O (M + H)<sup>+</sup>, 368.2696; found, 368.2698.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (7-Benzoyl-7-azaspiro[3.5]nonan-2-yl)(4-cyclobutylpiperazin-1-yl)methanone (<b>29i</b>)</h3><div class="NLM_p last">Benzoyl chloride (0.035 mL, 0.30 mmol) was added to a solution of (4-cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone <b>31g</b> (80 mg, 0.27 mmol) and DIPEA (0.058 mL, 0.33 mmol) in dichloromethane (8 mL). The reaction mixture was stirred for 3 days, and the solvent was concentrated. The crude material was purified on preparative HPLC MS using procedure B to provide the title compound as white solid (36.5 mg, 33.6%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.51 (br s, 1H), 1.62–1.68 (m, 2H), 1.68–1.80 (m, 3H), 1.80–1.95 (m, 2H), 1.96–2.11 (m, 4H), 2.16 (br s, 2H), 2.27 (q, <i>J</i> = 5.47 Hz, 4H), 2.71 (dq, <i>J</i> = 8.0, 7.7 Hz, 1H), 3.11–3.30 (m, 2H), 3.35 (br s, 3H), 3.55–3.67 (m, 3H), 3.72 (br s, 1H), 7.32–7.44 (m, 5H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>33</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 396.2645; found, 396.2650.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (7-Benzoyl-7-azaspiro[3.5]nonan-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone (<b>29j</b>)</h3><div class="NLM_p last">Benzoyl chloride (0.040 mL, 0.34 mmol) was added to a solution of (4-cyclobutyl-1,4-diazepan-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone <b>31g</b> (0.095 g, 0.31 mmol) and DIEA (0.081 mL, 0.47 mmol) in dichloromethane (10 mL). The reaction mixture was stirred overnight, and the solvent was concentrated. The crude material was purified on preparative HPLC using procedure B to provide the title compound as a white solid (0.082 g, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.53 (br s, 1H), 1.56–1.72 (m, 4H), 1.72–1.95 (m, 5H), 1.96–2.11 (m, 4H), 2.17 (br s, 2H), 2.35–2.45 (m, 2H), 2.45–2.54 (m, 2H), 2.76–2.91 (m, 1H), 3.26 (br s, 2H), 3.34 (br s, 1H), 3.42 (t, <i>J</i> = 5.86 Hz, 2H), 3.55–3.68 (m, 3H), 3.72, (br s, 1H), 7.31–7.49 (m, 5H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>35</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 410.2802; found, 410.2797.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Benzyl 2-(4-Cyclobutylpiperazine-1-carbonyl)-7-azaspiro[3.5]nonane-7-carboxylate (<b>30g</b>)</h3><div class="NLM_p last">HBTU (1.018 g, 2.68 mmol) and 1-cyclobutylpiperazine (342 mg, 2.44 mmol) were added to a solution of 7-(benzyloxycarbonyl)-7-azaspiro[3.5]nonane-2-carboxylic acid (0.74 g, 2.44 mmol) and DIEA (0.511 mL, 2.93 mmol) in DMF (60 mL). The reaction mixture was stirred for 3 h, and the solvent was concentrated. The product was purified on silica gel by using 3% MeOH and 5% acetone in CH<sub>2</sub>Cl<sub>2</sub> with 0.1 N ammonia as the eluent (80 g column; 20 mL/min then 40 mL/min) to provide the title compound (0.81 g, 78%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.43–1.57 (m, 3H), 1.56–1.67 (m, 2H), 1.67–1.82 (m, 2H), 1.82–1.98 (m, 3H), 1.98–2.08 (m, 3H), 2.08–2.18 (m, 2H), 2.26–2.35 (m, 3H), 2.69–2.80 (m, <i>J</i> = 8.20, 7.91, 7.76, 7.76 Hz, 1H), 3.18 (quin, <i>J</i> = 8.50 Hz, 1H), 3.33–3.42 (m, 4H), 3.41–3.50 (m, 2H), 3.58–3.69 (m, 2H), 5.12 (s, 2H), 7.29–7.41 (m, 5H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 426.3.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Benzyl 2-(4-Cyclobutyl-1,4-diazepane-1-carbonyl)-7-azaspiro[3.5]nonane-7-carboxylate (<b>30j</b>)</h3><div class="NLM_p last">Oxalyl chloride (0.970 mL, 11.08 mmol) was slowly added to a solution of 7-(benzyloxycarbonyl)-7-azaspiro[3.5]nonane-2-carboxylic acid (1.12 g, 3.69 mmol) in dichloromethane (50 mL) at 0 °C under a nitrogen atmosphere. The solution was stirred for 4 h while gradually warming to 15 °C. The solvent was concentrated under vacuum, and the residue was recovered in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The resulting solution was added dropwise over 15 min to a solution of 1-cyclobutyl-1,4-diazepane (0.62 g, 4.06 mmol) and DIEA (1.934 mL, 11.08 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred for 30 min and concentrated. The product was purified on SiO<sub>2</sub> (gradient of MeOH 3% in CH<sub>2</sub>Cl<sub>2</sub> (500 mL) to MeOH 5% in CH<sub>2</sub>Cl<sub>2</sub> (500 mL)). Impure fractions were resubjected to purification under the same conditions to give several batches of pure compound, which were combined to provide the title compound as a white solid (0.681 g, 42.0%). <i>t</i><sub>R</sub> = 1.80 min (5 min run). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 440.39. The material was used is as without further characterization.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (4-Cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (<b>31g</b>)</h3><div class="NLM_p last">A mixture of benzyl 2-(4-cyclobutylpiperazine-1-carbonyl)-7-azaspiro[3.5]nonane-7-carboxylate (0.80 g, 1.88 mmol), Pd/C (0.01 g, 0.09 mmol), and ethanol (100 mL) was shaken in a Parr apparatus under a 50 psi atmosphere of hydrogen for 4 h. The mixture was filtered over a Celite bed, and the solvent was concentrated to provide (4-cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (480 mg, 88%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.49–1.62 (m, 2H), 1.62–1.78 (m, 3H), 1.79–1.95 (m, <i>J</i> = 9.4, 9.4, 9.2, 8.9 Hz, 2H), 1.95–2.16 (m, 5H), 2.27 (q, <i>J</i> = 5.1 Hz, 4H), 2.60 (br s, 3H), 2.65–2.74 (m, 1H), 2.74–2.81 (m, 2H), 2.81–2.93 (m, 2H), 3.16 (quin, <i>J</i> = 8.7 Hz, 1H), 3.28–3.40 (m, 2H), 3.62 (t, <i>J</i> = 4.9 Hz, 2H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 292.2.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (4-Cyclobutyl-1,4-diazepan-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (<b>31j</b>)</h3><div class="NLM_p last">The title compound was prepared in an analogous manner to <b>31g</b> to yield a white solid (1.62 g, 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.49–1.58 (m, 2H), 1.58–1.74 (m, 3H), 1.74–1.93 (m, 4H), 1.93–2.17 (m, 8H), 2.36–2.45 (m, 2H), 2.48 (dt, <i>J</i> = 4.98, 2.15 Hz, 2H), 2.67–2.78 (m, 2H), 2.78–2.91 (m, 3H), 3.17 (quin, <i>J</i> = 8.79 Hz, 1H), 3.37–3.47 (m, 2H), 3.5 −3.67 (m, 2H).</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>tert</i>-Butyl 2-(4-Isopropylpiperazine-1-carbonyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (<b>33</b>)</h3><div class="NLM_p last">To a −78 °C cooled solution of 4-nitrophenyl carbonochloridate (0.384 g, 1.90 mmol) in THF (5 mL) was added DIPEA (1.00 mL, 5.71 mmol) followed by 1-isopropylpiperazine (0.28 mL, 1.90 mmol). This cloudy mixture was stirred 5 min, and then <i>tert</i>-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride (0.50 g, 1.90 mmol) was added. The reaction was warmed to room temperature and then refluxed for 12 h. The crude reaction was partitioned between EtOAc/NaHCO<sub>3</sub> (sat.). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed to give an amber gum. The material was chromatographed with SiO<sub>2</sub> chromatography (80 g, using a gradient of 0–10% MeOH to CH<sub>2</sub>Cl<sub>2</sub>) and dried to give a tan solid (0.525 g, 72%). <sup>1</sup>H NMR 500 MHz, CDCl<sub>3</sub>) δ 1.03 (d, <i>J</i> = 6.5 Hz, 6H), 1.45 (s, 9H), 1.69 (app t, <i>J</i> = 5.5 Hz, 4H), 2.47 (br s, 4H), 2.65 (m, 1H), 3.35–3.33 (m, 8H), 3.70 (s, 4H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 381.3.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (4-Isopropylpiperazin-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-2,7-diazaspiro[3.5]nonan-2-yl)methanone (<b>34</b>)</h3><div class="NLM_p last">To <i>tert</i>-butyl 2-(4-isopropylpiperazine-1-carbonyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (0.51 g, 1.34 mmol) was added MeOH (20 mL) that had been saturated with HCl gas. The reaction was stirred 1 h, the solvent was removed, and the white solid was put under high vacuum for 12 h (0.52 g). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 281.2. The material contained ∼50% impurity that was not removed but was used as is in the next reaction without further purification. To impure (4-isopropylpiperazin-1-yl)(2,7-diazaspiro[3.5]nonan-2-yl)methanone dihydrochloride (0.52 g, 1.49 mmol) were added MeOH (10 mL), TEA (0.621 mL, 4.46 mmol), Pd/C (63.3 mg, 0.06 mmol), and dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (0.55 mL, 5.94 mmol). The reaction was fitted with a balloon filled with H<sub>2</sub> and stirred for 24 h. The catalyst was filtered off, the solvent was removed under reduced pressure, and the resulting solids were collected. The material was purified with preparatory HPLC procedure A to provide the title compound as a white solid (0.155 g, 28%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.06 (s, 6H), 1.76–1.80 (m, 2H), 1.79–1.87 (m, 2H), 2.07–2.09 (2H), 2.34–2.35 (m, 2H), 2.47 (app t, <i>J</i> = 5 Hz, 4H), 2.64 (quintet, <i>J</i> = 6.5 Hz, 1H), 3.48–3.52 (m, 8H), 3.58–3.61 (m, 6H), 3.91–3.94 (m, 1H), 4.08 (dd, <i>J</i> = 11.7, 4.5 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>36</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 365.2911; found, 365.2913.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> <i>tert</i>-Butyl 2-(4-Cyclobutyl-1,4-diazepane-1-carbonyl)-2,7-diazaspiro[4.5]decane-7-carboxylate (<b>36a</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 2,7-diazaspiro[4.5]decane-7-carboxylate hydrochloride <b>35</b> (2.30 g, 8.32 mmol) was dissolved in dry THF (40 mL), and to this was added freshly recrystallized carbonyl diimidazole (1.48 g, 9.15 mmol). The reaction mixture was heated at reflux for 24 h, and then THF was removed in vacuo. The residue was dissolved in EtOAc (75 mL), washed with 5% NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to afford the title imidazole intermediate (3.13 g, 113%) as a yellowish oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.39 (s, 9H), 1.49–1.98 (m, 6H), 3.12–3.83 (m, 8H), 7.08 (s, 1H), 7.33 (s, 1H), 8.00 (s, 1H). This intermediate (2.78 g, 8.31 mmol) was dissolved in acetonitrile (20 mL), MeI (4.72 g, 33.25 mmol) was added, and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was concentrated to dryness to yield the intermediate imidazolium salt as a yellow solid (4.59 g, 158%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.45 (s, 9H), 1.51–2.03 (m, 6H), 3.34–3.91 (m, 8H), 7.72 (s, 1H), 8.04 (s, 1H), 9.52 (s, 1H). In a round-bottomed 50 mL flask were added the imidazolium salt (738 mg, 2.11 mmol), CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and Et<sub>3</sub>N (0.24 mL, 1.72 mmol). Another flask was charged with 1-cyclobutyl-1,4-diazepane dihydrochloride (400 mg, 1.76 mmol), CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and Et<sub>3</sub>N (0.50 mL, 3.56 mmol). Both mixtures were stirred 15 min, and the amine solution was transferred via syringe into the first flask. The reaction mixture was stirred 24 h at room temperature and then washed with NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified via preparatory HPLC using procedure C to produce the title compound (392 mg, 40%) as a yellowish oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.38 (s, 9H), 1.33–1.91 (m, 12H), 1.91–2.05 (m, 2H), 2.27–2.59 (m, 4H), 2.73–2.88 (m, 1H), 2.98–3.54 (m, 12H).</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>tert</i>-Butyl 2-(4-Isopropylpiperazine-1-carbonyl)-2,7-diazaspiro[4.5]decane-7-carboxylate (<b>36b</b>)</h3><div class="NLM_p last">The title compound was prepared in an analogous fashion to <b>36a</b> beginning with 1-isopropylpiperazine dihydrochloride to produce the title compound as a yellowish oil (392 mg, 40%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.94 (d, <i>J</i> = 6.5 Hz, 6H), 1.33 (s, 9H), 1.33–1.54 (m, 5H), 1.57–1.73 (m, 1H), 2.30–2.45 (m, 4H), 2.51–2.64 (m, 1H), 2.94–3.47 (m, 12H).</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (4-Cyclobutyl-1,4-diazepan-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-2,7-diazaspiro[4.5]decan-2-yl)methanone (<b>37a</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 2-(4-cyclobutyl-1,4-diazepane-1-carbonyl)-2,7-diazaspiro[4.5]decane-7-carboxylate <b>36a</b> (400 mg, 0.95 mmol) was dissolved in 6 N HCl <i>i</i>PrOH (5 mL) and stirred overnight at room temperature. The reaction mixture was concentrated to dryness, CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added followed by Et<sub>3</sub>N (0.29 mL, 2.08 mmol), and the reaction mixture was stirred 10 min. Dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (156 mg, 1.56 mmol) and AcOH (56 μL, 0.95 mmol) were added. After 15 min of stirring, NaBH(OAc)<sub>3</sub> (331 mg, 1.56 mmol) was added, and the reaction mixture was left stirring overnight at room temperature. The reaction mixture was washed with 5% NaHCO<sub>3</sub>, extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified via preparatory HPLC using procedure C to produce the title compound (150 mg, 36%) as a clear oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.18–2.01 (m, 19H), 2.18 (dd, <i>J</i> = 28.1, 10.9 Hz, 2H), 2.28–2.53 (m, 6H), 2.79 (m, 1H), 2.99 (d, <i>J</i> = 10.3 Hz, 1H), 3.16–3.40 (m, 7H), 3.66 (s, 2H), 3.82–3.93 (m, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>40</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 405.3229; found, 405.3224.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> (4-Isopropylpiperazin-1-yl)(7-(tetrahydro-2<i>H</i>-pyran-4-yl)-2,7-diazaspiro[4.5]decan-2-yl)methanone (<b>37b</b>)</h3><div class="NLM_p last">Material was prepared in an analogous manner to <b>37a</b> to provide the title compound (167 mg, 44%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.04 (d, <i>J</i> = 6.5 Hz, 6H), 1.29–1.69 (m, 10H), 1.77–1.88 (m, 1H), 2.28 (q, <i>J</i> = 11.0 Hz, 2H), 2.38–2.58 (m, 6H), 2.61–2.74 (m, 1H), 3.12 (d, <i>J</i> = 10.4 Hz, 1H), 3.22 −3.52 (m, 9H), 3.98 (d, <i>J</i> = 9.4 Hz, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>38</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 379.3073; found, 379.3080.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> (7-Benzoyl-2,7-diazaspiro[4.5]decan-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone (<b>37c</b>)</h3><div class="NLM_p last">(4-Cyclobutyl-1,4-diazepan-1-yl)(2,7-diazaspiro[4.5]decan-2-yl)methanone <b>36a</b> (200 mg, 0.51 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (3 mL). Triethylamine (0.21 mL, 1.53 mmol) was added, and the solution was stirred at room temperature for 10 min. Benzoyl chloride (0.07 mL, 0.61 mmol) was then added, and the mixture was stirred at room temperature for 4 h. The solution was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and washed with 5% aq. NaHCO<sub>3</sub> (1 × 10 mL) and brine (1 × 10 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The product was purified through flash-chromatography (SiO<sub>2</sub>, gradient of CH<sub>2</sub>Cl<sub>2</sub>/MeOH 100:0 to 80:20) and then on reverse phase (flow: 30 mL/min, H<sub>2</sub>O/CH<sub>3</sub>CN 100:0 to 5:95) to provide the title compound (103 mg, 48%) as an off-white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.44–2.16 (m, 13H), 2.21–2.65 (m, 6H), 2.75–2.92 (m, 1H), 2.99–3.71 (m, 10H), 3.72–3.94 (m, 1H), 7.30–7.45 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 13.4, 22.4, 23.6, 27.9, 33.9, 42.1, 46.6, 47.6, 47.8, 49.0, 51.4, 52.2, 54.2, 56.4, 56.7, 59.7, 126.8, 128.4, 129.4, 136.0, 163.0, 170.7. HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>36</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 425.2911; found, 425.2909.</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (4-Cyclobutyl-1,4-diazepan-1-yl)(7-(phenylsulfonyl)-2,7-diazaspiro[4.5]decan-2-yl)methanone (<b>37d</b>)</h3><div class="NLM_p last">(4-Cyclobutyl-1,4-diazepan-1-yl)(2,7-diazaspiro[4.5]decan-2-yl)methanone (200 mg, 0.51 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (3 mL). Triethylamine (0.21 mL, 1.53 mmol) was added, and the solution was stirred at room temperature for 10 min. Benzenesulfonyl chloride (0.078 mL, 0.61 mmol) was then added, and the mixture was stirred at room temperature for 4 h. The solution was then was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and washed with 5% aq. NaHCO<sub>3</sub> (1 × 10 mL) and brine (1 × 10 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The product was purified through flash-chromatography (SiO<sub>2</sub>, gradient of CH<sub>2</sub>Cl<sub>2</sub>/MeOH 100:0 to 80:20) and then on reverse phase (flow: 30 mL/min, H<sub>2</sub>O/CH<sub>3</sub>CN 100:0 to 5:95) to provide the title compound (117 mg, 50%) as an off-white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.38–1.44 (m, 2H), 1.52–1.73 (m, 5H), 1.77–1.94 (m, 4H), 1.98–2.07 (m, 2H), 2.17–2.28 (m, 1H), 2.35–2.48 (m, 2H), 2.50–2.57 (m, 2H), 2.66 (d, <i>J</i> = 11.4 Hz, 1H), 2.79–2.86 (m, 2H), 2.95 (d, <i>J</i> = 11.5 Hz, 1H), 3.05–3.10 (m, 1H), 3.18 (q, <i>J</i> = 10.9 Hz, 2H), 3.35–3.51 (m, 6H), 7.49–7.61 (m, 3H), 7.73 (d, <i>J</i> = 8.1 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 13.5, 22.6, 27.9, 28.1, 33,0, 33.8, 41.5, 46.6, 46.8, 47.6, 48.0, 51.5, 52.1, 53.1, 57.1, 59.7, 127.4, 129.0, 132.7, 136.3, 163.0. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 461.25. HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>36</sub>N<sub>4</sub>SO<sub>3</sub> (M + H)<sup>+</sup>, 461.2580; found, 461.2576.</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>tert</i>-Butyl 2-(4-Isopropylpiperazine-1-carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate (<b>40</b>)</h3><div class="NLM_p last">To a −78 °C cooled solution of 4-nitrophenyl carbonochloridate (0.36 g, 1.81 mmol) in THF (10 mL) was added DIPEA (0.95 mL, 5.42 mmol) and then 1-isopropylpiperazine (0.26 mL, 1.81 mmol). After stirring the mixture for 5 min, <i>tert</i>-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate hydrochloride (0.500 g, 1.81 mmol) was added, and the reaction was warmed to room temperature. The reaction was refluxed overnight for 12 h. The material was chromatographed with SiO<sub>2</sub> chromatography (80 g, using a gradient of 0–10% MeOH to CH<sub>2</sub>Cl<sub>2</sub>) and dried to give the title compound as white solid (0.20 g, 28%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.05 (d, <i>J</i> = 6.5 Hz, 6H), 1.45 (s, 9H), 1.49–1.52 (m, 4H), 1.71 (t, 2H, <i>J</i> = 7 Hz, 2H), 2.48–2.50 (m, 4H), 2.67–2.69 (m, 1H), 3.22 (s, 2H), 3.31–3.36 (m, 6H), 3.46–3.42 (m, 4H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 395.3.</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> <i>tert</i>-Butyl 2-(4-Cyclobutyl-1,4-diazepane-1-carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate (<b>40b</b>)</h3><div class="NLM_p last"><i><i>tert</i>-</i>Butyl 2,8-diazaspiro[4.5]decane-8-carboxylate hydrochloride <b>39</b> (1.0 g, 3.61 mmol) was dissolved in dry THF (20 mL), and then freshly recrystallized carbonyl diimidazole (644 mg, 3.97 mmol) was added. The reaction mixture was heated at reflux for 24 h, and THF was removed in vacuo. The residue was dissolved in EtOAc (50 mL), washed with NaHCO<sub>3</sub> (5%) and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to yield the intermediate imidazole (1.45 g, 120%) as a yellowish oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.46 (s, 9H), 1.50–1.65 (m, 4H), 1.89 (t, <i>J</i> = 7.1 Hz, 2 H), 3.28–3.57 (m, 6H), 3.73 (t, <i>J</i> = 7.1 Hz, 2H), 7.09 (s, 1H), 7.34 (s, 1H), 8.01 (s, 1H). This material (1.13 g, 2.71 mmol) was dissolved in acetonitrile (8 mL), MeI (1.54 g, 10.8 mmol) was added, and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was concentrated to dryness, and to this were added CH<sub>2</sub>Cl<sub>2</sub> (8 mL), Et<sub>3</sub>N (1.13 mL, 8.13 mmol), and 1-cyclobutyl-1,4-diazepane (616 mg, 2.71 mmol). The reaction mixture was stirred 24 h at room temperature, washed with NaHCO<sub>3</sub> (sat.) brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified via preparatory HPLC using procedure C and then reverse-phase preparatory HPLC (H<sub>2</sub>O/ACN, Flow: 30 mL/min, 12 g column, 100:0 to 0:100 over 30 min) to produce the title compound (742 mg, 65%) as a yellowish oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.37–1.56 (m, 13H), 1.56–1.76 (m, 6H), 1.76–1.95 (m, 4H), 1.95–2.09 (m, 2H), 2.37–2.57 (m, 4H), 2.77–2.91 (m, 1H), 3.21 (s, 2H), 3.24–3.37 (m, 2H), 3.37–3.54 (m, 6H).</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>tert</i>-Butyl 2-(4-Cyclobutylpiperazine-1-carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate (<b>40e</b>)</h3><div class="NLM_p last">Crude <i>tert</i>-butyl 2-(1<i>H</i>-imidazole-1-carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate (1.45 g, 3.61 mmol) was dissolved in acetonitrile (8 mL), MeI (2.05 g, 14.4 mmol) was added, and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was concentrated to dryness, and to this were added CH<sub>2</sub>Cl<sub>2</sub> (8 mL), Et<sub>3</sub>N (1.51 mL, 10.83 mmol), and 1-cyclobutylpiperazine (808 mg, 3.79 mmol). The reaction mixture was stirred 24 h at room temperature and then washed with NaHCO<sub>3</sub> and NaCl (sat.), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified via preparatory HPLC using procedure C and then reverse-phase preparatory HPLC (H<sub>2</sub>O/ACN, flow: 30 mL/min, 12 g column, 100:0 to 0:100 over 30 min) to produce the title compound (980 mg, 67%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.37–1.54 (m, 13H), 1.60–1.78 (m, 4H), 1.78–1.95 (m, 2H), 1.95–2.09 (m, 2H), 2.24–2.36 (m, 4H), 2.64–2.78 (m, 1H), 3.22 (s, 2H), 3.25–3.39 (m, 6H), 3.39–3.52 (m, 4H).</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> (4-Isopropylpiperazin-1-yl)(8-(tetrahydro-2<i>H</i>-pyran-4-yl)-2,8-diazaspiro[4.5]decan-2-yl)methanone (<b>41a</b>)</h3><div class="NLM_p last">To <i>tert</i>-butyl 2-(4-isopropylpiperazine-1-carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate (0.185 g, 0.47 mmol) was added MeOH (20 mL) that had been saturated with HCl gas. The reaction was stirred 1 h, the solvent was removed, and the white solid was put under high vacuum overnight to give the intermediate amine (0.120 g, 75%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, TFA shake) δ 1.24–1.25 (m, 6H), 1.61–1.67 (m, 4H), 1.75–1.77 (m, 2H), 2.98 (app t, <i>J</i> = 11.5 Hz, 2H), 2.98–3.00 (m, 4H), 3.15–3.18 (m, 2H), 3.22 (s, 2H), 3.40–3.48 (m, 5H), 3.49–3.57 (m, 1H), 3.75 (app d, <i>J</i> = 14.0 Hz, 2H). MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 295.3. To (4-isopropylpiperazin-1-yl)(2,8-diazaspiro[4.5]decan-2-yl)methanone dihydrochloride (0.20 g, 0.54 mmol) were added MeOH (5 mL), dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (0.20 mL, 2.18 mmol), TEA (0.23 mL, 1.63 mmol), and Pd/C (23.18 mg, 0.02 mmol), and a balloon filled with H<sub>2</sub> gas was fitted to the reaction. After stirring for 24 h, the catalyst was filtered off, the solvent was removed under reduced pressure, and solids were put under high vacuum. The material was purified with preparatory HPLC using procedure A to provide the title compound as a white solid (0.205 g, 62%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.03 (d, <i>J</i> = 6.5 Hz, 6H), 1.57–1.61 (m, 7H), 1.72 (t, <i>J</i> = 7.0 Hz, 2H), 1.70–1.75 (m, 1H), 2.42–2.49 (m, 7H), 2.57–2.58 (m, 2H), 2.67 (quin., <i>J</i> = 6.5 Hz, 1H), 3.19 (s, 2H), 3.30–3.28 (m, 4H), 3.36 (dt, <i>J</i> = 12, 2, Hz, 2H), 3.42 (t, <i>J</i> = 7.0 Hz, 2H), 4.00–4.03 (m, 2H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>38</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 379.3067; found, 379.3055.</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (8-Benzoyl-2,8-diazaspiro[4.5]decan-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone (<b>41b</b>)</h3><div class="NLM_p last">To <i>tert</i>-butyl 2-(4-cyclobutyl-1,4-diazepane-1-carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate <b>40b</b> (742 mg, 1.76 mmol) was added 6 N HCl in <i>i</i>PrOH (5 mL). The reaction mixture was stirred 4 h, and then Et<sub>2</sub>O (50 mL) was added. The salt was filtered under N<sub>2</sub> and dried in vacuo to make the intermediate amine (755 mg, 108%) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.72–2.01 (m, 7H), 2.15–2.43 (m, 6H), 2.92–3.28 (m, 7H), 3.35–3.90 (m, 11H). (4-Cyclobutyl-1,4-diazepan-1-yl)(2,8-diazaspiro[4.5]decan-2-yl)methanone (200 mg, 0.51 mmol) and Et<sub>3</sub>N (212 μL, 1.52 mmol) were mixed in a flask in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) and stirred 10 min. Benzoyl chloride (73 mg, 0.52 mmol) was added, and the reaction mixture was stirred for 2 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with 5% NaHCO<sub>3</sub> and brine, then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified via preparatory HPLC using procedure C and then reverse-phase preparatory HPLC (H<sub>2</sub>O/ACN, flow: 30 mL/min, 12 g column, 100:0 to 0:100 over 30 min) to produce the title compound (200 mg, 85%) as a clear oil after lyophilization (H<sub>2</sub>O/ACN). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.36–1.93 (m, 12H), 1.93–2.10 (m, 2H), 2.28–2.47 (m, 3H), 2.47–2.57 (m, 2H), 2.74–2.90 (m, 1H), 3.25 (s, 2H), 3.25–3.50 (m, 7H), 3.50–3.72 (m, 1H), 3.72–3.94 (m, 1H), 7.32–7.44 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 13.5, 27.9, 28.2, 34.0, 35.0, 35.8, 39.7, 40.2, 45.4, 46.7, 47.6, 48.0, 51.4, 52.1, 57.8, 59.7, 126.8, 128.4, 129.5, 136.0, 163.1, 170.3. HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>36</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 425.2911; found, 425.2910.</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> (4-Cyclobutyl-1,4-diazepan-1-yl)(8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl)methanone (<b>41c</b>)</h3><div class="NLM_p last">(4-Cyclobutyl-1,4-diazepan-1-yl)(2,8-diazaspiro[4.5]decan-2-yl)methanone <b>40b</b> (200 mg, 0.510 mmol) and Et<sub>3</sub>N (212 μL, 1.52 mmol) were mixed in a flask in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) and stirred 10 min. Benzenesulfonyl chloride (92 mg, 0.52 mmol) was added, and the reaction mixture was stirred 2 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with 5% NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified via preparatory HPLC using procedure C and then reverse-phase preparatory HPLC (H<sub>2</sub>O/ACN, flow: 30 mL/min, 12 g column, 100:0 to 0:100 over 30 min) to produce the title compound (180 mg, 77%) as a white solid after lyophilization (H<sub>2</sub>O/ACN). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.51–1.72 (m, 8H), 1.72–1.89 (m, 4H), 1.96–2.08 (m, 2H), 2.34–2.43 (m, 2H), 2.46–2.53 (m, 2H), 2.72–2.86 (m, 3H), 3.07 (s, 2H), 3.18–3.29 (m, 2H), 3.29–3.44 (m, 6H), 7.50–7.65 (m, 3H), 7.72–7.77 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 13.5, 28.0, 28.2, 33.7, 36.2, 39.1, 43.7, 46.7, 47.6, 48.1, 51.4, 52.1, 56.8, 59.7, 127.5, 129.0, 132.8, 136.0, 163.1. HPLC: 99%. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 461.25. HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>36</sub>N<sub>4</sub>SO<sub>3</sub> (M + H)<sup>+</sup>, 461.2580; found, 461.2581.</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (4-Cyclobutyl-1,4-diazepan-1-yl)(8-(isopropylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl)methanone (<b>41d</b>)</h3><div class="NLM_p last">The title compound was made in an analogous manner to <b>41c</b> using isopropyl sulfonyl choride to give the title compound in 80% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.33 (d, <i>J</i> = 6.8 Hz, 6H), 1.52–1.95 (m, 12H), 1.95–2.10 (m, 2H), 2.39–2.48 (m, 2H), 2.48–2.59 (m, 2H), 2.77–2.91 (m, 1H), 3.11–3.31 (m, 5H), 3.35–3.50 (m, 8H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 13.4, 16.7, 27.9, 28.2, 34.6, 35.9, 39.6, 43.8, 46.6, 47.6, 48.0, 51.4, 52.1, 53.2, 57.4, 59.6, 163.1. HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>38</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup>, 427.2737; found, 427.2738.</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> (8-Benzoyl-2,8-diazaspiro[4.5]decan-2-yl)(4-cyclobutylpiperazin-1-yl)methanone (<b>41e</b>)</h3><div class="NLM_p last">To <i>tert</i>-butyl 2-(4-cyclobutylpiperazine-1-carbonyl)-2,8-diazaspiro[4.5]decane-8-carboxylate <b>40e</b> (980 mg, 2.33 mmol) was added 6 N HCl in <i>i</i>PrOH (5 mL). The reaction mixture was stirred 4 h, and then Et<sub>2</sub>O (50 mL) was added. The salt was filtered under N<sub>2</sub> and dried in vacuo to yield the intermediate amine (800 mg, 91%) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.71–1.98 (m, 8H), 2.22–2.41 (m, 4H), 2.89–3.03 (m, 2H), 3.12–3.28 (m, 6H), 3.37 (s, 2H), 3.40–3.49 (m, 2H), 3.54 (t, <i>J</i> = 7.1 Hz, 2H), 3.65–3.80 (m, 1H), 3.87–3.97 (m, 2H). This intermediate (200 mg, 0.53 mmol) and Et<sub>3</sub>N (294 μL, 2.11 mmol) were mixed in a flask in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) and stirred 10 min. Benzoyl chloride (76 mg, 0.53 mmol) was added, and the reaction mixture was stirred for 2 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with 5% NaHCO<sub>3</sub> and brine and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The organic phase was filtered and concentrated in vacuo. The residue was purified via preparatory HPLC using procedure C and then reverse-phase preparatory HPLC (H<sub>2</sub>O/ACN, flow: 30 mL/min, 12 g column, 100:0 to 0:100 over 30 min) to give the title compound (190 mg, 88%) as a white solid after lyophilization (H<sub>2</sub>O/ACN). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.41–1.96 (m, 10H), 1.96–2.10 (m, 2H), 2.25–2.37 (m, 4H), 2.65–2.79 (m, 1H), 3.23–3.51 (m, 10H), 3.54–3.74 (m, 1H), 3.74–3.92 (m, 1H), 7.36–7.44 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 14.3, 26.9, 34.0, 35.0, 35.6, 39.6, 40.5, 45.2, 45.8, 46.4, 49.2, 57.8, 60.2, 126.8, 128.4, 129.6, 136.0, 162.6, 170.3. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 411.31. HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>34</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 411.2754; found, 411.2752.</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> (4-Cyclobutylpiperazin-1-yl)(8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl)methanone (<b>41f</b>)</h3><div class="NLM_p last">(4-Cyclobutylpiperazin-1-yl)(2,8-diazaspiro[4.5]decan-2-yl)methanone (200 mg, 0.53 mmol) and Et<sub>3</sub>N (220 μL, 1.58 mmol) were mixed in a flask in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) and stirred 10 min. Benzenesulfonyl chloride (95 mg, 0.54 mmol) was added, and the reaction mixture was stirred for 2 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with 5% NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified via preparatory HPLC using procedure C and then reverse-phase preparatory HPLC (H<sub>2</sub>O/ACN, flow: 30 mL/min, 12 g column, 100:0 to 0:100 over 30 min) to produce the title compound (200 mg, 85%) as a white solid after lyophilization (H<sub>2</sub>O/ACN). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.55–1.76 (m, 8H), 1.76–1.93 (m, 2H), 1.93–2.07 (m, 2H), 2.21–2.31 (m, 4H), 2.63–2.75 (m, 1H), 2.77–2.90 (m, 2H), 3.08 (s, 2H), 3.14–3.29 (m, 6H), 3.37 (t, <i>J</i> = 7.1 Hz, 2H), 7.50–7.65 (m, 3H), 7.71–7.79 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 14.3, 26.9, 33.7, 35.9, 39.3, 43.6, 45.7, 46.4, 49.2, 56.9, 60.2, 127.5, 129.1, 132.8, 136.0, 162.5. Analytical HPLC method D was employed. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 447.24.</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> (8-Benzoyl-2,8-diazaspiro[4.5]decan-2-yl)(1-cyclobutylpiperidin-4-yl)methanone (<b>41g</b>)</h3><div class="NLM_p">A mixture of <i>tert</i>-butyl 4-(8-benzoyl-2,8-diazaspiro[4.5]decane-2-carbonyl)piperidine-1-carboxylate (40 mg, 0.09 mmol) and a 4 M solution of HCl (0.2 mL, 0.80 mmol) in dioxane was stirred at room temperature for 2 days. The mixture was then concentrated under reduced pressure, basified with a solution of NaHCO<sub>3</sub> (sat.), and extracted with EtOAc (3×). The combined organic phases were then dried and concentrated under reduced pressure. The crude material was loaded on a 4 g silica gel column and purified on SiO<sub>2</sub>, eluting with 5–60% EtOAc in heptane and then flushed with MeOH to provide (8-benzoyl-2,8-diazaspiro[4.5]decan-2-yl)(piperidin-4-yl)methanone (20 mg, 64.1%) as an oil. The product was analyzed by analytical HPLC MS using procedure D. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 356.3. <i>t</i><sub>R</sub> = 1.60 min.</div><div class="NLM_p last">To a solution of (8-benzoyl-2,8-diazaspiro[4.5]decan-2-yl)(piperidin-4-yl)methanone (15 mg, 0.04 mmol) in DMF (3 mL) was added cyclobutanone (2.96 mg, 0.04 mmol), and the mixture was stirred for 30 min. NaCNBH<sub>4</sub> (2.65 mg, 0.04 mmol) was then added, and the mixture was stirred overnight. The mixture was then quenched with a saturated solution of NaHCO<sub>3</sub> and concentrated under reduced pressure. The residue was diluted in EtOAc, washed with brine, and concentrated under reduced pressure. The crude material was purified by preparative HPLC using procedure B to provide the title compound (7.0 mg, 37%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.86–0.99 (m, 2H), 1.24–1.49 (m, 6H), 1.52–1.64 (m, 1H), 1.64–1.77 (m, 1H), 1.80–2.13 (m, 5H), 2.15–2.28 (m, 1H), 2.28–2.43 (m, 1H), 2.77–2.93 (m, 1H), 3.41–3.62 (m, 5H), 3.62–3.89 (m, 6H), 4.19–4.26 (m, 1H), 7.35–7.44 (m, 2H), 7.44–7.53 (m, 3H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 410.2802; found, 410.2807.</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> (9-Benzoyl-2,9-diazaspiro[5.5]undecan-2-yl)(4-cyclobutyl-1,4-diazepan-1-yl)methanone (<b>41h</b>)</h3><div class="NLM_p last">This compound was made in an analogous manner to <b>41b</b> with commercially available <i>tert</i>-butyl 2,9-diazaspiro[5.5]undecane-9-carboxylate to give the title compound in 80% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.21–1.97 (m, 14H), 1.97–2.13 (m, 2H), 2.35–2.67 (m, 4H), 2.76–2.94 (m, 1H), 2.94–3.06 (m, 1H), 3.06–3.24 (m, 3H), 3.32–3.52 (m, 6H), 3.52–3.73 (m, 1H), 3.73–3.94 (m, 1H), 7.35–7.43 (m, 5H). HRMS (TOF) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>38</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 439.3067; found, 439.3077.</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> <i>tert</i>-Butyl 8-Benzoyl-2,8-diazaspiro[4.5]decane-2-carboxylate (<b>43</b>)</h3><div class="NLM_p last">A solution of <i>tert</i>-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate·HCl (0.13 g, 0.47 mmol), DIPEA (0.164 mL, 0.94 mmol), and benzoic acid (0.057 g, 0.47 mmol) in 2-methyl tetrahydrofuran (5 mL) was stirred for 1 h at room temperature. 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium (0.125 g, 0.52 mmol) was then added, and the mixture was stirred overnight. The mixture was quenched with water, concentrated under reduced pressure, diluted in EtOAc, washed with NaHCO<sub>3</sub> (sat.) and brine, and then concentrated under reduced pressure. The crude material was purified on SiO<sub>2</sub> (40 g), eluting with 5–80% EtOAc in heptane to provide <i>tert</i>-butyl 8-benzoyl-2,8-diazaspiro[4.5]decane-2-carboxylate (0.100 g, 61.8%) as an oil. The product was analyzed by analytical HPLC MS using procedure D. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 345.3. <i>t</i><sub>R</sub> = 2.23 min.</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> <i>tert</i>-Butyl 4-(8-Benzoyl-2,8-diazaspiro[4.5]decane-2-carbonyl)piperidine-1-carboxylate (<b>44</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 8-benzoyl-2,8-diazaspiro[4.5]decane-2-carboxylate (0.10 g, 0.29 mmol) was solubilized in MeOH (2 mL), and a 4 M solution of HCl (0.508 mL, 2.03 mmol) in dioxane was added. The mixture was then stirred at room temperature for 2 days. The mixture was concentrated under reduced pressure to provide phenyl(2,8-diazaspiro[4.5]decan-8-yl)methanone·HCl (0.120 g, 147%) as an oil. The product was analyzed by analytical HPLC-MS using procedure D. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 245.4. <i>t</i><sub>R</sub> = 1.42 min. A mixture of phenyl(2,8-diazaspiro[4.5]decan-8-yl)methanone·HCl (0.12 g, 0.43 mmol), DIPEA (0.136 mL, 0.78 mmol), and 1-(<i>tert</i>-butoxycarbonyl)piperidine-4-carboxylic acid (0.089 g, 0.39 mmol) in methyl THF (5 mL) was stirred at room temperature for 15 min. 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium (0.094 g, 0.39 mmol) was then added, and the mixture was stirred for 1 h. The solvent was removed under reduced pressure. The mixture was diluted in ethyl acetate, washed with a saturated solution of NaHCO<sub>3</sub> and brine, and then concentrated under reduced pressure. The crude material was purified on SiO<sub>2</sub>, eluting with 5–60% EtOAc in heptane to provide <i>tert</i>-butyl 4-(8-benzoyl-2,8-diazaspiro[4.5]decane-2-carbonyl)piperidine-1-carboxylate (0.040 g, 22.60%) as an oil. The product was analyzed by analytical HPLC MS using procedure D. MS <i>m</i>/<i>z</i> (ES+) [M + H]<sup>+</sup> = 456.3 (major peak: 356.3). <i>t</i><sub>R</sub> = 2.14 min.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> GTPγS Assay</h3><div class="NLM_p last">Functional antagonism of the human H<sub>3</sub>R long form (445 amino acids) was quantified using an agonist-induced [<sup>35</sup>S]GTPγS scintillation proximity binding assay.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Briefly, H<sub>3</sub>R-CHO-K1 membranes were incubated for 3 h with test compound, 25 nM <i>R</i>-α-methyl histamine, 10 μM GDP, 0.2 nM [<sup>35</sup>S]GTPγS, and 150 μg of WGA PVT SPA beads in a 100 μL total volume. The amount of [<sup>35</sup>S]GTPγS binding to the SPA beads was measured on a TopCount (PerkinElmer).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Binding Assay</h3><div class="NLM_p last">The affinity of test compounds to recombinant rat and human H<sub>3</sub>R was determined using a scintillation proximity binding assay with [<sup>3</sup>H]-<i>N</i>-α-methylhistamine as ligand. Human H<sub>3</sub>R-CHO-K1 membranes were incubated for 1.5 h with test compound, 1.4 nM radioligand, and 1750 μg of WGA PVT SPA beads in a 200 μL total volume. Imetit (10 μM) was used to define nonspecific binding. The amount of radioligand binding to the SPA beads was measured on a TopCount (PerkinElmer). Binding to H<sub>3</sub>R in rat brain membranes was performed using the same radioligand but in a filtration format using GF/B filters. Bound radioligand was determined by liquid scintillation counting on a TopCount.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> VCD Experimental</h3><div class="NLM_p last">For each compound, ∼20 mg of sample was dissolved in 0.5 mL of CDCl<sub>3</sub>. Each solution was then loaded into a 0.1 mm BaF<sub>2</sub> infrared cell for analysis 4 cm<sup>–1</sup> resolution using a 5 h, dual source, VCD scan protocol. All analyses were conducted using the BioTools ChiralIR instrument. The instrument incorporated a single photoelastic modulator set for polarization modulation at 37.024 kHz with λ/4 retardation (optimized for acquisition of the spectral region centered around 1400 cm<sup>–1</sup>). Lock-in amplification with a 30 μs time constant, a 20 kHz high-pass filter, and a 4 kHz low-pass filter was used. Polarity was verified with α-pinene.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Computational Spectral Simulations</h3><div class="NLM_p last">A MonteCarlo molecular mechanics search of low-energy conformers for the (<i>R</i>) configuration of the Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> compounds was conducted using MacroModel<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> within the Maestro graphical interface. The 32 lowest-energy conformers identified were used as starting points and minimized using density functional theory (DFT) within Gaussian 03. Optimized structures, harmonic vibrational frequencies/intensities, VCD rotational strengths, and free energies at standard temperature and pressure (STP, including zero-point energies) were determined for each conformer. In these calculations, the B3LYP generalized gradient approximation (GGA) exchange-correlation density functional was used in conjunction with the cc-pVTZ basis set. Simulations of infrared and VCD spectra for each conformer were generated using an in-house written program to fit Lorentzian line shapes (16 cm<sup>–1</sup> line width) to the computed spectra. In this manner, direct comparisons between simulated and experimental spectra were made.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i106"><a href="/doi/suppl/10.1021/jm4014828">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Secondary pharmacological targets and data for Cpd <b>6s</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4014828/suppl_file/jm4014828_si_001.pdf">jm4014828_si_001.pdf (151.14 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm4014828" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58567" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58567" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean G. Brown</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#81e5e4e0efafe3f3eef6efc1e0f2f5f3e0fbe4efe4e2e0afe2eeec"><span class="__cf_email__" data-cfemail="4e2a2b2f20602c3c2139200e2f3d3a3c2f342b202b2d2f602d2123">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter R. Bernstein</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Griffin</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Wesolowski</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denis Labrecque</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maxime C. Tremblay</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Sylvester</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Russell Mauger</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phillip D. Edwards</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott R. Throner</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James J. Folmer</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Cacciola</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clay Scott</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lois A. Lazor</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mehrnaz Pourashraf</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vijayaratnam Santhakumar</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William M. Potts</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Sydserff</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascall Giguère</span> - <span class="hlFld-Affiliation affiliation">OmegaChem, 480 Rue Perreault, Saint-Romuald, Québec G6W 7 V6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carine Lévesque</span> - <span class="hlFld-Affiliation affiliation">OmegaChem, 480 Rue Perreault, Saint-Romuald, Québec G6W 7 V6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohammed Dasser</span> - <span class="hlFld-Affiliation affiliation">OmegaChem, 480 Rue Perreault, Saint-Romuald, Québec G6W 7 V6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thierry Groblewski</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca
Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d893e8364-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53788" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53788" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge help from Francis Beaulieu, Thalia Daniels, James Hall, Helene Desfosses, Sandrine Leclerc, Bernard A. Lanoue, Ying Zhou, Ying Liu, Eric Miele, Erika Manyak, Debora Roaquin, Torcan Chemical, and Don Pivonka.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i111" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i111"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i112" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i112"> Abbreviations Used</h2><tr><td class="NLM_term">ADHD</td><td class="NLM_def"><p class="first last">attention deficit hyperactivity disoreder</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetics</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropyl ethyl amine</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethly-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">HOBT</td><td class="NLM_def"><p class="first last">hydroxy benzotriazole</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last"><i>human</i><i>ether-à-go-go-related gene</i> encoding for potassium ion channel</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-benzotriazole-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-uronium-hexafluoro-phosphate</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin-Darby canine kidney</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last">tetrabutylammonium bromide</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">(2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoracetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">VCD</td><td class="NLM_def"><p class="first last">vibrational circular dichroism</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i113">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86246" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86246" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Arrang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbarg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J. C.</span><span> </span><span class="NLM_article-title">Auto-inhibition of brain histamine release mediated by a novel class (H<sub>3</sub>) of histamine receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2F302832a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=6188956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=1983&pages=832-837&author=J.+M.+Arrangauthor=M.+Garbargauthor=J.+C.+Schwartz&title=Auto-inhibition+of+brain+histamine+release+mediated+by+a+novel+class+%28H3%29+of+histamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor</span></div><div class="casAuthors">Arrang, Jean Michel; Garbarg, Monique; Schwartz, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5911</span>),
    <span class="NLM_cas:pages">832-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The K+-induced release of 3H-labeled histamine (I)  [51-45-6] from rat cerebral cortex slices was inhibited by exogenous I, suggesting the presence of histaminic receptors by which this compd. can control its own release.  Although Nα-methylhistamine  [673-50-7] and Nα,Nα-dimethylhistamine  [673-46-1] also inhibited [3H]-I release, a no. of compds. known to exhibit agonist activities of H1 or H2 receptors had no significant effect.  Consequently, autoinhibition of I release by the brain is apparently mediated by a type of receptor (histaminic H3) that is clearly different from H1 and H2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpu3HYACgLprVg90H21EOLACvtfcHk0lgpNG47ynXc3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D&md5=891b1e95467aa9213317c930f12bf3b7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F302832a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F302832a0%26sid%3Dliteratum%253Aachs%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGarbarg%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DAuto-inhibition%2520of%2520brain%2520histamine%2520release%2520mediated%2520by%2520a%2520novel%2520class%2520%2528H3%2529%2520of%2520histamine%2520receptor%26jtitle%3DNature%26date%3D1983%26volume%3D302%26spage%3D832%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Brioni, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span> </span><span class="NLM_article-title">Discovery of histamine H<sub>3</sub> antagonists for the treatment of cognitive disorders and Alzheimer’s disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1124%2Fjpet.110.166876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=20864505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=38-46&author=J.+D.+Brioniauthor=T.+A.+Esbenshadeauthor=T.+R.+Garrisonauthor=S.+R.+Bitnerauthor=M.+D.+Cowart&title=Discovery+of+histamine+H3+antagonists+for+the+treatment+of+cognitive+disorders+and+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease</span></div><div class="casAuthors">Brioni, Jorge D.; Esbenshade, Tim A.; Garrison, Tiffany Runyan; Bitner, Scott R.; Cowart, Marlon D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-46</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  H3 antagonists increase the release of brain histamine, acetylcholine, noradrenaline, and dopamine, neurotransmitters that are known to modulate cognitive processes.  The ability to release brain histamine supports the effect on attention and vigilance, but histamine also modulates other cognitive domains such as short-term and long-term memory.  A no. of H3 antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1R,3R)-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clin. area for the potential treatment of human cognitive disorders.  H3 antagonists exhibited wake-promoting effects in humans and efficacy in narcoleptic patients, indicating target engagement, but some of them were not efficacious in patients suffering from attention-deficit hyperactivity disorder and schizophrenic patients.  Preclin. studies have also shown that H3 antagonists activate intracellular signaling pathways that may improve cognitive efficacy and disease-modifying effects in Alzheimer's disease.  Ongoing clin. studies will be able to det. the utility of H3 antagonists for the treatment of cognitive disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHvanX-UatFbVg90H21EOLACvtfcHk0lgpNG47ynXc3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ektw%253D%253D&md5=d8f3f6997a6b9c96be5e6eb836bd2951</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.166876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.166876%26sid%3Dliteratum%253Aachs%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DBitner%26aufirst%3DS.%2BR.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520histamine%2520H3%2520antagonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D38%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cowart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of A-960656, a histamine H<sub>3</sub> receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">684</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1016%2Fj.ejphar.2012.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=22504024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=684&publication_year=2012&pages=87-94&author=M.+Cowartauthor=G.+Hsiehauthor=L.+A.+Blackauthor=Z.+Zhanauthor=E.+J.+Gomezauthor=M.+Paiauthor=M.+Strakhovaauthor=A.+Manelliauthor=T.+Carrauthor=J.+Wetterauthor=A.+Leeauthor=G.+Diazauthor=T.+Garrisonauthor=J.+D.+Brioni&title=Pharmacological+characterization+of+A-960656%2C+a+histamine+H3+receptor+antagonist+with+efficacy+in+animal+models+of+osteoarthritis+and+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of A-960656, a histamine H3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain</span></div><div class="casAuthors">Cowart, Marlon; Hsieh, Gin; Black, Lawrence A.; Zhan, CenChen; Gomez, Erica J.; Pai, Madhavi; Strakhova, Marina; Manelli, Arlene; Carr, Tracy; Wetter, Jill; Lee, Anthony; Diaz, Gilbert; Garrison, Tiffany; Brioni, Jorge D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">684</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">87-94</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histamine H3 receptor antagonists have been widely reported to improve performance in preclin. models of cognition, but more recently efficacy in pain models has also been described.  Here, A-960656 ((R)-2-(2-(3-(piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazol-6-yl)pyridazin-3(2H)-one) was profiled as a new structural chemotype.  A-960656 was potent in vitro in histamine H3 receptor binding assays (rat Ki = 76 nM, human Ki = 21 nM), and exhibited functional antagonism in blocking agonist-induced [35S]GTPγS binding (rat H3 Kb = 107 nM, human H3 Kb = 22 nM), and was highly specific for H3 receptors in broad screens for non-H3 sites.  In a spinal nerve ligation model of neuropathic pain in rat, oral doses of 1 and 3 mg/kg were effective 60 min post dosing with an ED50 of 2.17 mg/kg and a blood EC50 of 639 ng/mL.  In a model of osteoarthritis pain, oral doses of 0.1, 0.3, and 1 mg/kg were effective 1 h post dosing with an ED50 of 0.52 mg/kg and a blood EC50 of 233 ng/mL.  The antinociceptive effect of A-960656 in both pain models was maintained after sub-chronic dosing up to 12 days.  A-960656 had excellent rat pharmacokinetics (t1/2 = 1.9 h, 84% oral bioavailability) with rapid and efficient brain penetration, and was well tolerated in CNS behavioral safety screens.  In summary, A-960656 has properties well suited to probe the pharmacol. of histamine H3 receptors in pain.  Its potency and efficacy in animal pain models provide support to the notion that histamine H3 receptor antagonists are effective in attenuating nociceptive processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5nYIPfseMLVg90H21EOLACvtfcHk0lgkr4nsy2l7LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFyrtL0%253D&md5=ee7cf0e3f1a0f462330069e20f91c927</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DCowart%26aufirst%3DM.%26aulast%3DHsieh%26aufirst%3DG.%26aulast%3DBlack%26aufirst%3DL.%2BA.%26aulast%3DZhan%26aufirst%3DZ.%26aulast%3DGomez%26aufirst%3DE.%2BJ.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DStrakhova%26aufirst%3DM.%26aulast%3DManelli%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DT.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DGarrison%26aufirst%3DT.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26atitle%3DPharmacological%2520characterization%2520of%2520A-960656%252C%2520a%2520histamine%2520H3%2520receptor%2520antagonist%2520with%2520efficacy%2520in%2520animal%2520models%2520of%2520osteoarthritis%2520and%2520neuropathic%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D684%26spage%3D87%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Weisler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandina, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gassman-Mayer, C.</span><span> </span><span class="NLM_article-title">Randomized clinical study of a histamine H<sub>3</sub> receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=421-434&author=R.+H.+Weislerauthor=G.+J.+Pandinaauthor=E.+J.+Dalyauthor=K.+Cooperauthor=C.+Gassman-Mayer&title=Randomized+clinical+study+of+a+histamine+H3+receptor+antagonist+for+the+treatment+of+adults+with+attention-deficit+hyperactivity+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeisler%26aufirst%3DR.%2BH.%26aulast%3DPandina%26aufirst%3DG.%2BJ.%26aulast%3DDaly%26aufirst%3DE.%2BJ.%26aulast%3DCooper%26aufirst%3DK.%26aulast%3DGassman-Mayer%26aufirst%3DC.%26atitle%3DRandomized%2520clinical%2520study%2520of%2520a%2520histamine%2520H3%2520receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520adults%2520with%2520attention-deficit%2520hyperactivity%2520disorder%26jtitle%3DCNS%2520Drugs%26date%3D2012%26volume%3D26%26spage%3D421%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Medhurst, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billinton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalziel, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessell, I. P.</span><span> </span><span class="NLM_article-title">Novel histamine H<sub>3</sub> receptor antagonist GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain</span> <span class="citation_source-journal">Pain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2008&pages=61-78&author=S.+J.+Medhurstauthor=S.+D.+Collinsauthor=A.+Billintonauthor=S.+Binghamauthor=R.+G.+Dalzielauthor=A.+Brassauthor=J.+C.+Robertsauthor=A.+D.+Medhurstauthor=I.+P.+Chessell&title=Novel+histamine+H3+receptor+antagonist+GSK189254+and+GSK334429+are+efficacious+in+surgically-induced+and+virally-induced+rat+models+of+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMedhurst%26aufirst%3DS.%2BJ.%26aulast%3DCollins%26aufirst%3DS.%2BD.%26aulast%3DBillinton%26aufirst%3DA.%26aulast%3DBingham%26aufirst%3DS.%26aulast%3DDalziel%26aufirst%3DR.%2BG.%26aulast%3DBrass%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%2BC.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DChessell%26aufirst%3DI.%2BP.%26atitle%3DNovel%2520histamine%2520H3%2520receptor%2520antagonist%2520GSK189254%2520and%2520GSK334429%2520are%2520efficacious%2520in%2520surgically-induced%2520and%2520virally-induced%2520rat%2520models%2520of%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2008%26volume%3D138%26spage%3D61%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Karagiannidis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnok, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolanczyk, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madruga-Garrido, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebebrand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nöthen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmkuhl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farkas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanska, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastasiou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stathias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Androutsos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsironi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koumoula, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mir, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschou, P.</span><span> </span><span class="NLM_article-title">Support of the histaminergic hypothesis in Tourette syndrome: Association of the histamine decarboxylase gene in a large sample of families</span> <span class="citation_source-journal">J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1136%2Fjmedgenet-2013-101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=23825391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOgu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2013&pages=760-764&author=I.+Karagiannidisauthor=S.+Dehningauthor=P.+Sandorauthor=Z.+Tarnokauthor=R.+Rizzoauthor=T.+Wolanczykauthor=M.+Madruga-Garridoauthor=J.+Hebebrandauthor=M.+M.+N%C3%B6thenauthor=G.+Lehmkuhlauthor=L.+Farkasauthor=P.+Nagyauthor=U.+Symanskaauthor=Z.+Anastasiouauthor=V.+Stathiasauthor=C.+Androutsosauthor=V.+Tsironiauthor=A.+Koumoulaauthor=C.+Bartaauthor=P.+Zillauthor=P.+Mirauthor=N.+M%C3%BCllerauthor=C.+Barrauthor=P.+Paschou&title=Support+of+the+histaminergic+hypothesis+in+Tourette+syndrome%3A+Association+of+the+histamine+decarboxylase+gene+in+a+large+sample+of+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Support of the histaminergic hypothesis in Tourette Syndrome: association of the histamine decarboxylase gene in a large sample of families</span></div><div class="casAuthors">Karagiannidis, Iordanis; Dehning, Sandra; Sandor, Paul; Tarnok, Zsanett; Rizzo, Renata; Wolanczyk, Tomasz; Madruga-Garrido, Marcos; Hebebrand, Johannes; Nothen, Markus M.; Lehmkuhl, Gerd; Farkas, Luca; Nagy, Peter; Szymanska, Urszula; Anastasiou, Zachos; Stathias, Vasileios; Androutsos, Christos; Tsironi, Vaia; Koumoula, Anastasia; Barta, Csaba; Zill, Peter; Mir, Pablo; Muller, Norbert; Barr, Cathy; Paschou, Peristera</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-764</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background Gilles de la Tourette Syndrome is a neurodevelopmental disorder that is caused by the interaction of environment with a complex genetic background.  The genetic etiol. of the disorder remains, so far, elusive, although multiple promising leads have been recently reported.  The recent implication of the histamine decarboxylase (HDC) gene, the key enzyme in histamine prodn., raises the intriguing hypothesis of a possible role of histaminergic dysfunction leading to TS onset.  Methods Following up on the finding of a nonsense mutation in a single family with TS, we investigated variation across the HDC gene for assocn. with TS.  As a result of a collaborative international effort, we studied a large sample of 520 nuclear families originating from seven European populations (Greek, Hungarian, Italian, Polish, German, Albanian, Spanish) as well as a sample collected in Canada.  Results and Conclusions Interrogating 12 tagging SNPs (tSNP) across the HDC region, we find strong over-transmission of alleles at two SNPs (rs854150 and rs1894236) in the complete sample, as well as a statistically significant assocd. haplotypes.  Anal. of individual populations also reveals signals of assocn. in the Canadian, German and Italian samples.  Our results provide strong support for the histaminergic hypothesis in TS etiol. and point to a possible role of histamine pathways in neuronal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcreCQj-_LLVg90H21EOLACvtfcHk0lhr7tNox0dzCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOgu73P&md5=e75c8a0878b055e23364b43b460be19f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1136%2Fjmedgenet-2013-101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmedgenet-2013-101637%26sid%3Dliteratum%253Aachs%26aulast%3DKaragiannidis%26aufirst%3DI.%26aulast%3DDehning%26aufirst%3DS.%26aulast%3DSandor%26aufirst%3DP.%26aulast%3DTarnok%26aufirst%3DZ.%26aulast%3DRizzo%26aufirst%3DR.%26aulast%3DWolanczyk%26aufirst%3DT.%26aulast%3DMadruga-Garrido%26aufirst%3DM.%26aulast%3DHebebrand%26aufirst%3DJ.%26aulast%3DN%25C3%25B6then%26aufirst%3DM.%2BM.%26aulast%3DLehmkuhl%26aufirst%3DG.%26aulast%3DFarkas%26aufirst%3DL.%26aulast%3DNagy%26aufirst%3DP.%26aulast%3DSymanska%26aufirst%3DU.%26aulast%3DAnastasiou%26aufirst%3DZ.%26aulast%3DStathias%26aufirst%3DV.%26aulast%3DAndroutsos%26aufirst%3DC.%26aulast%3DTsironi%26aufirst%3DV.%26aulast%3DKoumoula%26aufirst%3DA.%26aulast%3DBarta%26aufirst%3DC.%26aulast%3DZill%26aufirst%3DP.%26aulast%3DMir%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DN.%26aulast%3DBarr%26aufirst%3DC.%26aulast%3DPaschou%26aufirst%3DP.%26atitle%3DSupport%2520of%2520the%2520histaminergic%2520hypothesis%2520in%2520Tourette%2520syndrome%253A%2520Association%2520of%2520the%2520histamine%2520decarboxylase%2520gene%2520in%2520a%2520large%2520sample%2520of%2520families%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2013%26volume%3D50%26spage%3D760%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span> </span><span class="NLM_article-title">The H<sub>3</sub> receptor: An attractive target for the treatment of cognitive disorders</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2Fbjp.2008.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=18469850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1166-1181&author=T.+A.+Esbenshadeauthor=K.+E.+Browmanauthor=R.+S.+Bitnerauthor=M.+Strakhovaauthor=M.+D.+Cowartauthor=J.+D.+Brioni&title=The+H3+receptor%3A+An+attractive+target+for+the+treatment+of+cognitive+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</span></div><div class="casAuthors">Esbenshade, T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.; Brioni, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1166-1181</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous labs. as it represents an attractive drug target for a no. of indications including cognition.  The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclin. and clin. advancement.  Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in cognitive processes.  The cognitive-enhancing effects of H3 antagonists across multiple cognitive domains in a wide no. of preclin. cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia.  However, although a no. of clin. studies examg. the efficacy of H3 receptor antagonists for a variety of cognitive disorders are currently underway, no clin. proof of concept for an H3 receptor antagonist has been reported to date.  The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of cognitive disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.  British Journal of Pharmacol. (2008) 154, 1166-1181; doi:10.1038/bjp.2008.147; published online 12 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2N2Dg3cdZfrVg90H21EOLACvtfcHk0lhr7tNox0dzCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D&md5=05bcda7b1140e9d16b4ca4072902d925</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.147%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBitner%26aufirst%3DR.%2BS.%26aulast%3DStrakhova%26aufirst%3DM.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520H3%2520receptor%253A%2520An%2520attractive%2520target%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1166%26epage%3D1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Passani, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crochet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blandina, P.</span><span> </span><span class="NLM_article-title">The histamine H<sub>3</sub> receptor as a novel therapeutic target for cognitive and sleep disorders</span> <span class="citation_source-journal">Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1016%2Fj.tips.2004.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=618-625&author=M.+B.+Passaniauthor=J.+S.+Linauthor=A.+Hancockauthor=S.+Crochetauthor=P.+Blandina&title=The+histamine+H3+receptor+as+a+novel+therapeutic+target+for+cognitive+and+sleep+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders</span></div><div class="casAuthors">Passani, Maria Beatrice; Lin, Jian-Sheng; Hancock, Arthur; Crochet, Sylvain; Blandina, Patrizio</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">618-625</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Histamine H3 receptor pharmacol., functions and biochem. are far from being fully understood; however, progress is being made.  Activation of this Gi/Go-protein-coupled receptor affects cognition, the sleep-wake cycle, obesity and epilepsy, which are physiol. and pathol. conditions that are the main focus of research into the therapeutic potential of selective H3 receptor ligands.  This heterogeneity of targets can be reconciled partially by the fact that the histamine system constitutes one of the most important brain-activating systems and that H3 receptors regulate the activity of histamine and other neurotransmitter systems.  Furthermore, the H3 receptor shows functional constitutive activity, polymorphisms in humans and rodents with a differential distribution of splice variants in the CNS, and potential coupling to different intracellular signal transduction mechanisms.  In light of the genetic, pharmacol. and functional complexity of the H3 receptor, the importance of the histamine system as a therapeutic target to control the sleep-wake cycle and cognitive disorders will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsyz3ZrhlUXrVg90H21EOLACvtfcHk0lgcVHNMRgikTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVSjtro%253D&md5=1e5d66f01417b2d8018d8416d5a832db</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DPassani%26aufirst%3DM.%2BB.%26aulast%3DLin%26aufirst%3DJ.%2BS.%26aulast%3DHancock%26aufirst%3DA.%26aulast%3DCrochet%26aufirst%3DS.%26aulast%3DBlandina%26aufirst%3DP.%26atitle%3DThe%2520histamine%2520H3%2520receptor%2520as%2520a%2520novel%2520therapeutic%2520target%2520for%2520cognitive%2520and%2520sleep%2520disorders%26jtitle%3DPharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D618%26epage%3D625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Pharmacological properties of ABT-239 [4-(2{2-[(2R)-2-methylpyrrolidinyl]ethyl}benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H<sub>3</sub> receptor antagonist with drug-like properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1124%2Fjpet.104.078303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=15608078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=165-175&author=T.+A.+Esbenshadeauthor=G.+B.+Foxauthor=K.+M.+Kruegerauthor=T.+R.+Millerauthor=C.+H.+Kangauthor=L.+I.+Dennyauthor=D.+G.+Witteauthor=B.+B.+Yaoauthor=L.+Panauthor=J.+Wetterauthor=K.+Marshauthor=Y.+Bennaniauthor=M.+D.+Cowartauthor=J.+P.+Sullivanauthor=A.+A.+Hancock&title=Pharmacological+properties+of+ABT-239+%5B4-%282%7B2-%5B%282R%29-2-methylpyrrolidinyl%5Dethyl%7Dbenzofuran-5-yl%29benzonitrile%5D%3A+I.+Potent+and+selective+histamine+H3+receptor+antagonist+with+drug-like+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties</span></div><div class="casAuthors">Esbenshade, Timothy A.; Fox, Gerard B.; Krueger, Kathleen M.; Miller, Thomas R.; Kang, Chae Hee; Denny, Lynne I.; Witte, David G.; Yao, Betty B.; Pan, Liping; Wetter, Jill; Marsh, Kennan; Bennani, Youssef L.; Cowart, Marlon D.; Sullivan, James P.; Hancock, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-175</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Histamine H3 receptor antagonists are being developed to treat a variety of neurol. and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release.  Here, we present the in vitro pharmacol. and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H3 receptor antagonists.  ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pKi values of 9.4 and 8.9, resp., and is over 1000-fold selective vs. human H1, H2, and H4 histamine receptors.  ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pKb = 7.9 and 7.6, resp.), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPγS) binding (pKb = 9.0 and 8.3, resp.), and calcium mobilization (human pKb = 7.9).  ABT-239 also competitively reversed histamine-mediated inhibition of [3H]histamine release from rat brain cortical synaptosomes (pKb = 7.7) and agonist-induced inhibition of contractile responses in elec. field stimulated guinea pig ileal segments (pA2 = 8.7).  Addnl., ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPγS binding at both rat and human H3 receptors with resp. pEC50 values of 8.9 and 8.2.  ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%.  Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowcC95NH2bcLVg90H21EOLACvtfcHk0lgcVHNMRgikTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsL0%253D&md5=33248c15c96745da445a14853461c019</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078303%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DDenny%26aufirst%3DL.%2BI.%26aulast%3DWitte%26aufirst%3DD.%2BG.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DBennani%26aufirst%3DY.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520properties%2520of%2520ABT-239%2520%255B4-%25282%257B2-%255B%25282R%2529-2-methylpyrrolidinyl%255Dethyl%257Dbenzofuran-5-yl%2529benzonitrile%255D%253A%2520I.%2520Potent%2520and%2520selective%2520histamine%2520H3%2520receptor%2520antagonist%2520with%2520drug-like%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D165%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radek, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komater, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faghih, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benneni, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Pharmacological properties of ABT-239 [4-(2{2-[(2R)-2-methylpyrrolidinyl]ethyl}benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective H<sub>3</sub> receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1124%2Fjpet.104.078402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=15608077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=176-190&author=G.+B.+Foxauthor=T.+A.+Esbenshadeauthor=J.+B.+Panauthor=R.+J.+Radekauthor=K.+M.+Kruegerauthor=B.+B.+Yaoauthor=K.+E.+Browmanauthor=M.+J.+Buckleyauthor=M.+E.+Ballardauthor=V.+A.+Komaterauthor=H.+Minerauthor=M.+Zhangauthor=R.+Faghihauthor=L.+E.+Rueterauthor=R.+Bitnerauthor=K.+U.+Drescherauthor=J.+Wetterauthor=K.+Marshauthor=M.+Lemaireauthor=R.+D.+Porsoltauthor=Y.+L.+Benneniauthor=J.+P.+Sullivanauthor=M.+D.+Cowartauthor=M.+W.+Deckerauthor=A.+A.+Hancock&title=Pharmacological+properties+of+ABT-239+%5B4-%282%7B2-%5B%282R%29-2-methylpyrrolidinyl%5Dethyl%7Dbenzofuran-5-yl%29benzonitrile%5D%3A+II.+Neurophysiological+characterization+and+broad+preclinical+efficacy+in+cognition+and+schizophrenia+of+a+potent+and+selective+H3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist</span></div><div class="casAuthors">Fox, Gerard B.; Esbenshade, Timothy A.; Pan, Jia Bao; Radek, Richard J.; Krueger, Kathleen M.; Yao, Betty B.; Browman, Kaitlin E.; Buckley, Michael J.; Ballard, Michael E.; Komater, Victoria A.; Miner, Holly; Zhang, Min; Faghih, Ramin; Rueter, Lynne E.; Bitner, R. Scott; Drescher, Karla U.; Wetter, Jill; Marsh, Kennan; Lemaire, Martine; Porsolt, Roger D.; Bennani, Youssef L.; Sullivan, James P.; Cowart, Marlon D.; Decker, Michael W.; Hancock, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-190</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acute pharmacol. blockade of central histamine H3 receptors (H3Rs) enhances arousal/attention in rodents.  However, there is little information available for other behavioral domains or for repeated administration using selective compds.  ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] exemplifies such a selective, nonimidazole H3R antagonist with high affinity for rat (pKi = 8.9) and human (pKi = 9.5) H3Rs.  Acute functional blockade of central H3Rs was demonstrated by blocking the dipsogenia response to the selective H3R agonist (R)-α-methylhistamine in mice.  In cognition studies, acquisition of a five-trial, inhibitory avoidance test in rat pups was improved with ABT-239 (0.1-1.0 mg/kg), a 10- to 150-fold gain in potency, with similar efficacy, over previous antagonists such as thioperamide, ciproxifan, A-304121 [(4-(3-(4-((2R)-2-aminopropanoyl)-1-piperazinyl)propoxy)phenyl)(cyclopropyl) methanone], A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide], and A-349821 [(4'-(3-((R,R)2,5-dimethyl-pyrrolidin-1-yl)-propoxy)-biphenyl-4-yl)- morpholin-4-yl-methanone].  Efficacy in this model was maintained for 3 to 6 h and following repeated dosing with ABT-239.  Social memory was also improved in adult (0.01-0.3 mg/kg) and aged (0.3-1.0 mg/kg) rats.  In schizophrenia models, ABT-239 improved gating deficits in DBA/2 mice using prepulse inhibition of startle (1.0-3.0 mg/kg) and N40 (1.0-10.0 mg/kg).  Furthermore, ABT-239 (1.0 mg/kg) attenuated methamphetamine-induced hyperactivity in mice.  In freely moving rat microdialysis studies, ABT-239 enhanced acetylcholine release (0.1-3.0 mg/kg) in adult rat frontal cortex and hippocampus and enhanced dopamine release in frontal cortex (3.0 mg/kg), but not striatum.  In summary, broad efficacy was obsd. with ABT-239 across animal models such that potential clin. efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5hD1Q0ydnubVg90H21EOLACvtfcHk0lgcVHNMRgikTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D&md5=437e154a172071e4c5d31e44134ab1b5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078402%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DPan%26aufirst%3DJ.%2BB.%26aulast%3DRadek%26aufirst%3DR.%2BJ.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBuckley%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DM.%2BE.%26aulast%3DKomater%26aufirst%3DV.%2BA.%26aulast%3DMiner%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DFaghih%26aufirst%3DR.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26aulast%3DBitner%26aufirst%3DR.%26aulast%3DDrescher%26aufirst%3DK.%2BU.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBenneni%26aufirst%3DY.%2BL.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520properties%2520of%2520ABT-239%2520%255B4-%25282%257B2-%255B%25282R%2529-2-methylpyrrolidinyl%255Dethyl%257Dbenzofuran-5-yl%2529benzonitrile%255D%253A%2520II.%2520Neurophysiological%2520characterization%2520and%2520broad%2520preclinical%2520efficacy%2520in%2520cognition%2520and%2520schizophrenia%2520of%2520a%2520potent%2520and%2520selective%2520H3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D176%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Plancher, J.-M.</span><span> </span><span class="NLM_article-title">The histamine H<sub>3</sub> receptor as a therapeutic drug target for metabolic disorders: Status, challenges, and opportunities</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1430</span><span class="NLM_x">–</span> <span class="NLM_lpage">1446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.2174%2F156802611795860906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=21510840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1430-1446&author=J.-M.+Plancher&title=The+histamine+H3+receptor+as+a+therapeutic+drug+target+for+metabolic+disorders%3A+Status%2C+challenges%2C+and+opportunities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor as a therapeutic drug target for metabolic disorders: status, challenges and opportunities</span></div><div class="casAuthors">Plancher, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1430-1446</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the histamine-3 receptor (H3R) was cloned in 1999, huge efforts were made by most of the key players in the pharmaceutical industry as well as in smaller biotech companies to increase the knowledge on this peculiar receptor, with the ultimate goal of bringing new drugs to the market.  This review gives a survey on the most valuable chem. tools discovered so far and the significant pharmacol. expts. on metabolic disease models published to date.  Pharmacol. of H3R antagonists turns out to be very complex due to various functional activities, species selectivity, presence of H3R isoforms and the poorly understood dichotomy in efficacy between CNS and metabolic disease models.  Adding an extra layer of complexity, researchers have to cope with some recurrent safety concerns, some of them being tightly linked to the nature of the H3R pharmacophore.  Therefore this review also strives to summarize the major hurdles and some of the contradictions seen in the H3R field, together with a brief overview of the clin. trials currently running.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIR4QjoNcDD7Vg90H21EOLACvtfcHk0lhtcXN-e63Mog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbo%253D&md5=b1a1a3f40d15cb4b715590ded43d469c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F156802611795860906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795860906%26sid%3Dliteratum%253Aachs%26aulast%3DPlancher%26aufirst%3DJ.-M.%26atitle%3DThe%2520histamine%2520H3%2520receptor%2520as%2520a%2520therapeutic%2520drug%2520target%2520for%2520metabolic%2520disorders%253A%2520Status%252C%2520challenges%252C%2520and%2520opportunities%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1430%26epage%3D1446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Celanire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijtmans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talaga, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J. P.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptors reach out for the clinic</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1627</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1613-1627&author=S.+Celanireauthor=M.+Wijtmansauthor=P.+Talagaauthor=R.+Leursauthor=I.+J.+P.+de+Esch&title=Histamine+H3+receptors+reach+out+for+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCelanire%26aufirst%3DS.%26aulast%3DWijtmans%26aufirst%3DM.%26aulast%3DTalaga%26aufirst%3DP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26atitle%3DHistamine%2520H3%2520receptors%2520reach%2520out%2520for%2520the%2520clinic%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1613%26epage%3D1627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="note"><p class="first last">For a review, see</p></div><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddatz, R.</span><span> </span><span class="NLM_article-title">Recent advances in drug discovery of histamine H<sub>3</sub> antagonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=49-62&author=R.+L.+Hudkinsauthor=R.+Raddatz&title=Recent+advances+in+drug+discovery+of+histamine+H3+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DRaddatz%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520in%2520drug%2520discovery%2520of%2520histamine%2520H3%2520antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D49%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For a recent example, see</p></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adedoyin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aschmies, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowlby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platt, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comery, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, A. J.</span><span> </span><span class="NLM_article-title">2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2<i>H</i>)-one derivatives as potent and selective histamine-3 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2452</span><span class="NLM_x">–</span> <span class="NLM_lpage">2468</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300011d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2452-2468&author=D.+Zhouauthor=J.+L.+Grossauthor=A.+B.+Adedoyinauthor=S.+B.+Aschmiesauthor=J.+Brennanauthor=M.+Bowlbyauthor=L.+Diauthor=K.+Kubekauthor=B.+J.+Plattauthor=Z.+Wangauthor=G.+Zhangauthor=N.+Brandonauthor=T.+A.+Comeryauthor=A.+J.+Robichaud&title=2-%28Pyrrolidin-1-yl%29ethyl-3%2C4-dihydroisoquinolin-1%282H%29-one+derivatives+as+potent+and+selective+histamine-3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm300011d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300011d%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DGross%26aufirst%3DJ.%2BL.%26aulast%3DAdedoyin%26aufirst%3DA.%2BB.%26aulast%3DAschmies%26aufirst%3DS.%2BB.%26aulast%3DBrennan%26aufirst%3DJ.%26aulast%3DBowlby%26aufirst%3DM.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKubek%26aufirst%3DK.%26aulast%3DPlatt%26aufirst%3DB.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBrandon%26aufirst%3DN.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3D2-%2528Pyrrolidin-1-yl%2529ethyl-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2520derivatives%2520as%2520potent%2520and%2520selective%2520histamine-3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2452%26epage%3D2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiasen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddatz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H<sub>3</sub> receptor antagonists with potent cognition enhancing activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201295j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=414-423&author=M.+Taoauthor=L.+D.+Aimoneauthor=Z.+Huangauthor=J.+Mathiasenauthor=R.+Raddatzauthor=J.+Lyonsauthor=R.+L.+Hudkins&title=Optimization+of+5-pyridazin-3-one+phenoxypropylamines+as+potent%2C+selective+histamine+H3+receptor+antagonists+with+potent+cognition+enhancing+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm201295j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201295j%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DM.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMathiasen%26aufirst%3DJ.%26aulast%3DRaddatz%26aufirst%3DR.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DOptimization%2520of%25205-pyridazin-3-one%2520phenoxypropylamines%2520as%2520potent%252C%2520selective%2520histamine%2520H3%2520receptor%2520antagonists%2520with%2520potent%2520cognition%2520enhancing%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D414%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><div class="note"><p class="first last">For a recent review, see:</p></div><span class="NLM_contrib-group">Singh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadhav, H. R.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptor function and ligands: Recent developments</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=47-57&author=M.+Singhauthor=H.+R.+Jadhav&title=Histamine+H3+receptor+function+and+ligands%3A+Recent+developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DJadhav%26aufirst%3DH.%2BR.%26atitle%3DHistamine%2520H3%2520receptor%2520function%2520and%2520ligands%253A%2520Recent%2520developments%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D47%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Kuhne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijtmans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J. P.</span><span> </span><span class="NLM_article-title">Several down, a few to go: Histamine H<sub>3</sub> receptor ligands making the final push towards the market</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1629</span><span class="NLM_x">–</span> <span class="NLM_lpage">1648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1629-1648&author=S.+Kuhneauthor=M.+Wijtmansauthor=H.+D.+Limauthor=R.+Leursauthor=I.+J.+P.+de+Esch&title=Several+down%2C+a+few+to+go%3A+Histamine+H3+receptor+ligands+making+the+final+push+towards+the+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuhne%26aufirst%3DS.%26aulast%3DWijtmans%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26atitle%3DSeveral%2520down%252C%2520a%2520few%2520to%2520go%253A%2520Histamine%2520H3%2520receptor%2520ligands%2520making%2520the%2520final%2520push%2520towards%2520the%2520market%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1629%26epage%3D1648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Allison, B. D.; Carruthers, N. I.; Grice, C. A.; Letavic, M. A.</span><span> </span><span class="NLM_article-title">Cyclopropyl amines as modulators of the histamine H<sub>3</sub> receptor</span>. U.S. Patent Appl. 2007/0066821 A1, March 22,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=B.+D.+Allison&author=N.+I.+Carruthers&author=C.+A.+Grice&author=M.+A.+Letavic&title=Cyclopropyl+amines+as+modulators+of+the+histamine+H3+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllison%26aufirst%3DB.%2BD.%26atitle%3DCyclopropyl%2520amines%2520as%2520modulators%2520of%2520the%2520histamine%2520H3%2520receptor%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H<sub>3</sub> antagonists/inverse agonists</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=1103&author=A.+A.+Hancock&title=The+challenge+of+drug+discovery+of+a+GPCR+target%3A+Analysis+of+preclinical+pharmacology+of+histamine+H3+antagonists%2Finverse+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DThe%2520challenge%2520of%2520drug%2520discovery%2520of%2520a%2520GPCR%2520target%253A%2520Analysis%2520of%2520preclinical%2520pharmacology%2520of%2520histamine%2520H3%2520antagonists%252Finverse%2520agonists%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2006%26volume%3D71%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, S. J. F.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+MacDonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+Are+too+many+aromatic+rings+a+liability+in+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacDonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520Are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><div class="note"><p class="first last">hERG pharmacophore:</p></div><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K<sup>+</sup> channel blockers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3844</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+Insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0ljlxr4oEnjYnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520Insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Swanson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span> </span><span class="NLM_article-title">Apylsamine-1 and related analogs as histamine H<sub>3</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">900</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=897-900&author=D.+M.+Swansonauthor=S.+J.+Wilsonauthor=J.+D.+Boggsauthor=W.+Xiaoauthor=R.+Apodacaauthor=A.+J.+Barbierauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthers&title=Apylsamine-1+and+related+analogs+as+histamine+H3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%2BD.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26atitle%3DApylsamine-1%2520and%2520related%2520analogs%2520as%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D897%26epage%3D900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Santora, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covel, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofilena, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibarra, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulley, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinhouse, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grottick, A. J.</span><span> </span><span class="NLM_article-title">A new family of H<sub>3</sub> receptor antagonists based on the natural product conessine</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1490</span><span class="NLM_x">–</span> <span class="NLM_lpage">1494</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1490-1494&author=V.+J.+Santoraauthor=J.+A.+Covelauthor=R.+Hayashiauthor=B.+J.+Hofilenaauthor=J.+B.+Ibarraauthor=M.+D.+Pulleyauthor=M.+I.+Weinhouseauthor=D.+Senguptaauthor=J.+J.+Duffieldauthor=G.+Sempleauthor=R.+R.+Webbauthor=C.+Sageauthor=A.+Renauthor=G.+Pereiraauthor=J.+Knudsenauthor=J.+E.+Edwardsauthor=M.+Suarezauthor=J.+Frazerauthor=W.+Thomsenauthor=E.+Hauserauthor=K.+Whelanauthor=A.+J.+Grottick&title=A+new+family+of+H3+receptor+antagonists+based+on+the+natural+product+conessine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantora%26aufirst%3DV.%2BJ.%26aulast%3DCovel%26aufirst%3DJ.%2BA.%26aulast%3DHayashi%26aufirst%3DR.%26aulast%3DHofilena%26aufirst%3DB.%2BJ.%26aulast%3DIbarra%26aufirst%3DJ.%2BB.%26aulast%3DPulley%26aufirst%3DM.%2BD.%26aulast%3DWeinhouse%26aufirst%3DM.%2BI.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DDuffield%26aufirst%3DJ.%2BJ.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DWebb%26aufirst%3DR.%2BR.%26aulast%3DSage%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DG.%26aulast%3DKnudsen%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DJ.%2BE.%26aulast%3DSuarez%26aufirst%3DM.%26aulast%3DFrazer%26aufirst%3DJ.%26aulast%3DThomsen%26aufirst%3DW.%26aulast%3DHauser%26aufirst%3DE.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26atitle%3DA%2520new%2520family%2520of%2520H3%2520receptor%2520antagonists%2520based%2520on%2520the%2520natural%2520product%2520conessine%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1490%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalakrishnan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiffault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span> </span><span class="NLM_article-title">The alkaloid conessine and analogues as potent histamine H<sub>3</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5423</span><span class="NLM_x">–</span> <span class="NLM_lpage">5430</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8003625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5423-5430&author=C.+Zhaoauthor=M.+Sunauthor=Y.+L.+Bennaniauthor=S.+M.+Gopalakrishnanauthor=D.+G.+Witteauthor=T.+R.+Millerauthor=K.+M.+Kruegerauthor=K.+E.+Browmanauthor=C.+Thiffaultauthor=J.+Wetterauthor=K.+C.+Marshauthor=A.+A.+Hancockauthor=T.+A.+Esbenshadeauthor=M.+D.+Cowart&title=The+alkaloid+conessine+and+analogues+as+potent+histamine+H3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fjm8003625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8003625%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DGopalakrishnan%26aufirst%3DS.%2BM.%26aulast%3DWitte%26aufirst%3DD.%2BG.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DThiffault%26aufirst%3DC.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26atitle%3DThe%2520alkaloid%2520conessine%2520and%2520analogues%2520as%2520potent%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5423%26epage%3D5430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lannang, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangmouo, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krohn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhary, M. I.</span><span> </span><span class="NLM_article-title">Conessin isolated from <i>Holarrhena floribunda</i></span> <span class="citation_source-journal">Acta Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">E63</span><span class="NLM_x">, </span> <span class="NLM_fpage">o3980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=E63&publication_year=2007&pages=o3980&author=A.+M.+Lannangauthor=S.+Anjumauthor=J.+G.+Tangmouoauthor=K.+Krohnauthor=M.+I.+Choudhary&title=Conessin+isolated+from+Holarrhena+floribunda"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLannang%26aufirst%3DA.%2BM.%26aulast%3DAnjum%26aufirst%3DS.%26aulast%3DTangmouo%26aufirst%3DJ.%2BG.%26aulast%3DKrohn%26aufirst%3DK.%26aulast%3DChoudhary%26aufirst%3DM.%2BI.%26atitle%3DConessin%2520isolated%2520from%2520Holarrhena%2520floribunda%26jtitle%3DActa%2520Crystallogr.%26date%3D2007%26volume%3DE63%26spage%3Do3980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berridge, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laposky, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alusio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pudiak, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span> </span><span class="NLM_article-title">Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H<sub>3</sub> antagonist</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">661</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2Fsj.bjp.0705964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=15466448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2004&pages=649-661&author=A.+J.+Barbierauthor=C.+Berridgeauthor=A.+D.+Laposkyauthor=S.+J.+Wilsonauthor=J.+Boggsauthor=B.+Alusioauthor=C.+Mazurauthor=C.+M.+Pudiakauthor=X.+Langloisauthor=W.+Xiaoauthor=R.+Apodacaauthor=N.+I.+Carruthersauthor=T.+W.+Lovenberg&title=Acute+wake-promoting+actions+of+JNJ-5207852%2C+a+novel%2C+diamine-based+H3+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist</span></div><div class="casAuthors">Barbier, A. J.; Berridge, C.; Dugovic, C.; Laposky, A. D.; Wilson, S. J.; Boggs, J.; Aluisio, L.; Lord, B.; Mazur, C.; Pudiak, C. M.; Langlois, X.; Xiao, W.; Apodaca, R.; Carruthers, N. I.; Lovenberg, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">649-661</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperidine (JNJ-5207852) is a novel, nonimidazole histamine H3 receptor antagonist, with high affinity at the rat (pKi = 8.9) and human (pKi = 9.24) H3 receptor.  JNJ-5207852 is selective for the H3 receptor, with negligible binding to other receptors, transporters and ion channels at 1 μM.  JNJ-5207852 readily penetrates the brain tissue after s.c. administration, as detd. by ex vivo autoradiog. (ED50 of 0.13 mg kg-1 in mice).  In vitro autoradiog. with 3H-JNJ-5207852 in mouse brain slices shows a binding pattern identical to that of 3H-R-α-methylhistamine, with high specific binding in the cortex, striatum and hypothalamus.  No specific binding of 3H-JNJ-5207852 was obsd. in brains of H3 receptor knockout mice.  In mice and rats, JNJ-5207852 (1-10 mg kg-1 s.c.) increases time spent awake and decreases REM sleep and slow-wave sleep, but fails to have an effect on wakefulness or sleep in H3 receptor knockout mice.  No rebound hypersomnolence, as measured by slow-wave delta power, is obsd.  The wake-promoting effects of this H3 receptor antagonist are not assocd. with hypermotility.  A 4-wk daily treatment of mice with JNJ-5207852 (10 mg kg-1 i.p.) did not lead to a change in body wt., possibly due to the compd. being a neutral antagonist at the H3 receptor.  JNJ-5207852 is extensively absorbed after oral administration and reaches high brain levels.  The data indicate that JNJ-5207852 is a novel, potent and selective H3 antagonist with good in vitro and in vivo efficacy, and confirm the wake-promoting effects of H3 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm3xmKb95PeLVg90H21EOLACvtfcHk0ljR6o33VkvTiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitLzL&md5=bd8e27617d39c45cf3cea7d2aadad8a0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705964%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DBerridge%26aufirst%3DC.%26aulast%3DLaposky%26aufirst%3DA.%2BD.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DAlusio%26aufirst%3DB.%26aulast%3DMazur%26aufirst%3DC.%26aulast%3DPudiak%26aufirst%3DC.%2BM.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DAcute%2520wake-promoting%2520actions%2520of%2520JNJ-5207852%252C%2520a%2520novel%252C%2520diamine-based%2520H3%2520antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D143%26spage%3D649%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Dvorak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berridge, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span> </span><span class="NLM_article-title">4-Phenoxypiperidines: Potent, conformationally restricted, non-imidazole histamine H<sub>3</sub> antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2229</span><span class="NLM_x">–</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049212n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2229-2238&author=C.+A.+Dvorakauthor=R.+Apodacaauthor=A.+J.+Barbierauthor=C.+W.+Berridgeauthor=S.+J.+Wilsonauthor=J.+D.+Boggsauthor=W.+Xiaoauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthers&title=4-Phenoxypiperidines%3A+Potent%2C+conformationally+restricted%2C+non-imidazole+histamine+H3+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm049212n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049212n%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DBerridge%26aufirst%3DC.%2BW.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%2BD.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26atitle%3D4-Phenoxypiperidines%253A%2520Potent%252C%2520conformationally%2520restricted%252C%2520non-imidazole%2520histamine%2520H3%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2229%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Malmlof, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaragoza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golozoubova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Refsgaard, H. H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulff, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westerink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimvall, K.</span><span> </span><span class="NLM_article-title">Influence of a selective histamine receptor antagonist on hypothalamic neural activity, food intake, and body weight</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2Fsj.ijo.0803036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Smt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2005&pages=1402-1412&author=K.+Malmlofauthor=F.+Zaragozaauthor=V.+Golozoubovaauthor=H.+H.+F.+Refsgaardauthor=T.+Cremersauthor=K.+Raunauthor=B.+S.+Wulffauthor=P.+B.+Johansenauthor=B.+Westerinkauthor=K.+Rimvall&title=Influence+of+a+selective+histamine+receptor+antagonist+on+hypothalamic+neural+activity%2C+food+intake%2C+and+body+weight"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight</span></div><div class="casAuthors">Malmlof, K.; Zaragoza, F.; Golozoubova, V.; Refsgaard, H. H. F.; Cremers, T.; Raun, K.; Wulff, B. S.; Johansen, P. B.; Westerink, B.; Rimvall, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1402-1412</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: This study was conducted to elucidate whether antagonistic targeting of the histamine H3 receptor increases hypothalamic histamine levels, in parallel with decreases in food intake and body wt.  Methods: The competitive antagonist potency of a recently synthesized histamine H3 receptor antagonist, NNC 38-1049, was studied in intact HEK293 cells expressing human or rat histamine H3 receptor, in which NNC 38-1049 was allowed to antagonize the effect of the H3 receptor agonist R-α-methylhistamine on isoprenaline-induced accumulation of cAMP.  The affinity of NNC 38-1049 for a no. of variants of the histamine receptor was also detd.  Following single dosing of normal rats with NNC 38-1049, hypothalamic histamine levels were assessed by means of microdialysis.  Plasma and brain levels of NNC 38-1049 and acute effects on food intake and energy expenditure were followed after oral doses of 3-60 mg/kg.  Potential side effects were examd. with rat models of behavior satiety sequence (BSS), pica behavior and conditioned taste aversion (CTA).  Intakes of food and water together with body wt. were recorded for 15 days during daily dosing of dietary obese rats.  Results: NNC 38-1049 was found to be a highly specific and competitive antagonist towards both human and rat histamine H3 receptors, and measurable amts. of NNC 38-1049 were found in the plasma of rats following single oral doses of 3-60 mg/kg and in the brain after 15-60 mg/kg.  Following single i.p. injections of NNC 38-1049 (20 mg/kg), significant increases in extracellular histamine concns. were obsd.  The same dose did not change BSS or pica behavior acutely, nor did it induce CTA following repeated administration for 7 days.  Redns. in food intake were seen very soon after administration, and occurred in a dose-dependent fashion.  Energy expenditure was unchanged, but the RQ (RQ) tended to decrease at higher doses, indicating an increase in lipid oxidn.  Twice daily administration of 20 mg/kg of NNC 38-1049 in old and dietary obese rats resulted in sustained redn. of food intake throughout a 2-wk study, and was assocd. with a highly significant (P<0.01) decrease in body wt. compared with controls (-18.4±3.4 vs +0.4±2.7 g).  The same dose of NNC 38-1049 produced an acute decrease of water intake, but 24 h intakes were not significantly changed.  Conclusions: The results of this study strongly support the idea that an increase in the hypothalamic concn. of histamine produces a specific redn. of food intake and that this effect can be translated into a decrease in body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3CGytxXPxo7Vg90H21EOLACvtfcHk0ljdb5QuqpkEzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Smt7nE&md5=1d5ff13f52385ef3744d1f651bc239b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijo.0803036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijo.0803036%26sid%3Dliteratum%253Aachs%26aulast%3DMalmlof%26aufirst%3DK.%26aulast%3DZaragoza%26aufirst%3DF.%26aulast%3DGolozoubova%26aufirst%3DV.%26aulast%3DRefsgaard%26aufirst%3DH.%2BH.%2BF.%26aulast%3DCremers%26aufirst%3DT.%26aulast%3DRaun%26aufirst%3DK.%26aulast%3DWulff%26aufirst%3DB.%2BS.%26aulast%3DJohansen%26aufirst%3DP.%2BB.%26aulast%3DWesterink%26aufirst%3DB.%26aulast%3DRimvall%26aufirst%3DK.%26atitle%3DInfluence%2520of%2520a%2520selective%2520histamine%2520receptor%2520antagonist%2520on%2520hypothalamic%2520neural%2520activity%252C%2520food%2520intake%252C%2520and%2520body%2520weight%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2005%26volume%3D29%26spage%3D1402%26epage%3D1412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calver, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessell, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crook, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heslop, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ociepka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schogger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">Structurally novel histamine H<sub>3</sub> receptor antagonists GSK207040 and GSK 334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1182</span><span class="NLM_x">–</span> <span class="NLM_lpage">1194</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1182-1194&author=A.+D.+Medhurstauthor=M.+A.+Briggsauthor=G.+Brutonauthor=A.+R.+Calverauthor=I.+Chessellauthor=B.+Crookauthor=J.+B.+Davisauthor=R.+P.+Davisauthor=A.+G.+Foleyauthor=T.+Heslopauthor=W.+D.+Hirstauthor=S.+J.+Medhurstauthor=S.+Ociepkaauthor=A.+Rayauthor=C.+M.+Reganauthor=B.+Sargentauthor=J.+Schoggerauthor=T.+O.+Steanauthor=B.+K.+Trailauthor=N.+Uptonauthor=T.+Whiteauthor=B.+Orlekauthor=D.+M.+Wilson&title=Structurally+novel+histamine+H3+receptor+antagonists+GSK207040+and+GSK+334429+improve+scopolamine-induced+memory+impairment+and+capsaicin-induced+secondary+allodynia+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DBriggs%26aufirst%3DM.%2BA.%26aulast%3DBruton%26aufirst%3DG.%26aulast%3DCalver%26aufirst%3DA.%2BR.%26aulast%3DChessell%26aufirst%3DI.%26aulast%3DCrook%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DFoley%26aufirst%3DA.%2BG.%26aulast%3DHeslop%26aufirst%3DT.%26aulast%3DHirst%26aufirst%3DW.%2BD.%26aulast%3DMedhurst%26aufirst%3DS.%2BJ.%26aulast%3DOciepka%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DC.%2BM.%26aulast%3DSargent%26aufirst%3DB.%26aulast%3DSchogger%26aufirst%3DJ.%26aulast%3DStean%26aufirst%3DT.%2BO.%26aulast%3DTrail%26aufirst%3DB.%2BK.%26aulast%3DUpton%26aufirst%3DN.%26aulast%3DWhite%26aufirst%3DT.%26aulast%3DOrlek%26aufirst%3DB.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DStructurally%2520novel%2520histamine%2520H3%2520receptor%2520antagonists%2520GSK207040%2520and%2520GSK%2520334429%2520improve%2520scopolamine-induced%2520memory%2520impairment%2520and%2520capsaicin-induced%2520secondary%2520allodynia%2520in%2520rats%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1182%26epage%3D1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atack, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstein, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzolio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rynberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepassi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J.</span><span> </span><span class="NLM_article-title">Pre-clinical characterization of aryloxypyridine amides as histamine H<sub>3</sub> receptor antagonists: Identification of candidates for clinical development</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4210</span><span class="NLM_x">–</span> <span class="NLM_lpage">4214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4210-4214&author=M.+A.+Letavicauthor=L.+Aluisioauthor=J.+R.+Atackauthor=P.+Bonaventureauthor=N.+I.+Carruthersauthor=C.+Dugovicauthor=A.+Eversonauthor=M.+A.+Feinsteinauthor=I.+C.+Fraserauthor=K.+Hoeyauthor=X.+Jiangauthor=J.+M.+Keithauthor=T.+Koudriakovaauthor=P.+Leungauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=K.+S.+Lyauthor=K.+L.+Mortonauthor=S.+T.+Motleyauthor=D.+Nepomucenoauthor=M.+Rizzolioauthor=R.+Rynbergauthor=K.+Sepassiauthor=J.+Shelton&title=Pre-clinical+characterization+of+aryloxypyridine+amides+as+histamine+H3+receptor+antagonists%3A+Identification+of+candidates+for+clinical+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DAtack%26aufirst%3DJ.%2BR.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DA.%26aulast%3DFeinstein%26aufirst%3DM.%2BA.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DHoey%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DKeith%26aufirst%3DJ.%2BM.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLeung%26aufirst%3DP.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DLy%26aufirst%3DK.%2BS.%26aulast%3DMorton%26aufirst%3DK.%2BL.%26aulast%3DMotley%26aufirst%3DS.%2BT.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DRizzolio%26aufirst%3DM.%26aulast%3DRynberg%26aufirst%3DR.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DShelton%26aufirst%3DJ.%26atitle%3DPre-clinical%2520characterization%2520of%2520aryloxypyridine%2520amides%2520as%2520histamine%2520H3%2520receptor%2520antagonists%253A%2520Identification%2520of%2520candidates%2520for%2520clinical%2520development%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4210%26epage%3D4214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Galici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezvani, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoblock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span> </span><span class="NLM_article-title">JNJ-39220675, a novel selective histamine H<sub>3</sub> receptor antagonist, reduces the abuse-related effects of alcohol in rats</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2011&pages=829-841&author=R.+Galiciauthor=A.+H.+Rezvaniauthor=L.+Aluisioauthor=B.+Lordauthor=E.+D.+Levinauthor=I.+Fraserauthor=J.+Boggsauthor=N.+Weltyauthor=J.+R.+Shoblockauthor=S.+T.+Motleyauthor=M.+A.+Letavicauthor=N.+I.+Carruthersauthor=C.+Dugovicauthor=T.+W.+Lovenbergauthor=P.+Bonaventure&title=JNJ-39220675%2C+a+novel+selective+histamine+H3+receptor+antagonist%2C+reduces+the+abuse-related+effects+of+alcohol+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalici%26aufirst%3DR.%26aulast%3DRezvani%26aufirst%3DA.%2BH.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLevin%26aufirst%3DE.%2BD.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DWelty%26aufirst%3DN.%26aulast%3DShoblock%26aufirst%3DJ.%2BR.%26aulast%3DMotley%26aufirst%3DS.%2BT.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26atitle%3DJNJ-39220675%252C%2520a%2520novel%2520selective%2520histamine%2520H3%2520receptor%2520antagonist%252C%2520reduces%2520the%2520abuse-related%2520effects%2520of%2520alcohol%2520in%2520rats%26jtitle%3DPsychopharmacology%26date%3D2011%26volume%3D214%26spage%3D829%26epage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="note"><p class="first last">1-Cyclopropylpiperazine:</p></div><div class="NLM_citation" id="cit24a"><span><span class="NLM_contrib-group">Gillaspy, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefker, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hada, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoover, D. J.</span><span> </span><span class="NLM_article-title">A simple method for the formation of cyclopropylamines: The first synthesis of tricyclopropylamine</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">7399</span><span class="NLM_x">–</span> <span class="NLM_lpage">7402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1016%2F0040-4039%2895%2901560-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADyaK2MXoslOqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=7399-7402&author=M.+L.+Gillaspyauthor=B.+A.+Lefkerauthor=W.+A.+Hadaauthor=D.+J.+Hoover&title=A+simple+method+for+the+formation+of+cyclopropylamines%3A+The+first+synthesis+of+tricyclopropylamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A simple method for the formation of cyclopropylamines: the first synthesis of tricyclopropylamine.</span></div><div class="casAuthors">Gillaspy, Melissa; Lefker, Bruce A.; Hada, William A.; Hoover, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">7399-402</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Treatment of a variety of secondary and primary amines with [(1-ethoxycyclopropyl)oxy]trimethylsilane and NaBH3CN in MeOH gave mono- and dicyclopropylamines in 41-91% yield.  Sterically hindered di- and tricyclopropylamines, including tricyclopropylamine, were prepd.  The pKas of some mono-, di- and tricyclopropylamines were measured showing a redn. of ∼1-2 pKa unit per added cyclopropyl group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBHlBQO9wq2LVg90H21EOLACvtfcHk0lg6skU34hHdHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslOqu70%253D&md5=03d4a4010d1b5b4a9bf075b24fdc3b1d</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2901560-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252901560-4%26sid%3Dliteratum%253Aachs%26aulast%3DGillaspy%26aufirst%3DM.%2BL.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DHada%26aufirst%3DW.%2BA.%26aulast%3DHoover%26aufirst%3DD.%2BJ.%26atitle%3DA%2520simple%2520method%2520for%2520the%2520formation%2520of%2520cyclopropylamines%253A%2520The%2520first%2520synthesis%2520of%2520tricyclopropylamine%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D7399%26epage%3D7402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Preparation of 1-cyclopentylpiperazine dihydrochloride (for experimental):</p></div><span class="NLM_contrib-group">Zaragoza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulff, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimvall, K.</span><span> </span><span class="NLM_article-title">1-Alkyl-a-acylpiperazines as a new class of imidazole-free H<sub>3</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2833</span><span class="NLM_x">–</span> <span class="NLM_lpage">2838</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm031028z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2833-2838&author=F.+Zaragozaauthor=H.+Stephensenauthor=S.+M.+Knudsenauthor=L.+Pridalauthor=B.+S.+Wulffauthor=K.+Rimvall&title=1-Alkyl-a-acylpiperazines+as+a+new+class+of+imidazole-free+H3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1021%2Fjm031028z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031028z%26sid%3Dliteratum%253Aachs%26aulast%3DZaragoza%26aufirst%3DF.%26aulast%3DStephensen%26aufirst%3DH.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%26aulast%3DPridal%26aufirst%3DL.%26aulast%3DWulff%26aufirst%3DB.%2BS.%26aulast%3DRimvall%26aufirst%3DK.%26atitle%3D1-Alkyl-a-acylpiperazines%2520as%2520a%2520new%2520class%2520of%2520imidazole-free%2520H3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2833%26epage%3D2838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wolfe, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S.</span><span> </span><span class="NLM_article-title">Rational development of practical catalysts for aromatic carbon-nitrogen bond formation</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">818</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar9600650" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADyaK1cXms12itLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=805-818&author=J.+P.+Wolfeauthor=S.+Wagawauthor=J.-F.+Marcouxauthor=S.+Buchwald&title=Rational+development+of+practical+catalysts+for+aromatic+carbon-nitrogen+bond+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Development of Practical Catalysts for Aromatic Carbon-Nitrogen Bond Formation</span></div><div class="casAuthors">Wolfe, John P.; Wagaw, Seble; Marcoux, Jean-Francois; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">805-818</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 42 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5RUE_bzqLhLVg90H21EOLACvtfcHk0lg6skU34hHdHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms12itLk%253D&md5=faf0cf60b08747e77d48b39ec905110d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Far9600650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far9600650%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DJ.%2BP.%26aulast%3DWagaw%26aufirst%3DS.%26aulast%3DMarcoux%26aufirst%3DJ.-F.%26aulast%3DBuchwald%26aufirst%3DS.%26atitle%3DRational%2520development%2520of%2520practical%2520catalysts%2520for%2520aromatic%2520carbon-nitrogen%2520bond%2520formation%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1998%26volume%3D31%26spage%3D805%26epage%3D818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nafie, L. A.; Dukor, R. K.</span> In  <span class="citation_source-book">Applications of Vibrational Optical Activity in the Pharmaceutical Industry</span>; <span class="NLM_contrib-group">Pivonka, D. E.; Chalmers, J. M.; Griffiths, P. R.</span>, Eds.; <span class="NLM_publisher-name">John Wiley and Sons</span>: <span class="NLM_publisher-loc">Chichester, West Sussex, England</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=129-154&author=L.+A.+Nafie&author=R.+K.+Dukorauthor=D.+E.+Pivonka&author=J.+M.+Chalmers&author=P.+R.+Griffiths&title=Applications+of+Vibrational+Optical+Activity+in+the+Pharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNafie%26aufirst%3DL.%2BA.%26btitle%3DApplications%2520of%2520Vibrational%2520Optical%2520Activity%2520in%2520the%2520Pharmaceutical%2520Industry%26aulast%3DPivonka%26aufirst%3DD.%2BE.%26pub%3DJohn%2520Wiley%2520and%2520Sons%26date%3D2007%26spage%3D129%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Crawford, T. D.</span><span> </span><span class="NLM_article-title">Ab initio calculation of molecular chirooptical properties</span> <span class="citation_source-journal">Theor. Chem. Acc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1007%2Fs00214-005-0001-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjt1yksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2006&pages=227-245&author=T.+D.+Crawford&title=Ab+initio+calculation+of+molecular+chirooptical+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Ab initio calculation of molecular chiroptical properties</span></div><div class="casAuthors">Crawford, T. Daniel.</div><div class="citationInfo"><span class="NLM_cas:title">Theoretical Chemistry Accounts</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">227-245</span>CODEN:
                <span class="NLM_cas:coden">TCACFW</span>;
        ISSN:<span class="NLM_cas:issn">1432-881X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  This review describes the 1st-principles calcn. of chiroptical properties such as optical rotation, electronic and vibrational CD, and Raman optical activity.  Recent years have witnessed a flurry of activity in this area, esp. in the advancement of d.-functional and coupled cluster methods, with 2 ultimate goals: the elucidation of the fundamental relation between chiroptical properties and detailed mol. structure, and the development of a suite of computational tools for the assignment of the abs. configurations of chiral mols.  The underlying theory and the basic principles of such calcns. are given for each property, and a no. of representative applications are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUJGsUmSAgY7Vg90H21EOLACvtfcHk0lhCeDpYon_Hog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjt1yksbk%253D&md5=72b1f1eb5f53b57e64695dfa685fdad3</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1007%2Fs00214-005-0001-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00214-005-0001-4%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26atitle%3DAb%2520initio%2520calculation%2520of%2520molecular%2520chirooptical%2520properties%26jtitle%3DTheor.%2520Chem.%2520Acc.%26date%3D2006%26volume%3D115%26spage%3D227%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wesolowski, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivonka, D. E.</span><span> </span><span class="NLM_article-title">A rapid alternative to X-ray crystallography for chiral determination: Case studies of vibrational circular dichroism (VCD) to advance drug discovery projects</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4019</span><span class="NLM_x">–</span> <span class="NLM_lpage">4025</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4019-4025&author=S.+S.+Wesolowskiauthor=D.+E.+Pivonka&title=A+rapid+alternative+to+X-ray+crystallography+for+chiral+determination%3A+Case+studies+of+vibrational+circular+dichroism+%28VCD%29+to+advance+drug+discovery+projects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWesolowski%26aufirst%3DS.%2BS.%26aulast%3DPivonka%26aufirst%3DD.%2BE.%26atitle%3DA%2520rapid%2520alternative%2520to%2520X-ray%2520crystallography%2520for%2520chiral%2520determination%253A%2520Case%2520studies%2520of%2520vibrational%2520circular%2520dichroism%2520%2528VCD%2529%2520to%2520advance%2520drug%2520discovery%2520projects%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4019%26epage%3D4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Kaneko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokohama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkuro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span> </span><span class="NLM_article-title">Piperidine carboxylic acid derivatives of 10<i>H</i>-pyrazino[2,3-<i>b</i>][1,4]benzothiazine as orally-active adhesion molecule inhibitors</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=675-687&author=T.+Kanekoauthor=R.+S.+J.+Clarkauthor=N.+Ohiauthor=F.+Ozakiauthor=T.+Kawaharaauthor=A.+Kamadaauthor=K.+Okanoauthor=H.+Yokohamaauthor=M.+Ohkuroauthor=K.+Muramotoauthor=O.+Takenakaauthor=S.+Kobayashi&title=Piperidine+carboxylic+acid+derivatives+of+10H-pyrazino%5B2%2C3-b%5D%5B1%2C4%5Dbenzothiazine+as+orally-active+adhesion+molecule+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DClark%26aufirst%3DR.%2BS.%2BJ.%26aulast%3DOhi%26aufirst%3DN.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DKawahara%26aufirst%3DT.%26aulast%3DKamada%26aufirst%3DA.%26aulast%3DOkano%26aufirst%3DK.%26aulast%3DYokohama%26aufirst%3DH.%26aulast%3DOhkuro%26aufirst%3DM.%26aulast%3DMuramoto%26aufirst%3DK.%26aulast%3DTakenaka%26aufirst%3DO.%26aulast%3DKobayashi%26aufirst%3DS.%26atitle%3DPiperidine%2520carboxylic%2520acid%2520derivatives%2520of%252010H-pyrazino%255B2%252C3-b%255D%255B1%252C4%255Dbenzothiazine%2520as%2520orally-active%2520adhesion%2520molecule%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D675%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Wellendorph, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span> </span><span class="NLM_article-title">Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H<sub>3</sub> receptor</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2002&pages=929-940&author=P.+Wellendorphauthor=M.+W.+Goodmanauthor=E.+S.+Bursteinauthor=N.+R.+Nashauthor=M.+R.+Brannauthor=D.+M.+Weiner&title=Molecular+cloning+and+pharmacology+of+functionally+distinct+isoforms+of+the+human+histamine+H3+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWellendorph%26aufirst%3DP.%26aulast%3DGoodman%26aufirst%3DM.%2BW.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DNash%26aufirst%3DN.%2BR.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26atitle%3DMolecular%2520cloning%2520and%2520pharmacology%2520of%2520functionally%2520distinct%2520isoforms%2520of%2520the%2520human%2520histamine%2520H3%2520receptor%26jtitle%3DNeuropharmacology%26date%3D2002%26volume%3D42%26spage%3D929%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolodin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strulovici, B.</span><span> </span><span class="NLM_article-title">A fully automated [<sup>35</sup>S]GTPγS scintillation proximity assay for the high-throughput screening of Gi-linked G protein-coupled receptors</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=261-273&author=M.+Ferrerauthor=G.+Kolodinauthor=P.+Zuckauthor=R.+Peltierauthor=K.+Berryauthor=S.+Mandalaauthor=H.+Rosenauthor=H.+Otaauthor=S.+Ozakiauthor=J.+Ingleseauthor=B.+Strulovici&title=A+fully+automated+%5B35S%5DGTP%CE%B3S+scintillation+proximity+assay+for+the+high-throughput+screening+of+Gi-linked+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DKolodin%26aufirst%3DG.%26aulast%3DZuck%26aufirst%3DP.%26aulast%3DPeltier%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DK.%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DOta%26aufirst%3DH.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DStrulovici%26aufirst%3DB.%26atitle%3DA%2520fully%2520automated%2520%255B35S%255DGTP%25CE%25B3S%2520scintillation%2520proximity%2520assay%2520for%2520the%2520high-throughput%2520screening%2520of%2520Gi-linked%2520G%2520protein-coupled%2520receptors%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2003%26volume%3D1%26spage%3D261%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">This assay used the Cellomics ArrayScan to quantify the accumulation of phospholipid in the I-13.35 cell line after exposure to cationic amphiphilic drugs known to induce PLD in vitro and in vivo. NBD-PE fluorescent lipid probe (Molecular Probes) was used to measure cellular lipid transport taken up by the cellular lysosomes. Inhibited processing and degradation of phospholipids by test compounds led to an accumulation of NBD-PE in the cells. Ethidium Homodimer (EthD-2) is a dead-cell stain that was used to determine cell viability.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bernstein, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciaccio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, J.</span><span> </span><span class="NLM_article-title">Drug induced phospholipidosis</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=419-430&author=P.+Bernsteinauthor=P.+Ciaccioauthor=J.+Morelli&title=Drug+induced+phospholipidosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DP.%26aulast%3DCiaccio%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DJ.%26atitle%3DDrug%2520induced%2520phospholipidosis%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D419%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Mesens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steemans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheyen, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Goethem, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gompel, J.</span><span> </span><span class="NLM_article-title">Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in vitro assay to high throughput in silico assays</span> <span class="citation_source-journal">Toxicol. In Vitro</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1417-1425&author=N.+Mesensauthor=M.+Steemansauthor=E.+Hansenauthor=G.+R.+Verheyenauthor=F.+Van+Goethemauthor=J.+Van+Gompel&title=Screening+for+phospholipidosis+induced+by+central+nervous+drugs%3A+Comparing+the+predictivity+of+an+in+vitro+assay+to+high+throughput+in+silico+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesens%26aufirst%3DN.%26aulast%3DSteemans%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DE.%26aulast%3DVerheyen%26aufirst%3DG.%2BR.%26aulast%3DVan%2BGoethem%26aufirst%3DF.%26aulast%3DVan%2BGompel%26aufirst%3DJ.%26atitle%3DScreening%2520for%2520phospholipidosis%2520induced%2520by%2520central%2520nervous%2520drugs%253A%2520Comparing%2520the%2520predictivity%2520of%2520an%2520in%2520vitro%2520assay%2520to%2520high%2520throughput%2520in%2520silico%2520assays%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2010%26volume%3D24%26spage%3D1417%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Sydserff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirk, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciag, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christian, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudzik, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrzljak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smagin, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dan Widzowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. S.</span><span> </span><span class="NLM_article-title">Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=880-888&author=S.+Sydserffauthor=E.+J.+Suttonauthor=D.+Songauthor=M.+C.+Quirkauthor=C.+Maciagauthor=C.+Liauthor=G.+Jonakauthor=D.+Gurleyauthor=J.+C.+Gordonauthor=E.+P.+Christianauthor=J.+J.+Dohertyauthor=T.+Hudzikauthor=E.+Johnsonauthor=L.+Mrzljakauthor=T.+Piserauthor=G.+N.+Smaginauthor=Y.+Wangauthor=D.+Dan+Widzowskiauthor=J.+S.+Smith&title=Selective+%CE%B17+nicotinic+receptor+activation+by+AZD0328+enhances+cortical+dopamine+release+and+improves+learning+and+attentional+processes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSydserff%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DE.%2BJ.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DQuirk%26aufirst%3DM.%2BC.%26aulast%3DMaciag%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DJonak%26aufirst%3DG.%26aulast%3DGurley%26aufirst%3DD.%26aulast%3DGordon%26aufirst%3DJ.%2BC.%26aulast%3DChristian%26aufirst%3DE.%2BP.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DHudzik%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DMrzljak%26aufirst%3DL.%26aulast%3DPiser%26aufirst%3DT.%26aulast%3DSmagin%26aufirst%3DG.%2BN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDan%2BWidzowski%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%2BS.%26atitle%3DSelective%2520%25CE%25B17%2520nicotinic%2520receptor%2520activation%2520by%2520AZD0328%2520enhances%2520cortical%2520dopamine%2520release%2520and%2520improves%2520learning%2520and%2520attentional%2520processes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D78%26spage%3D880%26epage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bernstein, P. R.; Brown, D.; Cacciola, J.; Edwards, P.; Folmer, J.; Groblewski, T.; Sylvester, M.; Wesolowski, S.</span><span> </span><span class="NLM_article-title">Spirocyclopropylpiperidinecarboxamide derivatives as histamine H<sub>3</sub> receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases</span>, PCT Int. Appl. WO 2008147314 A1, December 4,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+R.+Bernstein&author=D.+Brown&author=J.+Cacciola&author=P.+Edwards&author=J.+Folmer&author=T.+Groblewski&author=M.+Sylvester&author=S.+Wesolowski&title=Spirocyclopropylpiperidinecarboxamide+derivatives+as+histamine+H3+receptor+agonists+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DP.%2BR.%26atitle%3DSpirocyclopropylpiperidinecarboxamide%2520derivatives%2520as%2520histamine%2520H3%2520receptor%2520agonists%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span>MacroModel, version 10.2; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MacroModel%2C+version+10.2%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span>ROCS, version 3.1.2; <span class="NLM_publisher-name">OpenEye Scientific Software, Inc.</span>: <span class="NLM_publisher-loc">Santa Fe, NM</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ROCS%2C+version+3.1.2%3B+OpenEye+Scientific+Software%2C+Inc.%3A+Santa+Fe%2C+NM%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DROCS%26pub%3DOpenEye%2520Scientific%2520Software%252C%2520Inc%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e','cit13f'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24a','cit24b'],'ref25':['cit25'],'ref26':['cit26a','cit26b','cit26c'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':[],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wan-Xu Wei, Yuke Li, Ya-Ting Wen, Ming Li, Xue-Song Li, Cui-Tian Wang, Hong-Chao Liu, Yu Xia, Bo-Sheng Zhang, Rui-Qiang Jiao, <span class="NLM_string-name hlFld-ContribAuthor">Yong-Min Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Experimental and Computational Studies of Palladium-Catalyzed Spirocyclization via a Narasaka–Heck/C(sp3 or sp2)–H Activation Cascade Reaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (20)
                                     , 7868-7875. <a href="https://doi.org/10.1021/jacs.1c04114" title="DOI URL">https://doi.org/10.1021/jacs.1c04114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c04114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c04114%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DExperimental%252Band%252BComputational%252BStudies%252Bof%252BPalladium-Catalyzed%252BSpirocyclization%252Bvia%252Ba%252BNarasaka%2525E2%252580%252593Heck%25252FC%252528sp3%252Bor%252Bsp2%252529%2525E2%252580%252593H%252BActivation%252BCascade%252BReaction%26aulast%3DWei%26aufirst%3DWan-Xu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19042021%26date%3D11052021%26volume%3D143%26issue%3D20%26spage%3D7868%26epage%3D7875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaokang  Li</span>, <span class="hlFld-ContribAuthor ">Huan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Lu</span>, <span class="hlFld-ContribAuthor ">Xinyu  Zheng</span>, <span class="hlFld-ContribAuthor ">Wei  Ni</span>, <span class="hlFld-ContribAuthor ">Jin  Zhu</span>, <span class="hlFld-ContribAuthor ">Yan  Fu</span>, <span class="hlFld-ContribAuthor ">Fulin  Lian</span>, <span class="hlFld-ContribAuthor ">Naixia  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Haiyan  Zhang</span>, and <span class="hlFld-ContribAuthor ">Fei  Mao</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8326-8344. <a href="https://doi.org/10.1021/acs.jmedchem.6b00636" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00636</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00636%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BMultifunctional%252BPyrimidinylthiourea%252BDerivatives%252Bas%252BPotential%252BAnti-Alzheimer%252BAgents%26aulast%3DLi%26aufirst%3DXiaokang%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D25042016%26date%3D06092016%26date%3D22092016%26date%3D23082016%26volume%3D59%26issue%3D18%26spage%3D8326%26epage%3D8344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E  Tang</span>, <span class="hlFld-ContribAuthor ">Weilin  Wang</span>, <span class="hlFld-ContribAuthor ">Yinjiao  Zhao</span>, <span class="hlFld-ContribAuthor ">Meng  Zhang</span>, and <span class="hlFld-ContribAuthor ">Xin  Dai</span>  . </span><span class="cited-content_cbyCitation_article-title">Catalytic and Atom-Economic Intermolecular Amidoselenenylation of Alkenes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2016,</strong> <em>18 </em>
                                    (2)
                                     , 176-179. <a href="https://doi.org/10.1021/acs.orglett.5b03157" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b03157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b03157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b03157%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCatalytic%252Band%252BAtom-Economic%252BIntermolecular%252BAmidoselenenylation%252Bof%252BAlkenes%26aulast%3DTang%26aufirst%3DE%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D01112015%26date%3D24122015%26date%3D15012016%26volume%3D18%26issue%3D2%26spage%3D176%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Woon-Yew  Siau</span> and <span class="hlFld-ContribAuthor ">Jeffrey W.  Bode</span>  . </span><span class="cited-content_cbyCitation_article-title">One-Step Synthesis of Saturated Spirocyclic N-Heterocycles with Stannyl Amine Protocol (SnAP) Reagents and Ketones. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2014,</strong> <em>136 </em>
                                    (51)
                                     , 17726-17729. <a href="https://doi.org/10.1021/ja511232b" title="DOI URL">https://doi.org/10.1021/ja511232b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja511232b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja511232b%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DOne-Step%252BSynthesis%252Bof%252BSaturated%252BSpirocyclic%252BN-Heterocycles%252Bwith%252BStannyl%252BAmine%252BProtocol%252B%252528SnAP%252529%252BReagents%252Band%252BKetones%26aulast%3DSiau%26aufirst%3DWoon-Yew%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D01112014%26date%3D09122014%26date%3D24122014%26date%3D07122014%26volume%3D136%26issue%3D51%26spage%3D17726%26epage%3D17729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenqiang  Yang</span>, <span class="hlFld-ContribAuthor ">Xingyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao  Jin</span>, <span class="hlFld-ContribAuthor ">Han  Sun</span>, <span class="hlFld-ContribAuthor ">Runan  Guo</span>, <span class="hlFld-ContribAuthor ">Wei  Xu</span>, <span class="hlFld-ContribAuthor ">Qian  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Copper‐Catalysed Double
              O
              ‐Arylation for Enantioselective Synthesis of
              oxa
              ‐Spirocycles. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (3)
                                     , 562-568. <a href="https://doi.org/10.1002/adsc.201801395" title="DOI URL">https://doi.org/10.1002/adsc.201801395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201801395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201801395%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DCopper%2525E2%252580%252590Catalysed%252BDouble%252BO%252B%2525E2%252580%252590Arylation%252Bfor%252BEnantioselective%252BSynthesis%252Bof%252Boxa%252B%2525E2%252580%252590Spirocycles%26aulast%3DYang%26aufirst%3DWenqiang%26date%3D2019%26date%3D2018%26volume%3D361%26issue%3D3%26spage%3D562%26epage%3D568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Dong</span>, <span class="hlFld-ContribAuthor ">Chunxia  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Xu</span>, <span class="hlFld-ContribAuthor ">Yue  Zhang</span>, <span class="hlFld-ContribAuthor ">Ying  Zhao</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Formation of β-Lactones by [2+2] Cycloaddition of Dichloroketene with Unreactive Carbonyl Compounds. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Chinese Universities</span><span> <strong>2018,</strong> <em>34 </em>
                                    (5)
                                     , 736-743. <a href="https://doi.org/10.1007/s40242-018-8088-z" title="DOI URL">https://doi.org/10.1007/s40242-018-8088-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40242-018-8088-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40242-018-8088-z%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Chinese%2520Universities%26atitle%3DFormation%252Bof%252B%2525CE%2525B2-Lactones%252Bby%252B%25255B2%25252B2%25255D%252BCycloaddition%252Bof%252BDichloroketene%252Bwith%252BUnreactive%252BCarbonyl%252BCompounds%26aulast%3DDong%26aufirst%3DXu%26date%3D2018%26date%3D2018%26volume%3D34%26issue%3D5%26spage%3D736%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gustavo  Provensi</span>, <span class="hlFld-ContribAuthor ">Alessia  Costa</span>, <span class="hlFld-ContribAuthor ">Maria Beatrice  Passani</span>. </span><span class="cited-content_cbyCitation_article-title">Histaminergic Modulation of Recognition Memory. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 415-445. <a href="https://doi.org/10.1016/B978-0-12-812012-5.00029-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-812012-5.00029-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-812012-5.00029-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-812012-5.00029-X%26sid%3Dliteratum%253Aachs%26atitle%3DHistaminergic%252BModulation%252Bof%252BRecognition%252BMemory%26aulast%3DProvensi%26aufirst%3DGustavo%26date%3D2018%26spage%3D415%26epage%3D445%26pub%3DElsevier%26atitle%3DHandbook%252Bof%252BObject%252BNovelty%252BRecognition%26date%3D2018%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel D.  Griggs</span>, <span class="hlFld-ContribAuthor ">Daniel T.  Tape</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for the synthesis of spiropiperidines – a review of the last 10 years. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (36)
                                     , 6620-6633. <a href="https://doi.org/10.1039/C8OB01271G" title="DOI URL">https://doi.org/10.1039/C8OB01271G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01271G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01271G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DStrategies%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bspiropiperidines%252B%2525E2%252580%252593%252Ba%252Breview%252Bof%252Bthe%252Blast%252B10%252Byears%26aulast%3DGriggs%26aufirst%3DSamuel%2BD.%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D36%26spage%3D6620%26epage%3D6633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.M.  Tice</span>, <span class="hlFld-ContribAuthor ">Y.  Zheng</span>, <span class="hlFld-ContribAuthor ">S.B.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Spirocyclic Scaffolds in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 211-263. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12291-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12291-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12291-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12291-7%26sid%3Dliteratum%253Aachs%26atitle%3DSpirocyclic%252BScaffolds%252Bin%252BDrug%252BDiscovery%26aulast%3DTice%26aufirst%3DC.M.%26date%3D2017%26spage%3D211%26epage%3D263%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Armin  Zlomuzica</span>, <span class="hlFld-ContribAuthor ">Dorothea  Dere</span>, <span class="hlFld-ContribAuthor ">Sonja  Binder</span>, <span class="hlFld-ContribAuthor ">Maria Angelica  De Souza Silva</span>, <span class="hlFld-ContribAuthor ">Joseph P.  Huston</span>, <span class="hlFld-ContribAuthor ">Ekrem  Dere</span>. </span><span class="cited-content_cbyCitation_article-title">Neuronal histamine and cognitive symptoms in Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2016,</strong> <em>106 </em>, 135-145. <a href="https://doi.org/10.1016/j.neuropharm.2015.05.007" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2015.05.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2015.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2015.05.007%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DNeuronal%252Bhistamine%252Band%252Bcognitive%252Bsymptoms%252Bin%252BAlzheimer%252527s%252Bdisease%26aulast%3DZlomuzica%26aufirst%3DArmin%26date%3D2016%26volume%3D106%26spage%3D135%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">B.  Sadek</span>, <span class="hlFld-ContribAuthor ">D.  Łażewska</span>, <span class="hlFld-ContribAuthor ">S.  Hagenow</span>, <span class="hlFld-ContribAuthor ">K.  Kieć-Kononowicz</span>, <span class="hlFld-ContribAuthor ">H.  Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Histamine H3R Antagonists: From Scaffold Hopping to Clinical Candidates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 109-155. <a href="https://doi.org/10.1007/978-3-319-40308-3_5" title="DOI URL">https://doi.org/10.1007/978-3-319-40308-3_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-40308-3_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-40308-3_5%26sid%3Dliteratum%253Aachs%26atitle%3DHistamine%252BH3R%252BAntagonists%25253A%252BFrom%252BScaffold%252BHopping%252Bto%252BClinical%252BCandidates%26aulast%3DSadek%26aufirst%3DB.%26date%3D2016%26date%3D2016%26spage%3D109%26epage%3D155%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHistamine%252BReceptors%26aulast%3DBlandina%26aufirst%3DPatrizio%26date%3D2016%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel W.  Kung</span>, <span class="hlFld-ContribAuthor ">David A.  Griffith</span>, <span class="hlFld-ContribAuthor ">William P.  Esler</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>, <span class="hlFld-ContribAuthor ">Alan M.  Mathiowetz</span>, <span class="hlFld-ContribAuthor ">Shawn D.  Doran</span>, <span class="hlFld-ContribAuthor ">Paul A.  Amor</span>, <span class="hlFld-ContribAuthor ">Scott W.  Bagley</span>, <span class="hlFld-ContribAuthor ">Tereece  Banks</span>, <span class="hlFld-ContribAuthor ">Shawn  Cabral</span>, <span class="hlFld-ContribAuthor ">Kristen  Ford</span>, <span class="hlFld-ContribAuthor ">Carmen N.  Garcia-Irizarry</span>, <span class="hlFld-ContribAuthor ">Margaret S.  Landis</span>, <span class="hlFld-ContribAuthor ">Kathrine  Loomis</span>, <span class="hlFld-ContribAuthor ">Kirk  McPherson</span>, <span class="hlFld-ContribAuthor ">Mark  Niosi</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Rockwell</span>, <span class="hlFld-ContribAuthor ">Colin  Rose</span>, <span class="hlFld-ContribAuthor ">Aaron C.  Smith</span>, <span class="hlFld-ContribAuthor ">James A.  Southers</span>, <span class="hlFld-ContribAuthor ">Susan  Tapley</span>, <span class="hlFld-ContribAuthor ">Meihua  Tu</span>, <span class="hlFld-ContribAuthor ">James J.  Valentine</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of spirocyclic-diamine inhibitors of mammalian acetyl CoA-carboxylase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (22)
                                     , 5352-5356. <a href="https://doi.org/10.1016/j.bmcl.2015.09.035" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.09.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.09.035%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bspirocyclic-diamine%252Binhibitors%252Bof%252Bmammalian%252Bacetyl%252BCoA-carboxylase%26aulast%3DKung%26aufirst%3DDaniel%2BW.%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5352%26epage%3D5356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yajun  Zheng</span>, <span class="hlFld-ContribAuthor ">Colin M.  Tice</span>, <span class="hlFld-ContribAuthor ">Suresh B.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">The use of spirocyclic scaffolds in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (16)
                                     , 3673-3682. <a href="https://doi.org/10.1016/j.bmcl.2014.06.081" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.06.081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.06.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.06.081%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Buse%252Bof%252Bspirocyclic%252Bscaffolds%252Bin%252Bdrug%252Bdiscovery%26aulast%3DZheng%26aufirst%3DYajun%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3673%26epage%3D3682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative H<sub>3</sub> scaffolds with dibasic, piperazine, and diazepane scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>PCH<sub>3</sub><sup>+</sup>Br<sup>–</sup>, <i>n</i>-BuLi, THF, 54%; (b) CuCN, ethyldiazoacetate, CH<sub>2</sub>Cl<sub>2</sub>, 45%; (c) EtOH, Pd/C, H<sub>2</sub>, 44%; (d) 1,2-DCE, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Na(OAc)<sub>3</sub>BH, rt, 64%; (e) LiOH, MeOH, quan.; (f) HBTU, DMF, DIPEA, amine, 34–80%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LiOH, THF, 94%; (b) HBTU, DIPEA, <i>tert</i>-butyl piperazine-1-carboxylate, 69%; (c) EtOH, Pd/C, H<sub>2</sub>, AcOH (cat.), 99%; (d) EtOH, NaBH<sub>3</sub>CN, AcOH (cat.), dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one; (e) CH<sub>2</sub>Cl<sub>2</sub>, TFA, 99%; (f) CH<sub>2</sub>Cl<sub>2</sub>, cyclohexanone, PS-CNBH<sub>4</sub>, 66%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HBTU, 1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperazine dihydrochloride, 11%; (b) Pd/C, H<sub>2</sub>, MeOH, cyclobutanone, 46%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, HBTU, DIPEA, 1-cyclohexylpiperazine, 70%; (b) MeOH, Pd/C, H<sub>2</sub>, rt, 95%; (c) 4-Cl-pyridine, K<sub>2</sub>CO<sub>3</sub>, DMSO, 26%; (d) PhMe, Li(HMDS), PhBr, PdCl<sub>2</sub>[P(<i>o</i>-tol)<sub>3</sub>]<sub>2</sub>, 12%; (e) 1,2-DCE, R<sub>2</sub>-CHO, Na(OAc)<sub>3</sub>BH, rt, 30–60%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Chiral SFC, quan.; (b) Pd/C, H<sub>2</sub>, EtOH, rt, 59% for <b>4a</b> and 82% for <b>4b</b>; (c) NaOH, MeOH, H<sub>2</sub>O, quan; (d) HBTU, 1-isopropylpiperazine, quan.; (e) Pd/C, H<sub>2</sub>, MeOH, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, 30 psi, 45% for <b>6r</b> and 68% for <b>6s</b>.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, NaH, (MeO)<sub>2</sub>PCH<sub>2</sub>CO<sub>2</sub>Me, cyclohexanone, 72%; (b) DMF, NaH, Me<sub>3</sub>S<sup>+</sup>I<sup>–</sup>, 49%; (c) LiOH, THF, quan.; (d) DMF, HBTU, DIPEA, cyclobutylpiperazine, 69%.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Zn–Cu, Et<sub>2</sub>O, Cl<sub>3</sub>COCl, 40%; (b) NH<sub>4</sub>Cl, MeOH, Zn, 97%; (c) NaBH<sub>4</sub>, MeOH, 99%; (d) Et<sub>3</sub>N, MsCl, CH<sub>2</sub>Cl<sub>2</sub>, 97%; (e) NaCN, TBAB, DMF, 57%; (f) EtOH, H<sub>2</sub>SO<sub>4</sub>; Boc<sub>2</sub>O, 41%; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 83%; (h) MeOH, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Pd/C, H<sub>2</sub>, rt, 58%; (i) MeOH, 1 N NaOH, reflux, quan.; (j) DMF, HBTU, amine, DIPEA, 76%; (k) CO<sub>2</sub>Cl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; DIPEA, R<sup>1</sup>-amine, CH<sub>2</sub>Cl<sub>2</sub>, 32–65%.</p></p></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Et<sub>2</sub>O, Zn–Cu, Cl<sub>3</sub>COCl, DME, 40%; (b) MeOH, NH<sub>4</sub>Cl, Zn, 74%; (c) THF, KO<i>t</i>-Bu, BuOH, Ph<sub>3</sub>PCH<sub>2</sub>OMe<sup>+</sup>Cl<sup>–</sup>, 48%; (d) CH<sub>2</sub>Cl<sub>2</sub>/NaHCO<sub>3</sub>, NaOCl, TEMPO, NaBr, 72%; (e) DMF, DIEA, amine, HBTU, 78% or SO<sub>2</sub>Cl<sub>2</sub>, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, quan.; (f) EtOH, Pd/C, H<sub>2</sub> 50 psi, 88–96%; (g) CH<sub>2</sub>Cl<sub>2</sub>, TEA, MeSO<sub>2</sub>Cl, 39%; (h) PhMe, Ph-Br, Pd(OAc)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, BINAP, 110 °C, 18h, 46%; (i) CH<sub>2</sub>Cl<sub>2</sub>, DIPEA, PhCOCl, 33–64%.</p></p></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, 4-NO<sub>2</sub>PhOCOCl, DIPEA, 1-isopropylpiperazine, reflux, 72%; (b) HCl, MeOH, rt, quan.; (c) MeOH, TEA, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Pd/C, H<sub>2</sub>, rt, 28%.</p></p></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 10. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, CDI, Et<sub>3</sub>N; (b) ACN, MeI; (c) CH<sub>2</sub>Cl<sub>2</sub>, R<sup>1</sup>-amine, Et<sub>3</sub>N, 40% steps a–c; (d) HCl, <i>i</i>PrOH, Et<sub>2</sub>O, quan.; (e) NaBH(OAc)<sub>3</sub>, 1,2-DCE, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, AcOH, Et<sub>3</sub>N, 40–44%; (f) THF, 4-NO<sub>2</sub>PhOCOCl, −78 °C, 1-isopropylpiperazine, reflux, DIPEA, 28%; (g) HCl, MeOH, 75%; (h) MeOH, TEA, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, Pd/C, H<sub>2</sub>, rt, 62%.</p></p></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 11. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, CDI, Et<sub>3</sub>N; (b) ACN, MeI; (c) CH<sub>2</sub>Cl<sub>2</sub>, R<sup>1</sup>-amine, Et<sub>3</sub>N, 40% steps a–c; (d) HCl, <i>i</i>PrOH, Et<sub>2</sub>O, quan.; (e) NaBH(OAc)<sub>3</sub>, 1,2-DCE, dihydro-2<i>H</i>-pyran-4-(3<i>H</i>)-one, AcOH, Et<sub>3</sub>N, 36%; (f) CH<sub>2</sub>Cl<sub>2</sub>, PhCOCl, TEA, 48%; (g) PhSO<sub>2</sub>Cl, TEA, 50%; (h) THF, CDI, Et<sub>3</sub>N, quan.; (i) ACN, MeI, quan.; (j) CH<sub>2</sub>Cl<sub>2</sub>, R<sup>1</sup>-amine, Et<sub>3</sub>N, 65–67%; (k) HCl, <i>i</i>PrOH, quan.; (l) CH<sub>2</sub>Cl<sub>2</sub>, PhCOCl, TEA, 85–88%; (m) R<sub>2</sub>SO<sub>2</sub>Cl, TEA, 77–85%.</p></p></figure><figure data-id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 12. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-MeTHF, PhCO<sub>2</sub>H, DIPEA, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium, 61%; (b) HCl, MeOH, quan.; (c) 2-MeTHF, DIPEA, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium, 1-(<i>tert</i>-butoxycarbonyl)piperidine-4-carboxylic acid, 22%; (d) dioxane, HCl, 64%; (e) DMF, NaCNBH<sub>4</sub>, cyclobutanone, 37%.</p></p></figure><figure data-id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 13. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, CDI, Et<sub>3</sub>N, quan.; (b) ACN, MeI, quan.; (c) CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 1-cyclobutyl-1,4-diazepane, 80%; (d) HCl, <i>i</i>PrOH, quan.; (e) benzoyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 75%.</p></p></figure><figure data-id="fig2" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (left) Molecular overlays of Conesine (gray, small-molecule X-ray structure) and <b>6s</b> (purple, low-lying conformation). (right) Molecular overlays of <b>29f</b> (red), <b>34</b> (green), and Bavisant (light blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plasma concentrations and arterial pharmacokinetic parameters of <b>6s</b> following a 3 μmol/kg IV (fasted rats) dose and 3 μmol/kg PO (fed rats) dose in male Sprague–Dawley rats using a crossover study design with a PO formulation of 10% DMA and 18% SBECD, pH 4.73.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>6s</b> significantly increased novel object exploration 30 min after acquisition relative to vehicle treatment in mice dosed with 1, 3, and 10 mg/kg 60 min prior to acquisition (<i>p</i> < 0.01, 0.05, and 0.05 respectively). All data are mean ± SD ratio of novel/familiar object interaction. Analysis was performed on manual assessment of interaction scores using ANOVA followed by Newman–Keuls posthoc analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/medium/jm-2013-014828_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. VCD Spectra of the Boltzmann-weighted average of the computed VCD spectra along with the experimental spectra for <b>4b</b> (<i>S</i>) and <b>4a</b> (<i>R</i>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm4014828/production/images/large/jm-2013-014828_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4014828&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i113">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Arrang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbarg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J. C.</span><span> </span><span class="NLM_article-title">Auto-inhibition of brain histamine release mediated by a novel class (H<sub>3</sub>) of histamine receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2F302832a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=6188956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=1983&pages=832-837&author=J.+M.+Arrangauthor=M.+Garbargauthor=J.+C.+Schwartz&title=Auto-inhibition+of+brain+histamine+release+mediated+by+a+novel+class+%28H3%29+of+histamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor</span></div><div class="casAuthors">Arrang, Jean Michel; Garbarg, Monique; Schwartz, Jean Charles</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5911</span>),
    <span class="NLM_cas:pages">832-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The K+-induced release of 3H-labeled histamine (I)  [51-45-6] from rat cerebral cortex slices was inhibited by exogenous I, suggesting the presence of histaminic receptors by which this compd. can control its own release.  Although Nα-methylhistamine  [673-50-7] and Nα,Nα-dimethylhistamine  [673-46-1] also inhibited [3H]-I release, a no. of compds. known to exhibit agonist activities of H1 or H2 receptors had no significant effect.  Consequently, autoinhibition of I release by the brain is apparently mediated by a type of receptor (histaminic H3) that is clearly different from H1 and H2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpu3HYACgLprVg90H21EOLACvtfcHk0liMZcPLvTgsww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitFSmsbc%253D&md5=891b1e95467aa9213317c930f12bf3b7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F302832a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F302832a0%26sid%3Dliteratum%253Aachs%26aulast%3DArrang%26aufirst%3DJ.%2BM.%26aulast%3DGarbarg%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DAuto-inhibition%2520of%2520brain%2520histamine%2520release%2520mediated%2520by%2520a%2520novel%2520class%2520%2528H3%2529%2520of%2520histamine%2520receptor%26jtitle%3DNature%26date%3D1983%26volume%3D302%26spage%3D832%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Brioni, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span> </span><span class="NLM_article-title">Discovery of histamine H<sub>3</sub> antagonists for the treatment of cognitive disorders and Alzheimer’s disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1124%2Fjpet.110.166876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=20864505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=38-46&author=J.+D.+Brioniauthor=T.+A.+Esbenshadeauthor=T.+R.+Garrisonauthor=S.+R.+Bitnerauthor=M.+D.+Cowart&title=Discovery+of+histamine+H3+antagonists+for+the+treatment+of+cognitive+disorders+and+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease</span></div><div class="casAuthors">Brioni, Jorge D.; Esbenshade, Tim A.; Garrison, Tiffany Runyan; Bitner, Scott R.; Cowart, Marlon D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-46</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  H3 antagonists increase the release of brain histamine, acetylcholine, noradrenaline, and dopamine, neurotransmitters that are known to modulate cognitive processes.  The ability to release brain histamine supports the effect on attention and vigilance, but histamine also modulates other cognitive domains such as short-term and long-term memory.  A no. of H3 antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1R,3R)-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clin. area for the potential treatment of human cognitive disorders.  H3 antagonists exhibited wake-promoting effects in humans and efficacy in narcoleptic patients, indicating target engagement, but some of them were not efficacious in patients suffering from attention-deficit hyperactivity disorder and schizophrenic patients.  Preclin. studies have also shown that H3 antagonists activate intracellular signaling pathways that may improve cognitive efficacy and disease-modifying effects in Alzheimer's disease.  Ongoing clin. studies will be able to det. the utility of H3 antagonists for the treatment of cognitive disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHvanX-UatFbVg90H21EOLACvtfcHk0liMZcPLvTgsww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ektw%253D%253D&md5=d8f3f6997a6b9c96be5e6eb836bd2951</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.166876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.166876%26sid%3Dliteratum%253Aachs%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DBitner%26aufirst%3DS.%2BR.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520histamine%2520H3%2520antagonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D38%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cowart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of A-960656, a histamine H<sub>3</sub> receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">684</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1016%2Fj.ejphar.2012.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=22504024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=684&publication_year=2012&pages=87-94&author=M.+Cowartauthor=G.+Hsiehauthor=L.+A.+Blackauthor=Z.+Zhanauthor=E.+J.+Gomezauthor=M.+Paiauthor=M.+Strakhovaauthor=A.+Manelliauthor=T.+Carrauthor=J.+Wetterauthor=A.+Leeauthor=G.+Diazauthor=T.+Garrisonauthor=J.+D.+Brioni&title=Pharmacological+characterization+of+A-960656%2C+a+histamine+H3+receptor+antagonist+with+efficacy+in+animal+models+of+osteoarthritis+and+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of A-960656, a histamine H3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain</span></div><div class="casAuthors">Cowart, Marlon; Hsieh, Gin; Black, Lawrence A.; Zhan, CenChen; Gomez, Erica J.; Pai, Madhavi; Strakhova, Marina; Manelli, Arlene; Carr, Tracy; Wetter, Jill; Lee, Anthony; Diaz, Gilbert; Garrison, Tiffany; Brioni, Jorge D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">684</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">87-94</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histamine H3 receptor antagonists have been widely reported to improve performance in preclin. models of cognition, but more recently efficacy in pain models has also been described.  Here, A-960656 ((R)-2-(2-(3-(piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazol-6-yl)pyridazin-3(2H)-one) was profiled as a new structural chemotype.  A-960656 was potent in vitro in histamine H3 receptor binding assays (rat Ki = 76 nM, human Ki = 21 nM), and exhibited functional antagonism in blocking agonist-induced [35S]GTPγS binding (rat H3 Kb = 107 nM, human H3 Kb = 22 nM), and was highly specific for H3 receptors in broad screens for non-H3 sites.  In a spinal nerve ligation model of neuropathic pain in rat, oral doses of 1 and 3 mg/kg were effective 60 min post dosing with an ED50 of 2.17 mg/kg and a blood EC50 of 639 ng/mL.  In a model of osteoarthritis pain, oral doses of 0.1, 0.3, and 1 mg/kg were effective 1 h post dosing with an ED50 of 0.52 mg/kg and a blood EC50 of 233 ng/mL.  The antinociceptive effect of A-960656 in both pain models was maintained after sub-chronic dosing up to 12 days.  A-960656 had excellent rat pharmacokinetics (t1/2 = 1.9 h, 84% oral bioavailability) with rapid and efficient brain penetration, and was well tolerated in CNS behavioral safety screens.  In summary, A-960656 has properties well suited to probe the pharmacol. of histamine H3 receptors in pain.  Its potency and efficacy in animal pain models provide support to the notion that histamine H3 receptor antagonists are effective in attenuating nociceptive processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5nYIPfseMLVg90H21EOLACvtfcHk0lj3gC1j871StQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFyrtL0%253D&md5=ee7cf0e3f1a0f462330069e20f91c927</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DCowart%26aufirst%3DM.%26aulast%3DHsieh%26aufirst%3DG.%26aulast%3DBlack%26aufirst%3DL.%2BA.%26aulast%3DZhan%26aufirst%3DZ.%26aulast%3DGomez%26aufirst%3DE.%2BJ.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DStrakhova%26aufirst%3DM.%26aulast%3DManelli%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DT.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DGarrison%26aufirst%3DT.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26atitle%3DPharmacological%2520characterization%2520of%2520A-960656%252C%2520a%2520histamine%2520H3%2520receptor%2520antagonist%2520with%2520efficacy%2520in%2520animal%2520models%2520of%2520osteoarthritis%2520and%2520neuropathic%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D684%26spage%3D87%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Weisler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandina, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gassman-Mayer, C.</span><span> </span><span class="NLM_article-title">Randomized clinical study of a histamine H<sub>3</sub> receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=421-434&author=R.+H.+Weislerauthor=G.+J.+Pandinaauthor=E.+J.+Dalyauthor=K.+Cooperauthor=C.+Gassman-Mayer&title=Randomized+clinical+study+of+a+histamine+H3+receptor+antagonist+for+the+treatment+of+adults+with+attention-deficit+hyperactivity+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeisler%26aufirst%3DR.%2BH.%26aulast%3DPandina%26aufirst%3DG.%2BJ.%26aulast%3DDaly%26aufirst%3DE.%2BJ.%26aulast%3DCooper%26aufirst%3DK.%26aulast%3DGassman-Mayer%26aufirst%3DC.%26atitle%3DRandomized%2520clinical%2520study%2520of%2520a%2520histamine%2520H3%2520receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520adults%2520with%2520attention-deficit%2520hyperactivity%2520disorder%26jtitle%3DCNS%2520Drugs%26date%3D2012%26volume%3D26%26spage%3D421%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Medhurst, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billinton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalziel, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessell, I. P.</span><span> </span><span class="NLM_article-title">Novel histamine H<sub>3</sub> receptor antagonist GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain</span> <span class="citation_source-journal">Pain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2008&pages=61-78&author=S.+J.+Medhurstauthor=S.+D.+Collinsauthor=A.+Billintonauthor=S.+Binghamauthor=R.+G.+Dalzielauthor=A.+Brassauthor=J.+C.+Robertsauthor=A.+D.+Medhurstauthor=I.+P.+Chessell&title=Novel+histamine+H3+receptor+antagonist+GSK189254+and+GSK334429+are+efficacious+in+surgically-induced+and+virally-induced+rat+models+of+neuropathic+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMedhurst%26aufirst%3DS.%2BJ.%26aulast%3DCollins%26aufirst%3DS.%2BD.%26aulast%3DBillinton%26aufirst%3DA.%26aulast%3DBingham%26aufirst%3DS.%26aulast%3DDalziel%26aufirst%3DR.%2BG.%26aulast%3DBrass%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%2BC.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DChessell%26aufirst%3DI.%2BP.%26atitle%3DNovel%2520histamine%2520H3%2520receptor%2520antagonist%2520GSK189254%2520and%2520GSK334429%2520are%2520efficacious%2520in%2520surgically-induced%2520and%2520virally-induced%2520rat%2520models%2520of%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2008%26volume%3D138%26spage%3D61%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Karagiannidis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnok, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolanczyk, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madruga-Garrido, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebebrand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nöthen, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmkuhl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farkas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanska, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastasiou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stathias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Androutsos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsironi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koumoula, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mir, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschou, P.</span><span> </span><span class="NLM_article-title">Support of the histaminergic hypothesis in Tourette syndrome: Association of the histamine decarboxylase gene in a large sample of families</span> <span class="citation_source-journal">J. Med. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1136%2Fjmedgenet-2013-101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=23825391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOgu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2013&pages=760-764&author=I.+Karagiannidisauthor=S.+Dehningauthor=P.+Sandorauthor=Z.+Tarnokauthor=R.+Rizzoauthor=T.+Wolanczykauthor=M.+Madruga-Garridoauthor=J.+Hebebrandauthor=M.+M.+N%C3%B6thenauthor=G.+Lehmkuhlauthor=L.+Farkasauthor=P.+Nagyauthor=U.+Symanskaauthor=Z.+Anastasiouauthor=V.+Stathiasauthor=C.+Androutsosauthor=V.+Tsironiauthor=A.+Koumoulaauthor=C.+Bartaauthor=P.+Zillauthor=P.+Mirauthor=N.+M%C3%BCllerauthor=C.+Barrauthor=P.+Paschou&title=Support+of+the+histaminergic+hypothesis+in+Tourette+syndrome%3A+Association+of+the+histamine+decarboxylase+gene+in+a+large+sample+of+families"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Support of the histaminergic hypothesis in Tourette Syndrome: association of the histamine decarboxylase gene in a large sample of families</span></div><div class="casAuthors">Karagiannidis, Iordanis; Dehning, Sandra; Sandor, Paul; Tarnok, Zsanett; Rizzo, Renata; Wolanczyk, Tomasz; Madruga-Garrido, Marcos; Hebebrand, Johannes; Nothen, Markus M.; Lehmkuhl, Gerd; Farkas, Luca; Nagy, Peter; Szymanska, Urszula; Anastasiou, Zachos; Stathias, Vasileios; Androutsos, Christos; Tsironi, Vaia; Koumoula, Anastasia; Barta, Csaba; Zill, Peter; Mir, Pablo; Muller, Norbert; Barr, Cathy; Paschou, Peristera</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-764</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background Gilles de la Tourette Syndrome is a neurodevelopmental disorder that is caused by the interaction of environment with a complex genetic background.  The genetic etiol. of the disorder remains, so far, elusive, although multiple promising leads have been recently reported.  The recent implication of the histamine decarboxylase (HDC) gene, the key enzyme in histamine prodn., raises the intriguing hypothesis of a possible role of histaminergic dysfunction leading to TS onset.  Methods Following up on the finding of a nonsense mutation in a single family with TS, we investigated variation across the HDC gene for assocn. with TS.  As a result of a collaborative international effort, we studied a large sample of 520 nuclear families originating from seven European populations (Greek, Hungarian, Italian, Polish, German, Albanian, Spanish) as well as a sample collected in Canada.  Results and Conclusions Interrogating 12 tagging SNPs (tSNP) across the HDC region, we find strong over-transmission of alleles at two SNPs (rs854150 and rs1894236) in the complete sample, as well as a statistically significant assocd. haplotypes.  Anal. of individual populations also reveals signals of assocn. in the Canadian, German and Italian samples.  Our results provide strong support for the histaminergic hypothesis in TS etiol. and point to a possible role of histamine pathways in neuronal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcreCQj-_LLVg90H21EOLACvtfcHk0lj3gC1j871StQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOgu73P&md5=e75c8a0878b055e23364b43b460be19f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1136%2Fjmedgenet-2013-101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmedgenet-2013-101637%26sid%3Dliteratum%253Aachs%26aulast%3DKaragiannidis%26aufirst%3DI.%26aulast%3DDehning%26aufirst%3DS.%26aulast%3DSandor%26aufirst%3DP.%26aulast%3DTarnok%26aufirst%3DZ.%26aulast%3DRizzo%26aufirst%3DR.%26aulast%3DWolanczyk%26aufirst%3DT.%26aulast%3DMadruga-Garrido%26aufirst%3DM.%26aulast%3DHebebrand%26aufirst%3DJ.%26aulast%3DN%25C3%25B6then%26aufirst%3DM.%2BM.%26aulast%3DLehmkuhl%26aufirst%3DG.%26aulast%3DFarkas%26aufirst%3DL.%26aulast%3DNagy%26aufirst%3DP.%26aulast%3DSymanska%26aufirst%3DU.%26aulast%3DAnastasiou%26aufirst%3DZ.%26aulast%3DStathias%26aufirst%3DV.%26aulast%3DAndroutsos%26aufirst%3DC.%26aulast%3DTsironi%26aufirst%3DV.%26aulast%3DKoumoula%26aufirst%3DA.%26aulast%3DBarta%26aufirst%3DC.%26aulast%3DZill%26aufirst%3DP.%26aulast%3DMir%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DN.%26aulast%3DBarr%26aufirst%3DC.%26aulast%3DPaschou%26aufirst%3DP.%26atitle%3DSupport%2520of%2520the%2520histaminergic%2520hypothesis%2520in%2520Tourette%2520syndrome%253A%2520Association%2520of%2520the%2520histamine%2520decarboxylase%2520gene%2520in%2520a%2520large%2520sample%2520of%2520families%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2013%26volume%3D50%26spage%3D760%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span> </span><span class="NLM_article-title">The H<sub>3</sub> receptor: An attractive target for the treatment of cognitive disorders</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2Fbjp.2008.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=18469850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1166-1181&author=T.+A.+Esbenshadeauthor=K.+E.+Browmanauthor=R.+S.+Bitnerauthor=M.+Strakhovaauthor=M.+D.+Cowartauthor=J.+D.+Brioni&title=The+H3+receptor%3A+An+attractive+target+for+the+treatment+of+cognitive+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</span></div><div class="casAuthors">Esbenshade, T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.; Brioni, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1166-1181</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous labs. as it represents an attractive drug target for a no. of indications including cognition.  The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclin. and clin. advancement.  Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in cognitive processes.  The cognitive-enhancing effects of H3 antagonists across multiple cognitive domains in a wide no. of preclin. cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia.  However, although a no. of clin. studies examg. the efficacy of H3 receptor antagonists for a variety of cognitive disorders are currently underway, no clin. proof of concept for an H3 receptor antagonist has been reported to date.  The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of cognitive disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.  British Journal of Pharmacol. (2008) 154, 1166-1181; doi:10.1038/bjp.2008.147; published online 12 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2N2Dg3cdZfrVg90H21EOLACvtfcHk0ljX5Yy3SxCEQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D&md5=05bcda7b1140e9d16b4ca4072902d925</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.147%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBitner%26aufirst%3DR.%2BS.%26aulast%3DStrakhova%26aufirst%3DM.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520H3%2520receptor%253A%2520An%2520attractive%2520target%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1166%26epage%3D1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Passani, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crochet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blandina, P.</span><span> </span><span class="NLM_article-title">The histamine H<sub>3</sub> receptor as a novel therapeutic target for cognitive and sleep disorders</span> <span class="citation_source-journal">Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1016%2Fj.tips.2004.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=618-625&author=M.+B.+Passaniauthor=J.+S.+Linauthor=A.+Hancockauthor=S.+Crochetauthor=P.+Blandina&title=The+histamine+H3+receptor+as+a+novel+therapeutic+target+for+cognitive+and+sleep+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders</span></div><div class="casAuthors">Passani, Maria Beatrice; Lin, Jian-Sheng; Hancock, Arthur; Crochet, Sylvain; Blandina, Patrizio</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">618-625</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Histamine H3 receptor pharmacol., functions and biochem. are far from being fully understood; however, progress is being made.  Activation of this Gi/Go-protein-coupled receptor affects cognition, the sleep-wake cycle, obesity and epilepsy, which are physiol. and pathol. conditions that are the main focus of research into the therapeutic potential of selective H3 receptor ligands.  This heterogeneity of targets can be reconciled partially by the fact that the histamine system constitutes one of the most important brain-activating systems and that H3 receptors regulate the activity of histamine and other neurotransmitter systems.  Furthermore, the H3 receptor shows functional constitutive activity, polymorphisms in humans and rodents with a differential distribution of splice variants in the CNS, and potential coupling to different intracellular signal transduction mechanisms.  In light of the genetic, pharmacol. and functional complexity of the H3 receptor, the importance of the histamine system as a therapeutic target to control the sleep-wake cycle and cognitive disorders will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsyz3ZrhlUXrVg90H21EOLACvtfcHk0ljX5Yy3SxCEQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVSjtro%253D&md5=1e5d66f01417b2d8018d8416d5a832db</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2004.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2004.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DPassani%26aufirst%3DM.%2BB.%26aulast%3DLin%26aufirst%3DJ.%2BS.%26aulast%3DHancock%26aufirst%3DA.%26aulast%3DCrochet%26aufirst%3DS.%26aulast%3DBlandina%26aufirst%3DP.%26atitle%3DThe%2520histamine%2520H3%2520receptor%2520as%2520a%2520novel%2520therapeutic%2520target%2520for%2520cognitive%2520and%2520sleep%2520disorders%26jtitle%3DPharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D618%26epage%3D625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Pharmacological properties of ABT-239 [4-(2{2-[(2R)-2-methylpyrrolidinyl]ethyl}benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H<sub>3</sub> receptor antagonist with drug-like properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1124%2Fjpet.104.078303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=15608078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=165-175&author=T.+A.+Esbenshadeauthor=G.+B.+Foxauthor=K.+M.+Kruegerauthor=T.+R.+Millerauthor=C.+H.+Kangauthor=L.+I.+Dennyauthor=D.+G.+Witteauthor=B.+B.+Yaoauthor=L.+Panauthor=J.+Wetterauthor=K.+Marshauthor=Y.+Bennaniauthor=M.+D.+Cowartauthor=J.+P.+Sullivanauthor=A.+A.+Hancock&title=Pharmacological+properties+of+ABT-239+%5B4-%282%7B2-%5B%282R%29-2-methylpyrrolidinyl%5Dethyl%7Dbenzofuran-5-yl%29benzonitrile%5D%3A+I.+Potent+and+selective+histamine+H3+receptor+antagonist+with+drug-like+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties</span></div><div class="casAuthors">Esbenshade, Timothy A.; Fox, Gerard B.; Krueger, Kathleen M.; Miller, Thomas R.; Kang, Chae Hee; Denny, Lynne I.; Witte, David G.; Yao, Betty B.; Pan, Liping; Wetter, Jill; Marsh, Kennan; Bennani, Youssef L.; Cowart, Marlon D.; Sullivan, James P.; Hancock, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-175</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Histamine H3 receptor antagonists are being developed to treat a variety of neurol. and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release.  Here, we present the in vitro pharmacol. and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H3 receptor antagonists.  ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pKi values of 9.4 and 8.9, resp., and is over 1000-fold selective vs. human H1, H2, and H4 histamine receptors.  ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pKb = 7.9 and 7.6, resp.), guanosine 5'-O-(3-[35S]thio) triphosphate ([35S]GTPγS) binding (pKb = 9.0 and 8.3, resp.), and calcium mobilization (human pKb = 7.9).  ABT-239 also competitively reversed histamine-mediated inhibition of [3H]histamine release from rat brain cortical synaptosomes (pKb = 7.7) and agonist-induced inhibition of contractile responses in elec. field stimulated guinea pig ileal segments (pA2 = 8.7).  Addnl., ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPγS binding at both rat and human H3 receptors with resp. pEC50 values of 8.9 and 8.2.  ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%.  Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowcC95NH2bcLVg90H21EOLACvtfcHk0ljX5Yy3SxCEQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsL0%253D&md5=33248c15c96745da445a14853461c019</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078303%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DDenny%26aufirst%3DL.%2BI.%26aulast%3DWitte%26aufirst%3DD.%2BG.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DBennani%26aufirst%3DY.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520properties%2520of%2520ABT-239%2520%255B4-%25282%257B2-%255B%25282R%2529-2-methylpyrrolidinyl%255Dethyl%257Dbenzofuran-5-yl%2529benzonitrile%255D%253A%2520I.%2520Potent%2520and%2520selective%2520histamine%2520H3%2520receptor%2520antagonist%2520with%2520drug-like%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D165%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Fox, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radek, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komater, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faghih, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benneni, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">Pharmacological properties of ABT-239 [4-(2{2-[(2R)-2-methylpyrrolidinyl]ethyl}benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective H<sub>3</sub> receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1124%2Fjpet.104.078402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=15608077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2005&pages=176-190&author=G.+B.+Foxauthor=T.+A.+Esbenshadeauthor=J.+B.+Panauthor=R.+J.+Radekauthor=K.+M.+Kruegerauthor=B.+B.+Yaoauthor=K.+E.+Browmanauthor=M.+J.+Buckleyauthor=M.+E.+Ballardauthor=V.+A.+Komaterauthor=H.+Minerauthor=M.+Zhangauthor=R.+Faghihauthor=L.+E.+Rueterauthor=R.+Bitnerauthor=K.+U.+Drescherauthor=J.+Wetterauthor=K.+Marshauthor=M.+Lemaireauthor=R.+D.+Porsoltauthor=Y.+L.+Benneniauthor=J.+P.+Sullivanauthor=M.+D.+Cowartauthor=M.+W.+Deckerauthor=A.+A.+Hancock&title=Pharmacological+properties+of+ABT-239+%5B4-%282%7B2-%5B%282R%29-2-methylpyrrolidinyl%5Dethyl%7Dbenzofuran-5-yl%29benzonitrile%5D%3A+II.+Neurophysiological+characterization+and+broad+preclinical+efficacy+in+cognition+and+schizophrenia+of+a+potent+and+selective+H3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist</span></div><div class="casAuthors">Fox, Gerard B.; Esbenshade, Timothy A.; Pan, Jia Bao; Radek, Richard J.; Krueger, Kathleen M.; Yao, Betty B.; Browman, Kaitlin E.; Buckley, Michael J.; Ballard, Michael E.; Komater, Victoria A.; Miner, Holly; Zhang, Min; Faghih, Ramin; Rueter, Lynne E.; Bitner, R. Scott; Drescher, Karla U.; Wetter, Jill; Marsh, Kennan; Lemaire, Martine; Porsolt, Roger D.; Bennani, Youssef L.; Sullivan, James P.; Cowart, Marlon D.; Decker, Michael W.; Hancock, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-190</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acute pharmacol. blockade of central histamine H3 receptors (H3Rs) enhances arousal/attention in rodents.  However, there is little information available for other behavioral domains or for repeated administration using selective compds.  ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] exemplifies such a selective, nonimidazole H3R antagonist with high affinity for rat (pKi = 8.9) and human (pKi = 9.5) H3Rs.  Acute functional blockade of central H3Rs was demonstrated by blocking the dipsogenia response to the selective H3R agonist (R)-α-methylhistamine in mice.  In cognition studies, acquisition of a five-trial, inhibitory avoidance test in rat pups was improved with ABT-239 (0.1-1.0 mg/kg), a 10- to 150-fold gain in potency, with similar efficacy, over previous antagonists such as thioperamide, ciproxifan, A-304121 [(4-(3-(4-((2R)-2-aminopropanoyl)-1-piperazinyl)propoxy)phenyl)(cyclopropyl) methanone], A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide], and A-349821 [(4'-(3-((R,R)2,5-dimethyl-pyrrolidin-1-yl)-propoxy)-biphenyl-4-yl)- morpholin-4-yl-methanone].  Efficacy in this model was maintained for 3 to 6 h and following repeated dosing with ABT-239.  Social memory was also improved in adult (0.01-0.3 mg/kg) and aged (0.3-1.0 mg/kg) rats.  In schizophrenia models, ABT-239 improved gating deficits in DBA/2 mice using prepulse inhibition of startle (1.0-3.0 mg/kg) and N40 (1.0-10.0 mg/kg).  Furthermore, ABT-239 (1.0 mg/kg) attenuated methamphetamine-induced hyperactivity in mice.  In freely moving rat microdialysis studies, ABT-239 enhanced acetylcholine release (0.1-3.0 mg/kg) in adult rat frontal cortex and hippocampus and enhanced dopamine release in frontal cortex (3.0 mg/kg), but not striatum.  In summary, broad efficacy was obsd. with ABT-239 across animal models such that potential clin. efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5hD1Q0ydnubVg90H21EOLACvtfcHk0lhiINPRQgujtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlSnsLo%253D&md5=437e154a172071e4c5d31e44134ab1b5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078402%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BB.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DPan%26aufirst%3DJ.%2BB.%26aulast%3DRadek%26aufirst%3DR.%2BJ.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBuckley%26aufirst%3DM.%2BJ.%26aulast%3DBallard%26aufirst%3DM.%2BE.%26aulast%3DKomater%26aufirst%3DV.%2BA.%26aulast%3DMiner%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DFaghih%26aufirst%3DR.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26aulast%3DBitner%26aufirst%3DR.%26aulast%3DDrescher%26aufirst%3DK.%2BU.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DLemaire%26aufirst%3DM.%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBenneni%26aufirst%3DY.%2BL.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DPharmacological%2520properties%2520of%2520ABT-239%2520%255B4-%25282%257B2-%255B%25282R%2529-2-methylpyrrolidinyl%255Dethyl%257Dbenzofuran-5-yl%2529benzonitrile%255D%253A%2520II.%2520Neurophysiological%2520characterization%2520and%2520broad%2520preclinical%2520efficacy%2520in%2520cognition%2520and%2520schizophrenia%2520of%2520a%2520potent%2520and%2520selective%2520H3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D313%26spage%3D176%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Plancher, J.-M.</span><span> </span><span class="NLM_article-title">The histamine H<sub>3</sub> receptor as a therapeutic drug target for metabolic disorders: Status, challenges, and opportunities</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1430</span><span class="NLM_x">–</span> <span class="NLM_lpage">1446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.2174%2F156802611795860906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=21510840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1430-1446&author=J.-M.+Plancher&title=The+histamine+H3+receptor+as+a+therapeutic+drug+target+for+metabolic+disorders%3A+Status%2C+challenges%2C+and+opportunities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor as a therapeutic drug target for metabolic disorders: status, challenges and opportunities</span></div><div class="casAuthors">Plancher, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1430-1446</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the histamine-3 receptor (H3R) was cloned in 1999, huge efforts were made by most of the key players in the pharmaceutical industry as well as in smaller biotech companies to increase the knowledge on this peculiar receptor, with the ultimate goal of bringing new drugs to the market.  This review gives a survey on the most valuable chem. tools discovered so far and the significant pharmacol. expts. on metabolic disease models published to date.  Pharmacol. of H3R antagonists turns out to be very complex due to various functional activities, species selectivity, presence of H3R isoforms and the poorly understood dichotomy in efficacy between CNS and metabolic disease models.  Adding an extra layer of complexity, researchers have to cope with some recurrent safety concerns, some of them being tightly linked to the nature of the H3R pharmacophore.  Therefore this review also strives to summarize the major hurdles and some of the contradictions seen in the H3R field, together with a brief overview of the clin. trials currently running.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIR4QjoNcDD7Vg90H21EOLACvtfcHk0lhiINPRQgujtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOrtbo%253D&md5=b1a1a3f40d15cb4b715590ded43d469c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F156802611795860906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795860906%26sid%3Dliteratum%253Aachs%26aulast%3DPlancher%26aufirst%3DJ.-M.%26atitle%3DThe%2520histamine%2520H3%2520receptor%2520as%2520a%2520therapeutic%2520drug%2520target%2520for%2520metabolic%2520disorders%253A%2520Status%252C%2520challenges%252C%2520and%2520opportunities%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1430%26epage%3D1446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Celanire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijtmans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talaga, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J. P.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptors reach out for the clinic</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1627</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1613-1627&author=S.+Celanireauthor=M.+Wijtmansauthor=P.+Talagaauthor=R.+Leursauthor=I.+J.+P.+de+Esch&title=Histamine+H3+receptors+reach+out+for+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCelanire%26aufirst%3DS.%26aulast%3DWijtmans%26aufirst%3DM.%26aulast%3DTalaga%26aufirst%3DP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26atitle%3DHistamine%2520H3%2520receptors%2520reach%2520out%2520for%2520the%2520clinic%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1613%26epage%3D1627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="note"><p class="first last">For a review, see</p></div><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddatz, R.</span><span> </span><span class="NLM_article-title">Recent advances in drug discovery of histamine H<sub>3</sub> antagonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=49-62&author=R.+L.+Hudkinsauthor=R.+Raddatz&title=Recent+advances+in+drug+discovery+of+histamine+H3+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DRaddatz%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520in%2520drug%2520discovery%2520of%2520histamine%2520H3%2520antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D49%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For a recent example, see</p></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adedoyin, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aschmies, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowlby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platt, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comery, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, A. J.</span><span> </span><span class="NLM_article-title">2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2<i>H</i>)-one derivatives as potent and selective histamine-3 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2452</span><span class="NLM_x">–</span> <span class="NLM_lpage">2468</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300011d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2452-2468&author=D.+Zhouauthor=J.+L.+Grossauthor=A.+B.+Adedoyinauthor=S.+B.+Aschmiesauthor=J.+Brennanauthor=M.+Bowlbyauthor=L.+Diauthor=K.+Kubekauthor=B.+J.+Plattauthor=Z.+Wangauthor=G.+Zhangauthor=N.+Brandonauthor=T.+A.+Comeryauthor=A.+J.+Robichaud&title=2-%28Pyrrolidin-1-yl%29ethyl-3%2C4-dihydroisoquinolin-1%282H%29-one+derivatives+as+potent+and+selective+histamine-3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm300011d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300011d%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DGross%26aufirst%3DJ.%2BL.%26aulast%3DAdedoyin%26aufirst%3DA.%2BB.%26aulast%3DAschmies%26aufirst%3DS.%2BB.%26aulast%3DBrennan%26aufirst%3DJ.%26aulast%3DBowlby%26aufirst%3DM.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKubek%26aufirst%3DK.%26aulast%3DPlatt%26aufirst%3DB.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBrandon%26aufirst%3DN.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3D2-%2528Pyrrolidin-1-yl%2529ethyl-3%252C4-dihydroisoquinolin-1%25282H%2529-one%2520derivatives%2520as%2520potent%2520and%2520selective%2520histamine-3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2452%26epage%3D2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiasen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddatz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span> </span><span class="NLM_article-title">Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H<sub>3</sub> receptor antagonists with potent cognition enhancing activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201295j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=414-423&author=M.+Taoauthor=L.+D.+Aimoneauthor=Z.+Huangauthor=J.+Mathiasenauthor=R.+Raddatzauthor=J.+Lyonsauthor=R.+L.+Hudkins&title=Optimization+of+5-pyridazin-3-one+phenoxypropylamines+as+potent%2C+selective+histamine+H3+receptor+antagonists+with+potent+cognition+enhancing+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm201295j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201295j%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DM.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMathiasen%26aufirst%3DJ.%26aulast%3DRaddatz%26aufirst%3DR.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26atitle%3DOptimization%2520of%25205-pyridazin-3-one%2520phenoxypropylamines%2520as%2520potent%252C%2520selective%2520histamine%2520H3%2520receptor%2520antagonists%2520with%2520potent%2520cognition%2520enhancing%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D414%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><div class="note"><p class="first last">For a recent review, see:</p></div><span class="NLM_contrib-group">Singh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadhav, H. R.</span><span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> receptor function and ligands: Recent developments</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=47-57&author=M.+Singhauthor=H.+R.+Jadhav&title=Histamine+H3+receptor+function+and+ligands%3A+Recent+developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DJadhav%26aufirst%3DH.%2BR.%26atitle%3DHistamine%2520H3%2520receptor%2520function%2520and%2520ligands%253A%2520Recent%2520developments%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D47%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Kuhne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijtmans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J. P.</span><span> </span><span class="NLM_article-title">Several down, a few to go: Histamine H<sub>3</sub> receptor ligands making the final push towards the market</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1629</span><span class="NLM_x">–</span> <span class="NLM_lpage">1648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1629-1648&author=S.+Kuhneauthor=M.+Wijtmansauthor=H.+D.+Limauthor=R.+Leursauthor=I.+J.+P.+de+Esch&title=Several+down%2C+a+few+to+go%3A+Histamine+H3+receptor+ligands+making+the+final+push+towards+the+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKuhne%26aufirst%3DS.%26aulast%3DWijtmans%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26atitle%3DSeveral%2520down%252C%2520a%2520few%2520to%2520go%253A%2520Histamine%2520H3%2520receptor%2520ligands%2520making%2520the%2520final%2520push%2520towards%2520the%2520market%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D1629%26epage%3D1648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Allison, B. D.; Carruthers, N. I.; Grice, C. A.; Letavic, M. A.</span><span> </span><span class="NLM_article-title">Cyclopropyl amines as modulators of the histamine H<sub>3</sub> receptor</span>. U.S. Patent Appl. 2007/0066821 A1, March 22,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=B.+D.+Allison&author=N.+I.+Carruthers&author=C.+A.+Grice&author=M.+A.+Letavic&title=Cyclopropyl+amines+as+modulators+of+the+histamine+H3+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllison%26aufirst%3DB.%2BD.%26atitle%3DCyclopropyl%2520amines%2520as%2520modulators%2520of%2520the%2520histamine%2520H3%2520receptor%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hancock, A. A.</span><span> </span><span class="NLM_article-title">The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H<sub>3</sub> antagonists/inverse agonists</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=1103&author=A.+A.+Hancock&title=The+challenge+of+drug+discovery+of+a+GPCR+target%3A+Analysis+of+preclinical+pharmacology+of+histamine+H3+antagonists%2Finverse+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DA.%2BA.%26atitle%3DThe%2520challenge%2520of%2520drug%2520discovery%2520of%2520a%2520GPCR%2520target%253A%2520Analysis%2520of%2520preclinical%2520pharmacology%2520of%2520histamine%2520H3%2520antagonists%252Finverse%2520agonists%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2006%26volume%3D71%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, S. J. F.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+MacDonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+Are+too+many+aromatic+rings+a+liability+in+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacDonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520Are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><div class="note"><p class="first last">hERG pharmacophore:</p></div><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K<sup>+</sup> channel blockers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3844</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+Insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0liys8Rmj_M89A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520Insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Swanson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span> </span><span class="NLM_article-title">Apylsamine-1 and related analogs as histamine H<sub>3</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">897</span><span class="NLM_x">–</span> <span class="NLM_lpage">900</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=897-900&author=D.+M.+Swansonauthor=S.+J.+Wilsonauthor=J.+D.+Boggsauthor=W.+Xiaoauthor=R.+Apodacaauthor=A.+J.+Barbierauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthers&title=Apylsamine-1+and+related+analogs+as+histamine+H3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%2BD.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26atitle%3DApylsamine-1%2520and%2520related%2520analogs%2520as%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D897%26epage%3D900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Santora, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covel, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofilena, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibarra, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulley, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinhouse, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grottick, A. J.</span><span> </span><span class="NLM_article-title">A new family of H<sub>3</sub> receptor antagonists based on the natural product conessine</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1490</span><span class="NLM_x">–</span> <span class="NLM_lpage">1494</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1490-1494&author=V.+J.+Santoraauthor=J.+A.+Covelauthor=R.+Hayashiauthor=B.+J.+Hofilenaauthor=J.+B.+Ibarraauthor=M.+D.+Pulleyauthor=M.+I.+Weinhouseauthor=D.+Senguptaauthor=J.+J.+Duffieldauthor=G.+Sempleauthor=R.+R.+Webbauthor=C.+Sageauthor=A.+Renauthor=G.+Pereiraauthor=J.+Knudsenauthor=J.+E.+Edwardsauthor=M.+Suarezauthor=J.+Frazerauthor=W.+Thomsenauthor=E.+Hauserauthor=K.+Whelanauthor=A.+J.+Grottick&title=A+new+family+of+H3+receptor+antagonists+based+on+the+natural+product+conessine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantora%26aufirst%3DV.%2BJ.%26aulast%3DCovel%26aufirst%3DJ.%2BA.%26aulast%3DHayashi%26aufirst%3DR.%26aulast%3DHofilena%26aufirst%3DB.%2BJ.%26aulast%3DIbarra%26aufirst%3DJ.%2BB.%26aulast%3DPulley%26aufirst%3DM.%2BD.%26aulast%3DWeinhouse%26aufirst%3DM.%2BI.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DDuffield%26aufirst%3DJ.%2BJ.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DWebb%26aufirst%3DR.%2BR.%26aulast%3DSage%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DG.%26aulast%3DKnudsen%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DJ.%2BE.%26aulast%3DSuarez%26aufirst%3DM.%26aulast%3DFrazer%26aufirst%3DJ.%26aulast%3DThomsen%26aufirst%3DW.%26aulast%3DHauser%26aufirst%3DE.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26atitle%3DA%2520new%2520family%2520of%2520H3%2520receptor%2520antagonists%2520based%2520on%2520the%2520natural%2520product%2520conessine%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1490%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennani, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalakrishnan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiffault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span> </span><span class="NLM_article-title">The alkaloid conessine and analogues as potent histamine H<sub>3</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5423</span><span class="NLM_x">–</span> <span class="NLM_lpage">5430</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8003625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5423-5430&author=C.+Zhaoauthor=M.+Sunauthor=Y.+L.+Bennaniauthor=S.+M.+Gopalakrishnanauthor=D.+G.+Witteauthor=T.+R.+Millerauthor=K.+M.+Kruegerauthor=K.+E.+Browmanauthor=C.+Thiffaultauthor=J.+Wetterauthor=K.+C.+Marshauthor=A.+A.+Hancockauthor=T.+A.+Esbenshadeauthor=M.+D.+Cowart&title=The+alkaloid+conessine+and+analogues+as+potent+histamine+H3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fjm8003625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8003625%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DGopalakrishnan%26aufirst%3DS.%2BM.%26aulast%3DWitte%26aufirst%3DD.%2BG.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DKrueger%26aufirst%3DK.%2BM.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DThiffault%26aufirst%3DC.%26aulast%3DWetter%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26atitle%3DThe%2520alkaloid%2520conessine%2520and%2520analogues%2520as%2520potent%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5423%26epage%3D5430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lannang, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangmouo, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krohn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhary, M. I.</span><span> </span><span class="NLM_article-title">Conessin isolated from <i>Holarrhena floribunda</i></span> <span class="citation_source-journal">Acta Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">E63</span><span class="NLM_x">, </span> <span class="NLM_fpage">o3980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=E63&publication_year=2007&pages=o3980&author=A.+M.+Lannangauthor=S.+Anjumauthor=J.+G.+Tangmouoauthor=K.+Krohnauthor=M.+I.+Choudhary&title=Conessin+isolated+from+Holarrhena+floribunda"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLannang%26aufirst%3DA.%2BM.%26aulast%3DAnjum%26aufirst%3DS.%26aulast%3DTangmouo%26aufirst%3DJ.%2BG.%26aulast%3DKrohn%26aufirst%3DK.%26aulast%3DChoudhary%26aufirst%3DM.%2BI.%26atitle%3DConessin%2520isolated%2520from%2520Holarrhena%2520floribunda%26jtitle%3DActa%2520Crystallogr.%26date%3D2007%26volume%3DE63%26spage%3Do3980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berridge, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laposky, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alusio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pudiak, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langlois, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span> </span><span class="NLM_article-title">Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H<sub>3</sub> antagonist</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">661</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2Fsj.bjp.0705964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm4014828&amp;key=15466448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2004&pages=649-661&author=A.+J.+Barbierauthor=C.+Berridgeauthor=A.+D.+Laposkyauthor=S.+J.+Wilsonauthor=J.+Boggsauthor=B.+Alusioauthor=C.+Mazurauthor=C.+M.+Pudiakauthor=X.+Langloisauthor=W.+Xiaoauthor=R.+Apodacaauthor=N.+I.+Carruthersauthor=T.+W.+Lovenberg&title=Acute+wake-promoting+actions+of+JNJ-5207852%2C+a+novel%2C+diamine-based+H3+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist</span></div><div class="casAuthors">Barbier, A. J.; Berridge, C.; Dugovic, C.; Laposky, A. D.; Wilson, S. J.; Boggs, J.; Aluisio, L.; Lord, B.; Mazur, C.; Pudiak, C. M.; Langlois, X.; Xiao, W.; Apodaca, R.; Carruthers, N. I.; Lovenberg, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">649-661</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperidine (JNJ-5207852) is a novel, nonimidazole histamine H3 receptor antagonist, with high affinity at the rat (pKi = 8.9) and human (pKi = 9.24) H3 receptor.  JNJ-5207852 is selective for the H3 receptor, with negligible binding to other receptors, transporters and ion channels at 1 μM.  JNJ-5207852 readily penetrates the brain tissue after s.c. administration, as detd. by ex vivo autoradiog. (ED50 of 0.13 mg kg-1 in mice).  In vitro autoradiog. with 3H-JNJ-5207852 in mouse brain slices shows a binding pattern identical to that of 3H-R-α-methylhistamine, with high specific binding in the cortex, striatum and hypothalamus.  No specific binding of 3H-JNJ-5207852 was obsd. in brains of H3 receptor knockout mice.  In mice and rats, JNJ-5207852 (1-10 mg kg-1 s.c.) increases time spent awake and decreases REM sleep and slow-wave sleep, but fails to have an effect on wakefulness or sleep in H3 receptor knockout mice.  No rebound hypersomnolence, as measured by slow-wave delta power, is obsd.  The wake-promoting effects of this H3 receptor antagonist are not assocd. with hypermotility.  A 4-wk daily treatment of mice with JNJ-5207852 (10 mg kg-1 i.p.) did not lead to a change in body wt., possibly due to the compd. being a neutral antagonist at the H3 receptor.  JNJ-5207852 is extensively absorbed after oral administration and reaches high brain levels.  The data indicate that JNJ-5207852 is a novel, potent and selective H3 antagonist with good in vitro and in vivo efficacy, and confirm the wake-promoting effects of H3 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm3xmKb95PeLVg90H21EOLACvtfcHk0ligjpvOkTKcnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitLzL&md5=bd8e27617d39c45cf3cea7d2aadad8a0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705964%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DBerridge%26aufirst%3DC.%26aulast%3DLaposky%26aufirst%3DA.%2BD.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DAlusio%26aufirst%3DB.%26aulast%3DMazur%26aufirst%3DC.%26aulast%3DPudiak%26aufirst%3DC.%2BM.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DAcute%2520wake-promoting%2520actions%2520of%2520JNJ-5207852%252C%2520a%2520novel%252C%2520diamine-based%2520H3%2520antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D143%26spage%3D649%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Dvorak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berridge, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span> </span><span class="NLM_article-title">4-Phenoxypiperidines: Potent, conformationally restricted, non-imidazole histamine H<sub>3</sub> antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2229</span><span class="NLM_x">–</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049212n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2229-2238&author=C.+A.+Dvorakauthor=R.+Apodacaauthor=A.+J.+Barbierauthor=C.+W.+Berridgeauthor=S.+J.+Wilsonauthor=J.+D.+Boggsauthor=W.+Xiaoauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthers&title=4-Phenoxypiperidines%3A+Potent%2C+conformationally+restricted%2C+non-imidazole+histamine+H3+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm049212n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049212n%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DBerridge%26aufirst%3DC.%2BW.%26aulast%3DWilson%26aufirst%3DS.%2BJ.%26aulast%3DBoggs%26aufirst%3DJ.%2BD.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26atitle%3D4-Phenoxypiperidines%253A%2520Potent%252C%2520conformationally%2520restricted%252C%2520non-imidazole%2520histamine%2520H3%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2229%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Malmlof, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaragoza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golozoubova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Refsgaard, H. H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulff, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westerink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimvall, K.</span><span> </span><span class="NLM_article-title">Influence of a selective histamine receptor antagonist on hypothalamic neural activity, food intake, and body weight</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1038%2Fsj.ijo.0803036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Smt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2005&pages=1402-1412&author=K.+Malmlofauthor=F.+Zaragozaauthor=V.+Golozoubovaauthor=H.+H.+F.+Refsgaardauthor=T.+Cremersauthor=K.+Raunauthor=B.+S.+Wulffauthor=P.+B.+Johansenauthor=B.+Westerinkauthor=K.+Rimvall&title=Influence+of+a+selective+histamine+receptor+antagonist+on+hypothalamic+neural+activity%2C+food+intake%2C+and+body+weight"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight</span></div><div class="casAuthors">Malmlof, K.; Zaragoza, F.; Golozoubova, V.; Refsgaard, H. H. F.; Cremers, T.; Raun, K.; Wulff, B. S.; Johansen, P. B.; Westerink, B.; Rimvall, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1402-1412</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: This study was conducted to elucidate whether antagonistic targeting of the histamine H3 receptor increases hypothalamic histamine levels, in parallel with decreases in food intake and body wt.  Methods: The competitive antagonist potency of a recently synthesized histamine H3 receptor antagonist, NNC 38-1049, was studied in intact HEK293 cells expressing human or rat histamine H3 receptor, in which NNC 38-1049 was allowed to antagonize the effect of the H3 receptor agonist R-α-methylhistamine on isoprenaline-induced accumulation of cAMP.  The affinity of NNC 38-1049 for a no. of variants of the histamine receptor was also detd.  Following single dosing of normal rats with NNC 38-1049, hypothalamic histamine levels were assessed by means of microdialysis.  Plasma and brain levels of NNC 38-1049 and acute effects on food intake and energy expenditure were followed after oral doses of 3-60 mg/kg.  Potential side effects were examd. with rat models of behavior satiety sequence (BSS), pica behavior and conditioned taste aversion (CTA).  Intakes of food and water together with body wt. were recorded for 15 days during daily dosing of dietary obese rats.  Results: NNC 38-1049 was found to be a highly specific and competitive antagonist towards both human and rat histamine H3 receptors, and measurable amts. of NNC 38-1049 were found in the plasma of rats following single oral doses of 3-60 mg/kg and in the brain after 15-60 mg/kg.  Following single i.p. injections of NNC 38-1049 (20 mg/kg), significant increases in extracellular histamine concns. were obsd.  The same dose did not change BSS or pica behavior acutely, nor did it induce CTA following repeated administration for 7 days.  Redns. in food intake were seen very soon after administration, and occurred in a dose-dependent fashion.  Energy expenditure was unchanged, but the RQ (RQ) tended to decrease at higher doses, indicating an increase in lipid oxidn.  Twice daily administration of 20 mg/kg of NNC 38-1049 in old and dietary obese rats resulted in sustained redn. of food intake throughout a 2-wk study, and was assocd. with a highly significant (P<0.01) decrease in body wt. compared with controls (-18.4±3.4 vs +0.4±2.7 g).  The same dose of NNC 38-1049 produced an acute decrease of water intake, but 24 h intakes were not significantly changed.  Conclusions: The results of this study strongly support the idea that an increase in the hypothalamic concn. of histamine produces a specific redn. of food intake and that this effect can be translated into a decrease in body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3CGytxXPxo7Vg90H21EOLACvtfcHk0ligjpvOkTKcnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Smt7nE&md5=1d5ff13f52385ef3744d1f651bc239b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijo.0803036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijo.0803036%26sid%3Dliteratum%253Aachs%26aulast%3DMalmlof%26aufirst%3DK.%26aulast%3DZaragoza%26aufirst%3DF.%26aulast%3DGolozoubova%26aufirst%3DV.%26aulast%3DRefsgaard%26aufirst%3DH.%2BH.%2BF.%26aulast%3DCremers%26aufirst%3DT.%26aulast%3DRaun%26aufirst%3DK.%26aulast%3DWulff%26aufirst%3DB.%2BS.%26aulast%3DJohansen%26aufirst%3DP.%2BB.%26aulast%3DWesterink%26aufirst%3DB.%26aulast%3DRimvall%26aufirst%3DK.%26atitle%3DInfluence%2520of%2520a%2520selective%2520histamine%2520receptor%2520antagonist%2520on%2520hypothalamic%2520neural%2520activity%252C%2520food%2520intake%252C%2520and%2520body%2520weight%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2005%26volume%3D29%26spage%3D1402%26epage%3D1412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calver, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessell, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crook, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heslop, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ociepka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schogger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">Structurally novel histamine H<sub>3</sub> receptor antagonists GSK207040 and GSK 334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1182</span><span class="NLM_x">–</span> <span class="NLM_lpage">1194</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2007&pages=1182-1194&author=A.+D.+Medhurstauthor=M.+A.+Briggsauthor=G.+Brutonauthor=A.+R.+Calverauthor=I.+Chessellauthor=B.+Crookauthor=J.+B.+Davisauthor=R.+P.+Davisauthor=A.+G.+Foleyauthor=T.+Heslopauthor=W.+D.+Hirstauthor=S.+J.+Medhurstauthor=S.+Ociepkaauthor=A.+Rayauthor=C.+M.+Reganauthor=B.+Sargentauthor=J.+Schoggerauthor=T.+O.+Steanauthor=B.+K.+Trailauthor=N.+Uptonauthor=T.+Whiteauthor=B.+Orlekauthor=D.+M.+Wilson&title=Structurally+novel+histamine+H3+receptor+antagonists+GSK207040+and+GSK+334429+improve+scopolamine-induced+memory+impairment+and+capsaicin-induced+secondary+allodynia+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DBriggs%26aufirst%3DM.%2BA.%26aulast%3DBruton%26aufirst%3DG.%26aulast%3DCalver%26aufirst%3DA.%2BR.%26aulast%3DChessell%26aufirst%3DI.%26aulast%3DCrook%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DDavis%26aufirst%3DR.%2BP.%26aulast%3DFoley%26aufirst%3DA.%2BG.%26aulast%3DHeslop%26aufirst%3DT.%26aulast%3DHirst%26aufirst%3DW.%2BD.%26aulast%3DMedhurst%26aufirst%3DS.%2BJ.%26aulast%3DOciepka%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DC.%2BM.%26aulast%3DSargent%26aufirst%3DB.%26aulast%3DSchogger%26aufirst%3DJ.%26aulast%3DStean%26aufirst%3DT.%2BO.%26aulast%3DTrail%26aufirst%3DB.%2BK.%26aulast%3DUpton%26aufirst%3DN.%26aulast%3DWhite%26aufirst%3DT.%26aulast%3DOrlek%26aufirst%3DB.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DStructurally%2520novel%2520histamine%2520H3%2520receptor%2520antagonists%2520GSK207040%2520and%2520GSK%2520334429%2520improve%2520scopolamine-induced%2520memory%2520impairment%2520and%2520capsaicin-induced%2520secondary%2520allodynia%2520in%2520rats%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2007%26volume%3D73%26spage%3D1182%26epage%3D1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atack, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstein, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzolio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rynberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepassi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J.</span><span> </span><span class="NLM_article-title">Pre-clinical characterization of aryloxypyridine amides as histamine H<sub>3</sub> receptor antagonists: Identification of candidates for clinical development</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4210</span><span class="NLM_x">–</span> <span class="NLM_lpage">4214</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4210-4214&author=M.+A.+Letavicauthor=L.+Aluisioauthor=J.+R.+Atackauthor=P.+Bonaventureauthor=N.+I.+Carruthersauthor=C.+Dugovicauthor=A.+Eversonauthor=M.+A.+Feinsteinauthor=I.+C.+Fraserauthor=K.+Hoeyauthor=X.+Jiangauthor=J.+M.+Keithauthor=T.+Koudriakovaauthor=P.+Leungauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=K.+S.+Lyauthor=K.+L.+Mortonauthor=S.+T.+Motleyauthor=D.+Nepomucenoauthor=M.+Rizzolioauthor=R.+Rynbergauthor=K.+Sepassiauthor=J.+Shelton&title=Pre-clinical+characterization+of+aryloxypyridine+amides+as+histamine+H3+receptor+antagonists%3A+Identification+of+candidates+for+clinical+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DAtack%26aufirst%3DJ.%2BR.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DA.%26aulast%3DFeinstein%26aufirst%3DM.%2BA.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DHoey%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DKeith%26aufirst%3DJ.%2BM.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLeung%26aufirst%3DP.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DLy%26aufirst%3DK.%2BS.%26aulast%3DMorton%26aufirst%3DK.%2BL.%26aulast%3DMotley%26aufirst%3DS.%2BT.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DRizzolio%26aufirst%3DM.%26aulast%3DRynberg%26aufirst%3DR.%26aulast%3DSepassi%26aufirst%3DK.%26aulast%3DShelton%26aufirst%3DJ.%26atitle%3DPre-clinical%2520characterization%2520of%2520aryloxypyridine%2520amides%2520as%2520histamine%2520H3%2520receptor%2520antagonists%253A%2520Identification%2520of%2520candidates%2520for%2520clinical%2520development%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4210%26epage%3D4214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Galici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezvani, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoblock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span> </span><span class="NLM_article-title">JNJ-39220675, a novel selective histamine H<sub>3</sub> receptor antagonist, reduces the abuse-related effects of alcohol in rats</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2011&pages=829-841&author=R.+Galiciauthor=A.+H.+Rezvaniauthor=L.+Aluisioauthor=B.+Lordauthor=E.+D.+Levinauthor=I.+Fraserauthor=J.+Boggsauthor=N.+Weltyauthor=J.+R.+Shoblockauthor=S.+T.+Motleyauthor=M.+A.+Letavicauthor=N.+I.+Carruthersauthor=C.+Dugovicauthor=T.+W.+Lovenbergauthor=P.+Bonaventure&title=JNJ-39220675%2C+a+novel+selective+histamine+H3+receptor+antagonist%2C+reduces+the+abuse-related+effects+of+alcohol+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalici%26aufirst%3DR.%26aulast%3DRezvani%26aufirst%3DA.%2BH.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLevin%26aufirst%3DE.%2BD.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DWelty%26aufirst%3DN.%26aulast%3DShoblock%26aufirst%3DJ.%2BR.%26aulast%3DMotley%26aufirst%3DS.%2BT.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26atitle%3DJNJ-39220675%252C%2520a%2520novel%2520selective%2520histamine%2520H3%2520receptor%2520antagonist%252C%2520reduces%2520the%2520abuse-related%2520effects%2520of%2520alcohol%2520in%2520rats%26jtitle%3DPsychopharmacology%26date%3D2011%26volume%3D214%26spage%3D829%26epage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="note"><p class="first last">1-Cyclopropylpiperazine:</p></div><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_contrib-group">Gillaspy, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefker, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hada, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoover, D. J.</span><span> </span><span class="NLM_article-title">A simple method for the formation of cyclopropylamines: The first synthesis of tricyclopropylamine</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">7399</span><span class="NLM_x">–</span> <span class="NLM_lpage">7402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1016%2F0040-4039%2895%2901560-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADyaK2MXoslOqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=7399-7402&author=M.+L.+Gillaspyauthor=B.+A.+Lefkerauthor=W.+A.+Hadaauthor=D.+J.+Hoover&title=A+simple+method+for+the+formation+of+cyclopropylamines%3A+The+first+synthesis+of+tricyclopropylamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A simple method for the formation of cyclopropylamines: the first synthesis of tricyclopropylamine.</span></div><div class="casAuthors">Gillaspy, Melissa; Lefker, Bruce A.; Hada, William A.; Hoover, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">7399-402</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Treatment of a variety of secondary and primary amines with [(1-ethoxycyclopropyl)oxy]trimethylsilane and NaBH3CN in MeOH gave mono- and dicyclopropylamines in 41-91% yield.  Sterically hindered di- and tricyclopropylamines, including tricyclopropylamine, were prepd.  The pKas of some mono-, di- and tricyclopropylamines were measured showing a redn. of ∼1-2 pKa unit per added cyclopropyl group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBHlBQO9wq2LVg90H21EOLACvtfcHk0lj1dacqyKVpGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslOqu70%253D&md5=03d4a4010d1b5b4a9bf075b24fdc3b1d</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2901560-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252901560-4%26sid%3Dliteratum%253Aachs%26aulast%3DGillaspy%26aufirst%3DM.%2BL.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DHada%26aufirst%3DW.%2BA.%26aulast%3DHoover%26aufirst%3DD.%2BJ.%26atitle%3DA%2520simple%2520method%2520for%2520the%2520formation%2520of%2520cyclopropylamines%253A%2520The%2520first%2520synthesis%2520of%2520tricyclopropylamine%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D7399%26epage%3D7402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Preparation of 1-cyclopentylpiperazine dihydrochloride (for experimental):</p></div><span class="NLM_contrib-group">Zaragoza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulff, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimvall, K.</span><span> </span><span class="NLM_article-title">1-Alkyl-a-acylpiperazines as a new class of imidazole-free H<sub>3</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2833</span><span class="NLM_x">–</span> <span class="NLM_lpage">2838</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm031028z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2833-2838&author=F.+Zaragozaauthor=H.+Stephensenauthor=S.+M.+Knudsenauthor=L.+Pridalauthor=B.+S.+Wulffauthor=K.+Rimvall&title=1-Alkyl-a-acylpiperazines+as+a+new+class+of+imidazole-free+H3+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1021%2Fjm031028z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031028z%26sid%3Dliteratum%253Aachs%26aulast%3DZaragoza%26aufirst%3DF.%26aulast%3DStephensen%26aufirst%3DH.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%26aulast%3DPridal%26aufirst%3DL.%26aulast%3DWulff%26aufirst%3DB.%2BS.%26aulast%3DRimvall%26aufirst%3DK.%26atitle%3D1-Alkyl-a-acylpiperazines%2520as%2520a%2520new%2520class%2520of%2520imidazole-free%2520H3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2833%26epage%3D2838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wolfe, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S.</span><span> </span><span class="NLM_article-title">Rational development of practical catalysts for aromatic carbon-nitrogen bond formation</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">818</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar9600650" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADyaK1cXms12itLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=805-818&author=J.+P.+Wolfeauthor=S.+Wagawauthor=J.-F.+Marcouxauthor=S.+Buchwald&title=Rational+development+of+practical+catalysts+for+aromatic+carbon-nitrogen+bond+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Development of Practical Catalysts for Aromatic Carbon-Nitrogen Bond Formation</span></div><div class="casAuthors">Wolfe, John P.; Wagaw, Seble; Marcoux, Jean-Francois; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">805-818</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 42 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5RUE_bzqLhLVg90H21EOLACvtfcHk0ljsO_m3ZFUWGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms12itLk%253D&md5=faf0cf60b08747e77d48b39ec905110d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Far9600650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far9600650%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DJ.%2BP.%26aulast%3DWagaw%26aufirst%3DS.%26aulast%3DMarcoux%26aufirst%3DJ.-F.%26aulast%3DBuchwald%26aufirst%3DS.%26atitle%3DRational%2520development%2520of%2520practical%2520catalysts%2520for%2520aromatic%2520carbon-nitrogen%2520bond%2520formation%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1998%26volume%3D31%26spage%3D805%26epage%3D818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nafie, L. A.; Dukor, R. K.</span> In  <span class="citation_source-book">Applications of Vibrational Optical Activity in the Pharmaceutical Industry</span>; <span class="NLM_contrib-group">Pivonka, D. E.; Chalmers, J. M.; Griffiths, P. R.</span>, Eds.; <span class="NLM_publisher-name">John Wiley and Sons</span>: <span class="NLM_publisher-loc">Chichester, West Sussex, England</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=129-154&author=L.+A.+Nafie&author=R.+K.+Dukorauthor=D.+E.+Pivonka&author=J.+M.+Chalmers&author=P.+R.+Griffiths&title=Applications+of+Vibrational+Optical+Activity+in+the+Pharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNafie%26aufirst%3DL.%2BA.%26btitle%3DApplications%2520of%2520Vibrational%2520Optical%2520Activity%2520in%2520the%2520Pharmaceutical%2520Industry%26aulast%3DPivonka%26aufirst%3DD.%2BE.%26pub%3DJohn%2520Wiley%2520and%2520Sons%26date%3D2007%26spage%3D129%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Crawford, T. D.</span><span> </span><span class="NLM_article-title">Ab initio calculation of molecular chirooptical properties</span> <span class="citation_source-journal">Theor. Chem. Acc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm4014828&amp;key=10.1007%2Fs00214-005-0001-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm4014828&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjt1yksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2006&pages=227-245&author=T.+D.+Crawford&title=Ab+initio+calculation+of+molecular+chirooptical+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Ab initio calculation of molecular chiroptical properties</span></div><div class="casAuthors">Crawford, T. Daniel.</div><div class="citationInfo"><span class="NLM_cas:title">Theoretical Chemistry Accounts</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">227-245</span>CODEN:
                <span class="NLM_cas:coden">TCACFW</span>;
        ISSN:<span class="NLM_cas:issn">1432-881X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  This review describes the 1st-principles calcn. of chiroptical properties such as optical rotation, electronic and vibrational CD, and Raman optical activity.  Recent years have witnessed a flurry of activity in this area, esp. in the advancement of d.-functional and coupled cluster methods, with 2 ultimate goals: the elucidation of the fundamental relation between chiroptical properties and detailed mol. structure, and the development of a suite of computational tools for the assignment of the abs. configurations of chiral mols.  The underlying theory and the basic principles of such calcns. are given for each property, and a no. of representative applications are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUJGsUmSAgY7Vg90H21EOLACvtfcHk0ljsO_m3ZFUWGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjt1yksbk%253D&md5=72b1f1eb5f53b57e64695dfa685fdad3</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1007%2Fs00214-005-0001-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00214-005-0001-4%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26atitle%3DAb%2520initio%2520calculation%2520of%2520molecular%2520chirooptical%2520properties%26jtitle%3DTheor.%2520Chem.%2520Acc.%26date%3D2006%26volume%3D115%26spage%3D227%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wesolowski, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivonka, D. E.</span><span> </span><span class="NLM_article-title">A rapid alternative to X-ray crystallography for chiral determination: Case studies of vibrational circular dichroism (VCD) to advance drug discovery projects</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4019</span><span class="NLM_x">–</span> <span class="NLM_lpage">4025</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4019-4025&author=S.+S.+Wesolowskiauthor=D.+E.+Pivonka&title=A+rapid+alternative+to+X-ray+crystallography+for+chiral+determination%3A+Case+studies+of+vibrational+circular+dichroism+%28VCD%29+to+advance+drug+discovery+projects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWesolowski%26aufirst%3DS.%2BS.%26aulast%3DPivonka%26aufirst%3DD.%2BE.%26atitle%3DA%2520rapid%2520alternative%2520to%2520X-ray%2520crystallography%2520for%2520chiral%2520determination%253A%2520Case%2520studies%2520of%2520vibrational%2520circular%2520dichroism%2520%2528VCD%2529%2520to%2520advance%2520drug%2520discovery%2520projects%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4019%26epage%3D4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Kaneko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokohama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkuro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span> </span><span class="NLM_article-title">Piperidine carboxylic acid derivatives of 10<i>H</i>-pyrazino[2,3-<i>b</i>][1,4]benzothiazine as orally-active adhesion molecule inhibitors</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=675-687&author=T.+Kanekoauthor=R.+S.+J.+Clarkauthor=N.+Ohiauthor=F.+Ozakiauthor=T.+Kawaharaauthor=A.+Kamadaauthor=K.+Okanoauthor=H.+Yokohamaauthor=M.+Ohkuroauthor=K.+Muramotoauthor=O.+Takenakaauthor=S.+Kobayashi&title=Piperidine+carboxylic+acid+derivatives+of+10H-pyrazino%5B2%2C3-b%5D%5B1%2C4%5Dbenzothiazine+as+orally-active+adhesion+molecule+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DClark%26aufirst%3DR.%2BS.%2BJ.%26aulast%3DOhi%26aufirst%3DN.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DKawahara%26aufirst%3DT.%26aulast%3DKamada%26aufirst%3DA.%26aulast%3DOkano%26aufirst%3DK.%26aulast%3DYokohama%26aufirst%3DH.%26aulast%3DOhkuro%26aufirst%3DM.%26aulast%3DMuramoto%26aufirst%3DK.%26aulast%3DTakenaka%26aufirst%3DO.%26aulast%3DKobayashi%26aufirst%3DS.%26atitle%3DPiperidine%2520carboxylic%2520acid%2520derivatives%2520of%252010H-pyrazino%255B2%252C3-b%255D%255B1%252C4%255Dbenzothiazine%2520as%2520orally-active%2520adhesion%2520molecule%2520inhibitors%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D675%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Wellendorph, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burstein, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span> </span><span class="NLM_article-title">Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H<sub>3</sub> receptor</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2002&pages=929-940&author=P.+Wellendorphauthor=M.+W.+Goodmanauthor=E.+S.+Bursteinauthor=N.+R.+Nashauthor=M.+R.+Brannauthor=D.+M.+Weiner&title=Molecular+cloning+and+pharmacology+of+functionally+distinct+isoforms+of+the+human+histamine+H3+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWellendorph%26aufirst%3DP.%26aulast%3DGoodman%26aufirst%3DM.%2BW.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26aulast%3DNash%26aufirst%3DN.%2BR.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26atitle%3DMolecular%2520cloning%2520and%2520pharmacology%2520of%2520functionally%2520distinct%2520isoforms%2520of%2520the%2520human%2520histamine%2520H3%2520receptor%26jtitle%3DNeuropharmacology%26date%3D2002%26volume%3D42%26spage%3D929%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolodin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inglese, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strulovici, B.</span><span> </span><span class="NLM_article-title">A fully automated [<sup>35</sup>S]GTPγS scintillation proximity assay for the high-throughput screening of Gi-linked G protein-coupled receptors</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=261-273&author=M.+Ferrerauthor=G.+Kolodinauthor=P.+Zuckauthor=R.+Peltierauthor=K.+Berryauthor=S.+Mandalaauthor=H.+Rosenauthor=H.+Otaauthor=S.+Ozakiauthor=J.+Ingleseauthor=B.+Strulovici&title=A+fully+automated+%5B35S%5DGTP%CE%B3S+scintillation+proximity+assay+for+the+high-throughput+screening+of+Gi-linked+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DKolodin%26aufirst%3DG.%26aulast%3DZuck%26aufirst%3DP.%26aulast%3DPeltier%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DK.%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DOta%26aufirst%3DH.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DStrulovici%26aufirst%3DB.%26atitle%3DA%2520fully%2520automated%2520%255B35S%255DGTP%25CE%25B3S%2520scintillation%2520proximity%2520assay%2520for%2520the%2520high-throughput%2520screening%2520of%2520Gi-linked%2520G%2520protein-coupled%2520receptors%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2003%26volume%3D1%26spage%3D261%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">This assay used the Cellomics ArrayScan to quantify the accumulation of phospholipid in the I-13.35 cell line after exposure to cationic amphiphilic drugs known to induce PLD in vitro and in vivo. NBD-PE fluorescent lipid probe (Molecular Probes) was used to measure cellular lipid transport taken up by the cellular lysosomes. Inhibited processing and degradation of phospholipids by test compounds led to an accumulation of NBD-PE in the cells. Ethidium Homodimer (EthD-2) is a dead-cell stain that was used to determine cell viability.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bernstein, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciaccio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, J.</span><span> </span><span class="NLM_article-title">Drug induced phospholipidosis</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=419-430&author=P.+Bernsteinauthor=P.+Ciaccioauthor=J.+Morelli&title=Drug+induced+phospholipidosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DP.%26aulast%3DCiaccio%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DJ.%26atitle%3DDrug%2520induced%2520phospholipidosis%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D419%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Mesens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steemans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheyen, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Goethem, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gompel, J.</span><span> </span><span class="NLM_article-title">Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in vitro assay to high throughput in silico assays</span> <span class="citation_source-journal">Toxicol. In Vitro</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1417-1425&author=N.+Mesensauthor=M.+Steemansauthor=E.+Hansenauthor=G.+R.+Verheyenauthor=F.+Van+Goethemauthor=J.+Van+Gompel&title=Screening+for+phospholipidosis+induced+by+central+nervous+drugs%3A+Comparing+the+predictivity+of+an+in+vitro+assay+to+high+throughput+in+silico+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesens%26aufirst%3DN.%26aulast%3DSteemans%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DE.%26aulast%3DVerheyen%26aufirst%3DG.%2BR.%26aulast%3DVan%2BGoethem%26aufirst%3DF.%26aulast%3DVan%2BGompel%26aufirst%3DJ.%26atitle%3DScreening%2520for%2520phospholipidosis%2520induced%2520by%2520central%2520nervous%2520drugs%253A%2520Comparing%2520the%2520predictivity%2520of%2520an%2520in%2520vitro%2520assay%2520to%2520high%2520throughput%2520in%2520silico%2520assays%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2010%26volume%3D24%26spage%3D1417%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Sydserff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirk, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciag, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christian, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudzik, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrzljak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smagin, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dan Widzowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. S.</span><span> </span><span class="NLM_article-title">Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=880-888&author=S.+Sydserffauthor=E.+J.+Suttonauthor=D.+Songauthor=M.+C.+Quirkauthor=C.+Maciagauthor=C.+Liauthor=G.+Jonakauthor=D.+Gurleyauthor=J.+C.+Gordonauthor=E.+P.+Christianauthor=J.+J.+Dohertyauthor=T.+Hudzikauthor=E.+Johnsonauthor=L.+Mrzljakauthor=T.+Piserauthor=G.+N.+Smaginauthor=Y.+Wangauthor=D.+Dan+Widzowskiauthor=J.+S.+Smith&title=Selective+%CE%B17+nicotinic+receptor+activation+by+AZD0328+enhances+cortical+dopamine+release+and+improves+learning+and+attentional+processes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSydserff%26aufirst%3DS.%26aulast%3DSutton%26aufirst%3DE.%2BJ.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DQuirk%26aufirst%3DM.%2BC.%26aulast%3DMaciag%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DJonak%26aufirst%3DG.%26aulast%3DGurley%26aufirst%3DD.%26aulast%3DGordon%26aufirst%3DJ.%2BC.%26aulast%3DChristian%26aufirst%3DE.%2BP.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DHudzik%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DMrzljak%26aufirst%3DL.%26aulast%3DPiser%26aufirst%3DT.%26aulast%3DSmagin%26aufirst%3DG.%2BN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDan%2BWidzowski%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%2BS.%26atitle%3DSelective%2520%25CE%25B17%2520nicotinic%2520receptor%2520activation%2520by%2520AZD0328%2520enhances%2520cortical%2520dopamine%2520release%2520and%2520improves%2520learning%2520and%2520attentional%2520processes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D78%26spage%3D880%26epage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bernstein, P. R.; Brown, D.; Cacciola, J.; Edwards, P.; Folmer, J.; Groblewski, T.; Sylvester, M.; Wesolowski, S.</span><span> </span><span class="NLM_article-title">Spirocyclopropylpiperidinecarboxamide derivatives as histamine H<sub>3</sub> receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases</span>, PCT Int. Appl. WO 2008147314 A1, December 4,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+R.+Bernstein&author=D.+Brown&author=J.+Cacciola&author=P.+Edwards&author=J.+Folmer&author=T.+Groblewski&author=M.+Sylvester&author=S.+Wesolowski&title=Spirocyclopropylpiperidinecarboxamide+derivatives+as+histamine+H3+receptor+agonists+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DP.%2BR.%26atitle%3DSpirocyclopropylpiperidinecarboxamide%2520derivatives%2520as%2520histamine%2520H3%2520receptor%2520agonists%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span>MacroModel, version 10.2; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MacroModel%2C+version+10.2%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span>ROCS, version 3.1.2; <span class="NLM_publisher-name">OpenEye Scientific Software, Inc.</span>: <span class="NLM_publisher-loc">Santa Fe, NM</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ROCS%2C+version+3.1.2%3B+OpenEye+Scientific+Software%2C+Inc.%3A+Santa+Fe%2C+NM%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DROCS%26pub%3DOpenEye%2520Scientific%2520Software%252C%2520Inc%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i106"><a href="/doi/suppl/10.1021/jm4014828">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_87425"></div></div></div></div></div><hr /></hr><p class="last">Secondary pharmacological targets and data for Cpd <b>6s</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4014828/suppl_file/jm4014828_si_001.pdf">jm4014828_si_001.pdf (151.14 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm4014828&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-3%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm4014828%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm4014828" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799ca875c113d06","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
